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ABSTRACT 
 
N-Heterocyclic carbene and phosphorus ligands have been synthesized and used 
for many catalytic reactions including chiral analogs of Crabtree’s catalyst for 
asymmetric hydrogenation.  These catalysts have been studied extensively, especially on 
hydrogenation of "largely unfunctionalized" alkenes, for more than a decade.  These 
substrates, however, could not be easily modified leading to limited applications for 
organic synthesis.  As a result, asymmetric hydrogenations of substrates that have non-
coordinating functional groups have gained more attention because the products are 
chirons that could be used to synthesize many natural products. 
Even though many chiral analogs of Crabtree’s catalysts have been studied, none 
of these catalysts is perfect.  Different catalysts could be suitable for different substrates. 
This point motivated us to investigate asymmetric hydrogenation of different substrates 
using our N,carbene Crabtree’s catalyst analog; for example, α-methyl-γ-alkyl-γ-amino 
acid derivatives can be obtained with high stereoselectivities.  Moreover, the same point 
also inspired us to synthesize the new N-heterocyclic carbene ligands to compare the 
effect on different catalysts that have related structure.  
Design new ligands to obtain effective catalysts, however, needs high experience 
and it is possible time consuming with unpredictable outcomes.  Using the screening 
method with mono-chelating phosphorus ligands synthesized from cheap and easily 
obtained starting materials might be possible solution.  However, we cannot rule out the 
possibility that bi-chelating ligand of the related structure might give better selectivities.  
Cross metathesis is an easy method that can link two parts together to convert mono-
chelating ligand to bi-chelating one.  Using metathesis combined with catalysis 
“metacatalysis” is one method to compare catalytic activity of mono- and bi-dentate 
ligands.  However, the result indicated that most this method was suitable in some cases 
but not all.   
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CHAPTER I 
INTRODUCTION* 
 
N-Heterocyclic carbenes and phosphines have played an important role in 
organic chemistry as strong binding ligands for many transition metals, especially for 
asymmetric catalysis.1  Many active catalysts have been widely synthesized and studied 
to advantage of their unique strong σ-donors leading to advanced complexes including 
Grubbs olefin metathesis,2,3 palladium C–C coupling catalysts for Suzuki–Miyaura and 
Heck reactions,4 Ru-, Rh- and Ir-catalysts for asymmetric hydrogenation of alkenes.5,6   
Comparison between N-heterocyclic carbene and phosphine ligands have been 
extensively investigated to obtain comprehensive data for developing new 
organometallic catalysts.7-10 
During the last decade, enantioselective hydrogenation catalysts derived from 
Wilkinson's [Rh(PPh3)3Cl], Noyori’s [Ru(acetate)2(BINAP)] and Crabtree’s 
[Ir(COD)(PCy3)py]PF6 catalysts (Figure 1.1) have been synthesized to hydrogenate 
functionalized and unfunctionalized alkenes.11  Research on these complexes, especially 
with P,P-ligands, has shown impression on stereoselective hydrogenation of tri- and 
tetra-substituted alkenes with coordinating functional groups (CFGs) such as amides, 
carboxylic acids, and alcohols.12-15  Chiral analogs of Crabtree’s catalyst, ie N,P-Ir 
complexes, however, have been recognized as the most useful catalyst that can use for 
hydrogenation of olefin without coordinating functional groups.16-18 
 
 
 
 
                                                
* Reprinted in part with permission from “Comparison of Asymmetric Hydrogenation of Unsaturated 
Carboxylic Acids and Esters”, Sakunchai Khumsubdee and Kevin Burgess, ACS Catal. 2013, 3, 237-249.  
Copyright 2013 American Chemical Society.  
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Figure 1.1.  Structure of Noyori-liked, Wilkinson’s and Crabtree’s catalyst. 
 
1.1      Chiral iridium catalysts for hydrogenation 
Pfaltz et al, introduced the first chiral analogs of Crabtree’s catalyst, derived 
from phosphines and oxazolines in 1998, that could be used for hydrogenation of various 
unfunctionalized olefins giving excellent enantioselectivities.19  Moreover, this study 
also showed that using tetrakis[3,5-bis(triﬂuoromethyl)phenyl]borate (BARF-) could 
improve the conversion and reduce catalyst loading as low as 0.02 mol %.20  The study 
indicated that iridium complexes with this bulky and weakly coordinating anion were 
much less sensitive to moisture and reactions were very easy to handle without using any 
specially dried solvents.  This study has brought major effect into a lot of research 
leading to new design of efficient catalysts for enantioselective hydrogenations.  Figure 
1.2 showed examples of chiral analogs of the Crabtree’s catalyst with different P-
ligands.21-29 
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Figure 1.2.  Examples of chiral analogs of the Crabtree’s catalyst with different 
phosphine ligands. 
 
As mentioned above, phosphine ligands have been studied in comparison with N-
heterocyclic carbenes.  The latter was considered to be “phosphine mimics” analogs.  In 
2001, our group reported libraries of chiral analogs of Crabtree’s catalyst derived from 
N-heterocyclic carbenes and oxazolines.30  This study introduced the first effective 
unfunctionalized tri-substituted alkenes hydrogenation catalyst 1 (Figure 1.3) derived 
from N-heterocyclic carbenes by substitution of phosphines with imidazolylidene.30,31  
The catalyst could hydrogenated many unfunctionalized alkenes including tri-substituted 
monoenes, di- and tri-substituted dienes (examples in Figure 1.4) with good conversions 
and excellent stereoselectivities. 
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Figure 1.3. Chiral analogs of the Crabtree’s catalyst derived from oxazoline and N-
heterocyclic carbenes developed by our group. 
 
 
 
 
Figure 1.4. Examples of unfunctionalized alkene substrates investigated with catalyst 1. 
 
Mechanism of the hydrogenation reaction using chiral Crabtree’s analogs was 
also investigated by our group32-35 and others36 through DFT calculations.  Similar 
conclusions have been made that Ir(I) undergoes oxidative addition to a Ir(V) 
tetrahydride complex that is in a fast equilibrium with Ir(III) dihydrido-dihydrogen 
complex.  After that, migratory insertion was occurred following by reductive 
elimination then repeated the catalytic cycle. (Figure 1.5) 
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Figure 1.5. DFT calculations of iridium catalyzed hydrogenation pathways.  
 
In addition to oxazoline-based chiral Crabtree’s analogs, many hydrogenation 
catalysts have been synthesized using different sources of nitrogen chelating group such 
as pyridines, thiazoles, amides and ureas.  Figure 1.6 shows examples of these catalysts. 
Hydrogenation of unfunctionalized alkene using these catalysts showed good 
conversions and enantioselectivites.19,37-73  
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Figure 1.6. Examples of chiral analogs of Crabtree’s catalyst with different sources of 
nitrogen chelating group other than oxazoline. 
 
Although unfunctionalized alkenes are very unique substrates for hydrogenation 
using chiral analogs of Crabtree’s catalyst, they have limited application because they 
cannot be easily modified.  Therefore, research on these types of catalyst was then 
applied to more useful compounds that can be used as chirons or chiral building blocks.  
These compounds required at least one functional group (FG) that can be modified or 
homologated such as alcohols, acids, esters, ethers, vinyl phosphonates,74-77 vinyl 
fluorides,78,79 CF3-substituted olefins,80 vinyl silanes,81 enol phosphinate esters,82,83  enol 
ethers,21,84 vinyl boronates,85 enamines,86-88 allyl and vinyl sulfone.89  These chirons, 
except alcohols and acids, were considered to be non-coordinating functional groups, ie 
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non-CFGs, or weakly coordinating functional groups.  In order to obtain more 
application of catalyst 1, our group also investigated some simple alkenes other than 
nonfunctionalized olefins, such as tiglic alcohol and ethyl tiglate.  Figure 1.7 shows 
examples of the simple chirons with functional group hydrogenated with chiral 
Crabtree’s catalysts, shown in Figure 1.2, 1.3 and 1.6. 
 
 
Figure 1.7. Simple hydrogenation substrates using chiral analogs of Crabtree’s catalysts. 
 
Over the last decade, our group has studied many alkene hydrogenation 
substrates using catalyst 1 to give useful chirons.  Figure 1.8 shows the useful 
hydrogenation products obtained from catalyst 1.90 
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Figure 1.8. Important chirons prepared from catalyst 1. 
 
In addition to those shown in Figure 1.8, there are some chirons that can be used 
to build useful natural products that have yet to be made via alkene hydrogenations; for 
examples α,ω-functionalized 1,3-dihydroxy (for skipped polyols), 1,3-amino alcohols 
and α-methyl-γ-substituted amino acids still have not been studied especially by our 
catalyst 1 (Figure 1.9).  Investigation of hydrogenation of alkene precursors using 
catalyst 1 to obtain these chirons with good stereoselectivities could complete the series 
and indicate more application from the chiral Crabtree’s catalyst analogs. One part of my 
dissertation research of my Ph.D. studies is related to the application of catalyst 1 to 
synthesize α-methyl-γ-substituted amino acid chirons.   
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Figure 1.9. Important chirons that possible obtained from catalyst 1. 
 
Even though many catalysts were synthesized during the past decade, results 
form many studies indicated that different catalysts were suitable for different substrates; 
for instance, a catalyst for hydrogenation of α,β-unsaturated carboxylic ester might not 
be suitable for α,β-unsaturated acids and vice versa.  Unlike other substrates, carboxylic 
acids were considered to be coordinated functional groups that were able to hydrogenate 
using Wilkinson's and Noyori’s catalysts.11  To best of our knowledge, only some chiral 
analogs of Crabtree’s catalyst can hydrogenate these substrates with good selectivities.  
Figure 1.10 shows analogs of Crabtree’s catalysts that can hydrogenate the carboxylic 
acid substrates and obtain high stereoselectivities.55,91-95 
 
 
 
Figure 1.10. Chiral analogs of Crabtree’s catalysts used to hydrogenate carboxylic acid 
substrates with good stereoselectivities. 
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In 2010, our group also used catalyst 1 to study about suitable catalyst on 
different substrate.32  This study indicated that N,carbene-iridium complex, liked catalyst 
1, is less acidic than N,P-iridium complexes. Therefore, the catalyst 1 could be used to 
hydrogenate acid sensitive substrates, like enol ethers, without isomerization while the 
N,P-Iridium catalysts wasn’t suitable in this case  (Figure 1.11) 
 
 
 
Figure 1.11. Comparison of hydrogenation of acid sensitive substrate using chiral 
analogs of Crabtree’s catalysts 1, Pfaltz-A and -B.  
 
As a result from all investigation, design and synthesis of new catalysts might 
give opportunity to gain improvement of catalytic activity and stereoselectivity.  In 
recent years, ligand designs based on chiral natural products have gained attention from 
many chemists because they are cheap and easily accessible; for instance, pyranoside 
phosphinite-oxazoline derivatives, synthesized from glucosamines, were introduced by 
Andersson’ group (Figure 1.12).56,60  The studies for hydrogenation of many di- and tri-
substituted alkenes indicated that this type of complexes could be successfully applied as 
good hydrogenation catalysts. 
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Figure 1.12. Chiral analogs of Crabtree’s catalysts derived from chiral natural product, 
glucosamine. 
 
According to all new ligand designs, most of my dissertation research has been 
related to the syntheses of new catalysts mainly for catalytic hydrogenation including the 
ligands derived from natural product such as cinchona alkaloids. Syntheses of new 
catalysts can be related to new carbene,N- and P,N-ligands as in analogs of Crabtree’s 
catalyst, and also P,P-ligand as in analogs of Wilkinson’s Catalyst.  
 
1.2      Conclusions 
Chiral analogs of Crabtree’s catalyst both carbene,N- and P,N-catalysts have 
been introduced as a new class of asymmetric hydrogenation catalyst with excellent 
stereoselectivities uniquely for tri- and tetra-substituted unfunctionalized olefin.  
Moreover, these types of catalyst can be applied to hydrogenate mostly non-coordinating 
functional groups substrates including silyl ethers, enol ethers, esters, and enamines.  
Some of these catalysts can also be applied to substrates with coordination functional 
groups such as alcohols and acids.  These catalysts are suitable for syntheses of many 
valuable chirons due to their excellent yields and stereoselectivities.  Perfection of the 
catalysts, however, is still questionable because different catalysts are suitable to obtain 
excellent stereoselectivities for different substrates.  Investigation of these catalysts with 
different chirons can increase more applications for syntheses of natural products.  In 
addition, development of new catalysts might help improving on catalytic activities and 
stereoselectivities outcomes of olefin substrates.  My Ph.D. research is about 
stereoselective hydrogenations of chiral alkenes with the carbene,N-Ir catalyst 1 and 
mainly about development of new catalysts for hydrogenations. 
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CHAPTER II 
ASYMMETRIC HYDROGENATION APPROACHES TO γ-AMINO ACID 
DERIVATIVES* 
 
2.1       Introduction  
γ-Amino acids have gained attention due to their important roles in medicinal 
chemistry.  These compounds have been explored to have biological functions, 
especially in nervous system.  For instance, γ-aminobutyric acid (GABA) plays as the 
major inhibitory neurotransmitter in the central nervous system of mammals and 
vertebrate.1  As shown in several studies, GABA interacts with various types of 
receptors including ligand-gated ion channels96-98 and some G-coupled protein 
receptors.99  GABA deficiency is associated with several psychiatric and neurological 
disorders, such as anxiety, depression, epilepsy and Parkinson’s disease.2  Even though 
GABA is the major inhibitor, it is not an efficient therapy.  Low lipophilicity causes 
difficulty to pass through the blood brain barrier.100,101  Consequently, lipophilic, chiral 
analogs of GABA have enormously investigated to provide suitable pharmaceuticals like 
(R)-baclofen,102-104 (S)-pregabalin,105-107 and (S)-vigabatrin.108-110  Not only interacts with 
GABA receptors, some γ-amino acid derivatives, such as statine, also act as an inhibitor 
of aspartic acid protease which is an important part of proliferation of many diseases 
including AIDS (HIV protease), hypertension, malaria and Alzheimer’s disease.5  
                                                
* Reprinted in part with permission from “Asymmetric Syntheses Of α-Methyl-γ-amino Acid 
Derivatives”, Ye Zhu, Sakunchai Khumsubdee, Amber Schaefer and Kevin Burgess, J. Org. Chem. 2011, 
76, 7449-7457.  Copyright 2011 American Chemical Society. 
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Figure 2.1.  Important natural products containing optically active γ-amino acids. 
 
Figure 2.1 and 2.2 show examples of γ-amino acids derivatives with useful 
pharmacological properties.109  Only chiral derivatives of GABA, mostly in one 
particular enantiomeric form, with appropriate side-chains are found in some 
therapeutics experiment and can selectively interact with receptors modulated by GABA, 
including baclofen,111-113 pregabalin,114 vigabatrin,109 the experimental therapeutics in 
Figure 2.2, and tubulysins.  Consequently, asymmetric syntheses of these fragments have 
been a focus of attention.  Literature preparations tend to feature mostly classical 
methods like resolutions and diastereoselective reactions involving chiral auxiliaries.115-
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Figure 2.2.  Important synthetic compounds containing optically active γ-amino acids. 
 
Moreover, many biological active compounds, as shown in Figure 2.1, contain 
with α-γ-disubstituted-γ-amino acids including antitumor agents and tubulysins.  Figure 
2.3 shows examples of syntheses the α-γ-disubstituted-γ-amino acids derivatives using 
chiral auxiliaries studied by Friestad’s group.116,117  Even though mechanism studies 
showed reactions proceeded via radical addition, the diastereoselectives were 
surprisingly high with up to 98:2. 
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Figure 2.3.  Syntheses the α-γ-disubstituted-γ-amino acids derivatives using chiral 
auxiliaries. 
 
In the past decade, our group has synthesized and studied chiral analogs of 
Crabtree’s catalyst using carbene-oxazoline iridium complexes.  Chiral analogs of 
Crabtree’s catalyst are special catalysts that can mediate hydrogenations of alkenes 
without an obvious coordinating functional group.16,17  After many modifications of 
structures using different substitutents, 1 was proved to be the best catalyst for 
hydrogenations of many alkenes.  Because catalyst development to get a new ideal 
ligand can be slow and unpredictable, we decided to modify the substrates (alkene 
geometries, protecting or functional groups) to obtain high stereoselectivities from a 
good catalyst.  Hence, we started by modification of optically pure amino acid 
derivatives into appropriate alkenes (Figure 2.4). By matching the influence of our chiral 
catalyst 130,31 with the stereochemical vectors exerted by the substrate, we hypothesized 
that the alkenes could be hydrogenated with high stereoselectivities.  
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Figure 2.4.  Proposed asymmetric hydrogenation of optically pure allyl amines from 
amino acids. 
 
2.2       Results and discussion 
Dr. Amber Schaefer, the postdoc in our research group, initiated this project by 
modification of tert-butyloxycarbonyl, fluorenylmethyloxycarbonyl, phthalyl, or nosyl 
(here 2-nitrophenylsulfonyl, Ns) N-protecting α-amino acids by converting to known118 
Weinreb amide119 derivatives.  The Weinreb amide were then reduced to aldehydes 
using DIBAL,118 then immediately converted, without isolation, to allyl amines (Scheme 
2.1a).  These alkenes were hydrogenated using (S)-1. The best stereoselectivity of the 
reaction was about 13:1.0 (Scheme 2.1b).   However, we hypothesized that there were 
possibilities to improve selectivity by modifying the substrates. 
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Scheme 2.1.  a Preparation and b asymmetric hydrogenation of γ-aminobutenoate esters. 
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Scheme 2.1.  Continued. 
 
Following from those results, Dr. Ye Zhu, previous graduate student in our group 
who studied hydrogenation of chiral allylic alcohol derived from lactic acid,120 compared 
and showed that hydrogenations of ester A mediated by (S)-1 gave only moderate 
selectivity.  The allylic diol substrates B and C, however, were hydrogenated with higher 
selectivities.  As suggested from those observations, converting of γ-aminobutenoate 
esters 3 into similar structural substrates D would give better selectivity from 
hydrogenation (Figure 2.5). 
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Figure 2.5.  Proposed substrate modifications for enhancing the stereoselectivities in 
asymmetric hydrogenations.  
 
Using phenylalanine skeleton as a based core, Dr. Ye Zhu’s hypothesis was 
tested by reduction of ester 3a (R = Bn) to allylic alcohol 4a.  Deprotection of tert-
butyloxycarbonyl yielded the free amine 5a which was converted into the bulky silyl 
protecting products 6a and 7a (Scheme 2.2a).  The hydrogenation results showed 
moderate selectivity for 4a but no significant conversion was obtained from free amine 
6a.  Compound 7a, however, gave an excellent selectivity by using 5 mol % of (S)-1 
which is little high catalyst loading in our opinion (Scheme 2.2b).  Therefore, more 
modified substrates were synthesized to reduce the catalyst loading and to maintain the 
excellent selectivity. 
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Scheme 2.2.  Synthesis a and asymmetric hydrogenation b of N- or O-protected amino 
alcohol derivatives. 
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The results above indicated that protected amine can be hydrogenated with good 
conversions and selectivities.  However, hydrogenation of formamide 10a, which has 
potentially coordinating group, yielded poor conversion and selectivity.  Interestingly, 
compound 8a containing N-Boc and silyl ether gave a good selectivity in a favor of anti 
product that is opposite to other substrates discussed above. Using the results that 
substrates containing N-protected and silyl ether can be hydrogenated with good 
selectivities, compound (E)-9a (acetamido silyl ether) and (E)-11a (trifluroacetamido 
silyl ether) were synthesized and hydrogenated with excellent syn-selectivities.  The 
former, however, used lower catalyst loading (2 mol %) than the latter with same 
selectivity.  Therefore, substrate 9a was used as core structure to provide syn-isomer 
(Scheme 2.3). 
 
 
 
 
Scheme 2.3.  Synthesis (a) N- or O-protected amino alcohol derivatives from varying α-
amino acids and asymmetric hydrogenation (b) of N- or O-protected amino alcohol 
derivatives from phenylalanine. 
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Scheme 2.3.  Continued. 
 
To complete this series, Dr. Zhu aimed to get the anti-isomer.  Investigation of 
asymmetric hydrogenation using (S)-1 indicated that most reactions followed the 
substrate control that has 1,3-allylic strain effects121 as dominant influences.  Therefore, 
he hypothesized using Z-alkenes relative to their E-isomers should give anti-isomers.   
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Figure 2.6.  Hypothesis for obtaining the anti-skeletons of α-methyl-γ-amino acid 
derivatives. 
 
Z-Allylic alcohol was synthesized starting from reduction of the same Weinreb 
amide following by the Still-Gennari reaction to give (Z)-3a.122  Reduction and N, O-
protections give (Z)-9a overall about 53 %.  Without further modification, the results 
indicated that using 2 mol % of (S)-1 gave anti-isomer with very good 
diastereoselectivity. 
 
 
 
Scheme 2.4.  Synthesis and hydrogenation of (Z)-9a. 
 
Me
H
CO2Me
PHN 3
1
large group
shields top-face
H
PHN 3
1
minimized 1,3 allylic strain
OX
cat
a
H
PHN 3
1
OX
E
reversal of alkene geometry gives
opposite diastereomer?
b c
ZE
cat cat
N O
O
(i) DIBAL, CH2Cl2 
-78 °C, 4 h
(CF3CH2O)2P OMe
O BocHN
CO2Me
KHMDS, 18-crown-6
THF, -78 °C, 1 h
(ii)
(Z)-3a
68 %
Ph Ph
BocHN O
(i) DIBAL
CH2Cl2, -50 °C, 5 h
(ii)TBDPSCl, imidazole
CH2Cl2, 25 °C, 24 h
Boc N
H
HCl, dioxane
25 °C, 4 h
OTBDPSPh
(Z)-8a
  24 
 
 
Scheme 2.4.  Continued. 
 
As the syn- and anti-isomers were completed, my part in this project was to 
prove that this method could be expanded to other allylic amines based on the different 
amino acid starting materials with the correct stereochemistry of the final products.  The 
amino acid side-chains (alanine, serine, tyrosine and valine) were chosen from the useful 
biological active compounds as shown in Figure 2.1 and 2.2.  As a result, (E)- and (Z)-
forms of 9b – e were prepared by following the sequences used for (E)- and (Z)-forms of 
9a.  Table 2.1 shows the results obtained from hydrogenations gave excellent 
conversions and diastereoselectivities. 
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Table 2.1. Hydrogenation of various α-substituted alkene substrates using (S)-1 
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In order to confirm the stereoselectivity, alcohols 12a and 13a are known 
compounds.117,123  The stereochemistry of samples obtained from phenylalanine was 
determined by comparing 1H NMR spectra of these two materials.  
 
 
Figure 2.7.  Hypothesis for obtaining the anti-skeletons of α-methyl-γ-amino acid 
derivatives from phenylalanine. 
 
To confirm the selectivity of other α-methyl-γ-amino acid derivatives, alkenes 3b 
– e were hydrogenated using Pd/C and H2 under atmospheric pressure to give mixtures 
of syn and anti-esters.  This mixture of esters was hydrolyzed and recrystallized to yield 
the pure anti-diastereomer as confirmed by comparing spectral data with them in the 
literatures.124-127   The pure anti-diastereomer was reduced to corresponding alcohols, O-
TBDPS protected and the N-Boc group was removed (as shown in Scheme 2.2 and 2.3).  
Finally, N-acylation gave the pure anti-amino alcohol derivatives 2b - e.  These 
compounds were then used as standards to compare (typically by HPLC) with the 
hydrogenation products formed using (S)-1. 
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Scheme 2.5.  Syntheses of standard for pure anti-isomers. 
 
2.3      Conclusions 
In summary, we introduced the new method to synthesize α-methyl-γ-amino acid 
derivatives from catalytic hydrogenation reactions of allylic amines using N,carbene 
iridium catalyst.  The results indicated that hydrogenation of this chiron using (S)-1 gave 
excellent conversions and diastereoselectivities for both syn- and anti-isomers.  
Moreover, the method can be applied to different amino acid side-chains that have the 
same chiron which gave another alternative way to synthesize pure chiral compounds.   
The alkane products can be further applied in the part of biological active compounds in 
a few steps.  
Moreover, we found that modicafication of substrates by playing with substrate 
geometries, functional groups and protecting groups are easier way to obtain 
stereoselective compounds than one to modify the catalyst which sometimes cannot be 
predictable outcomes. 
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CHAPTER III 
HOMO-ROCHE ESTER DERIVATIVES BY ASYMMETRIC 
HYDROGENATION AND ORGANOCATALYSIS 
 
3.1       Introduction  
Roche ester derivatives E are some of the most widely appreciated chirons in 
organic syntheses128-131 because such compounds have both terminal functional groups 
that allow modification and homologation in bidirections, especially for incorporating 
methyl-substituted chiral centers.  It seems logical that the homologous chirons F would 
be similarly useful as chirons E if they were more readily available.  For the purposes of 
this study we refer to the generic class of fragments F as homo-Roche ester derivatives.    
 
 
 Figure 3.1.  Structure of Roche ester and homo-Roche ester derivatives. 
 
Scalable syntheses of chirons F have not gained much attention in the literature.  
The most directing route should be a homologation of the parent chirons E132 which is 
probably not the best option to obtain chirons F, even though they only contain one more 
skeletal carbon than E because the Roche ester is not a cheap starting material; small 
quantities tend to cost more than $1 per gram.  Another approach is via asymmetric 
hydrogenations of itaconic acid or the corresponding diesters to give the C5-building 
blocks G.133,134  Bidirectional homologation of chirons G requires efficient 
chemoselective modification of one of the two esters; we are aware of only one method 
for doing this, and it features a relatively expensive lipase in a chemoenzymatic 
hydrolysis to achieve a pure single monoester.133  It is possible to instead begin with a 
monoester of itaconic acid and hydrogenate that, but in fact the enantioselectivities for 
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this process tend to be less than the diacid or the diester.133,135  Alternatively it is possible 
to begin the syntheses with monoesters of itaconic acid, and indeed some of these are 
commercially available.  However, these starting materials are expensive so, overall, it is 
better to avoid this strategy.  Any strategy that uses hydrogenation of itaconic acid, in 
fact, is vulnerable to the types of deactivation pathways that have been documented 
previously.136,137  Another route to chirons I is via asymmetric additions of cuprates to 
α,β-unsaturated thioesters.138 
 
 
Figure 3.2.  Hydrogenation substrates to obtain compound G. 
 
Both the hydrogenation syntheses of chirons F described above feature 
bisphosphite complexes formed from Rh(COD)2+ in situ.  Hydrogenation of type H 
trisubstituted alkenes would give products that are chemically related to G, but these 
types of transformations tend to be difficult to achieve using RhP2 complexes because 
the double bonds are hindered.11    In fact, the preferred catalysts for the trisubstituted 
alkenes H tend to be N,P-Ir complexes, ie  chiral analogs of Crabtree’s catalyst.11  
Consequently, my work in this project was to use our particular chiral analog of 
Crabtree’s catalyst, (S)-1,30,31 to reduce H -type substrates via scalable transformations 
to obtain single enantiomer of chirons H.   The hydrogenated product was then further 
applied to obtain all stereoisomeric forms of the 2-substituted chirons I via 
organocatalytic modifications of the homo-Roche ester derivatives F which was done by 
Hua Zhou, another graduate student in our group.  Similar reactions of achiral substrates 
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via organocatalytic are well known, but finding appropriate organocatalysts to overcome 
the stereochemical bias exerted by the C3 chiral center was an open issue. 
 
 
Figure 3.3.  Structure of catalyst (S)-1 used for hydrogenation and general structure of 
organocatalysis product I. 
 
3.2       Results and discussion 
3.2.1 Synthesis of hydrogenation substrate 
Following a literature procedure, glyoxylic acid monohydrate was converted to 
the α,β-unsaturated ester J.139  The first new step in this work was to chemoselectively 
reduce the ester group of J in the presence of its carboxylic acid functionality140 to give 
the hydroxyacid 14141,142 which was isolated via acid-base extraction.141,142  
Subsequently, the hydroxyacid 14 was esterified to give the known143 hydroxyester 15.  
None of the steps described in Scheme 3.1 involve column chromatography, and the 
synthesis can give tens of grams of the product 15. 
 
 
 
Scheme 3.1. Scalable Synthesis of the hydrogenation substrate 15. 
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Hydrogenation of alkene 15 is the key transformation in this project (Scheme 
3.2).  Under the conditions shown in Scheme 3.2, approximately 15 g of the 
hydroxyester 15 can be hydrogenated with complete conversion to give 16 (a type F 
chiron), and the catalysts are still active at the end of this transformation.  Even though 
the hydrogenation worked perfectly, only high, but not perfect, enantioselectivities were 
obtained.  The acyclic product 16 was then lactonized to 17 then efficiently 
recrystallized under cold conditions to give optically pure material.  For subsequent 
applications of these products (here and perhaps elsewhere), the lactone 17 was 
converted to two other potentially useful acyclic chirons, the alcohol 16 (now as one 
enantiomer) and the silyl ether 18.  
 
 
 
Scheme 3.2.  Asymmetric hydrogenation of alkene 15, then recrystallization and 
TBDPS-protection to obtain ester 18. 
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The ester 18 was given to Hua Zhou, another graduate student in our group, to 
perform the application via organocatalysis as described below in this chapter.  To 
obtain an aldehyde 19, the ester 18 was reduced using Brookhart’s catalytic 
silylation/hydrolysis procedure144 (reaction 3.1).  This reduction afforded the aldehyde 
19 in good yield for elaboration via organocatalytic processes involving iminium and 
enamine intermediates. 
 
 
reaction 3.1 
 
3.2.2 Application with organocatalysis 
To the best of our knowledge, organocatalytic transformations of the homo-
Roche aldehydes 19 have not been reported before.  However, there is precedent for 
electrophilic α-substitutions of β-chiral aldehydes,145 and, of course, a great deal of 
literature for the parent reactions of acyclic non-chiral aldehydes.146  Catalysts and 
reagents for the organocatalytic transformation were chosen from a known literature147-
149 for each particular electrophiles then applied them to homo-Roche ester 19. 
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Figure 3.4.  Catalysts and reagents used in organocatalysis. 
 
Scheme 3.3 shows the data accumulated for the organocatalytic transformations 
of aldehyde 19.  Part a refers to chlorinations performed using MacMillan’s catalyst 
M•TFA150 (a commercial sample of the hydrochloride catalyst did not work in this 
reaction, so it was converted to the trifluoroacetate, ie the salt used by MacMillan’s 
group).  It emerged that the (S)-enantiomer of the catalyst matched147 the substrate bias 
and gave an excellent stereoselectivity for the syn-isomer of 20 after borohydride 
reduction.  However, in the mismatched case (R)-M•TFA overwhelmed the substrate 
bias hence a 10:1.0 ratio in favor of anti-7 was observed.  Similarly, MacMillan’s 
fluorination procedure148 using (R)-M•Cl2HCCO2- gave even better matched and 
mismatched selectivities in catalyst-controlled reactions to give the 2-fluoroalcohols 21 
after reduction.  For amination reactions it was desirable to use dibenzyl azocarboxylate 
rather than other alkyl derivatives for the reasons indicated below (Scheme 3.4), so we 
used List’s procedure that described application of exactly that electrophile.149  Just as in 
the chlorination and fluorination reactions, the aminations were catalyst-controlled.  
These transformations gave superb selectivity in the matched case for syn-22, and a 
13:1.0 ratio for the anti-isomer via the mismatched process.  
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Scheme 3.3.  Asymmetric transformations of substrates 19: a chlorination; b 
fluorination; and, c amination.  Throughout, selectivities were determined via analytical 
HPLC on a Chiralcel-OD column. 
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Reactions 3.2 and 3.3 showed how the isomeric 2-chloroalcohols 20 were 
efficiently ring closed to the corresponding epoxides 23.  These reactions were 
performed because the epoxides 23 are valuable chirons, but their use has been limited 
by the fact that syntheses of these materials require multiple steps and some routes are 
only practical for one or two of the four possible stereoisomers.151-153 
 
 
reaction 3.2 
 
 
reaction 3.3 
 
 
Figure 3.5.  Structure of derivatives of γ-hydroxyvaline P. 
 
Finally, derivatives of γ-hydroxyvaline P (Figure 3.5) were prepared to illustrate 
how the amination products 22 could be used in a novel short synthesis.  γ-
Hydroxyvalines are naturally occurring amino acids that have been associated with 
stimulation of insulin secretion.154  Hydrogenolysis of the benzyl protecting groups of 22 
and simultaneous homolysis of the N-N bond gave the N-protected amino alcohols 24 
after addition of Fmoc (Scheme 3.4).  Catalytic oxidation of those alcohols gave the N-
Fmoc-γ-silyl protected amino acid 25.  All four stereoisomers of 25 could be obtained 
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using this route, and one enantiomer of each of the syn- and anti-forms was made to 
prove this.  The final products 25 are suitably protected for many peptide synthesis 
strategies, so no attempt was made to obtain the corresponding γ-hydroxyvalines since 
we have no immediate application for these.  The synthesis of the 2S,3S-syn-isomer was 
performed on a large enough scale to obtain 0.42 g of product.  Previous syntheses of γ-
hydroxyvaline derivatives required either 12 steps to obtain an enantiomer of the N-
BOC-O-PMB-protected form of the reduced product (ie alcohol not carboxylic acid),155 
or via multistep routes to syn,anti-mixtures of various protected derivatives that were 
then separated (via crystallization of diastereomeric copper complexes,156 or via column 
chromatography157). 
 
 
 
Scheme 3.4.  Syntheses of α-N-γ-O-protected forms of γ-hydroxyvaline 
 
3.3      Conclusions 
The pivotal observation in this paper is that we may use type-H trisubstituted 
alkenes, specifically 15, to give the same product that would be formed from 
hydrogenation of itaconic acid (or the diester) and differentiation of the two carboxylate 
groups (then reduction).  Key to this study is the fact that chiral Crabtree’s analogs like 
(S)-1 can mediate hydrogenations of trisubstituted alkenes without suitable coordinating 
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functional groups (CFGs) for binding Rh-centers.  Fortunately, the starting material 18 is 
also easy to make and this facilitates the whole process. 
Prior to our studies, Alexakis and Mazet elegantly combined enantioselective 
iridium-mediated isomerization reactions158-161 with organocatalytic functionalization of 
aldehydes to form two chiral centers.145  The work we have performed here is 
conceptually similar except that it is based on production of a particularly high-value 
chiron, the homo-Roche ester, and elaboration of that in distinct steps.  Moreover, the 
initial chiral center is established here via hydrogenation rather than isomerization 
reactions.  
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CHAPTER IV 
A COMPARISON BETWEEN OXAZOLINE-IMIDAZOLINYLIDENE, -
IMIDAZOLYLIDINE AND -BENZIMIDAZOLYLIDENE HYDROGENATION 
CATALYSTS* 
 
4.1       Introduction  
Since N-heterocyclic carbenes were introduced, they have been used extensively, 
especially in catalytic reactions.  Different types of N-heteroocyclic carbenes have been 
synthesized and compared in both steric and electronic effects.  Steric effect of N-
heterocyclic carbenes have been usually compared by varied N-substituents substrates 
with different alkyl or aryl groups.  Comparison of their electronic effect can use the 
same method or it can be compared by changed core structure of N-heterocyclic carbene 
such as ligand a – c (Figure 4.1).  
Stereoelectronic variation is to be expected within the series of N-heterocyclic 
carbene ligands a – c.162,163  With respect to size, even members of this series with the 
same N-aryl substituents may have various steric influences because they have different 
flexibilities; for instance, the planar systems b and c are less flexible than the saturated 
one a.162  Flexibility in the ligands can also indirectly affect their electron donating 
properties.  Direct donation of π-electrons from the N-aryl substituents to the metal in 
these systems is significant,9,164 and it is bound to be orientation dependent.  
Consequently, differences in the carbene core that perturbs the preferred orientations of 
the aryl groups also modulate the electron densities they donate to the metal.165  
Moreover, the saturated imidazolinylidene a is the only member of this series that is not 
aromatic and this has ill-defined impacts on its electron donating properties relative to 
the other two.1   
                                                
* Reprinted in whole with permission from “A Comparison between Oxazoline-imidazolinylidene, -
imidazolylidine, -benzimidazolylidene Hydrogenation Catalysts”, Sakunchai Khumsubdee, Yubo Fan and 
Kevin Burgess, J. Org. Chem. 2013, 78, 9969-9974.  Copyright 2013 American Chemical Society. 
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Figure 4.1.  Core structure of N-heterocyclic carbenes, imidazoline, a; imidazole, b and 
benzimidazole, c. 
 
Several strategies have been devised to gauge stereoelectronic differences in the 
series of ligands a – c.  These approaches consider dimerization of the parent carbene,166 
IR and Raman spectra7 of CO ligands in the same complex (sometimes interpreted in 
terms of the Tolman electronic parameter),8 electrochemical studies,9 and theoretical 
approaches.10 Overall, the most general conclusions from these studies are that all three 
ligands are stronger σ-donors than any phosphine, but electronic effects within the series 
tend to be small.10,162  For instance, carbonyl complexes containing ligands a - c may 
have IR absorbance within 3 cm-1 of each other, while others have almost identical 
REDOX potentials.9 
Even if electronic variability in the series a – c is small, and the N-aryl groups are 
identical, substitution of one of these ligands for another one can have significant effects 
on catalytic performance.  Evidence for this assertion comes from the Grubbs’ 
metathesis catalysts.  Early work had shown that ring closing metatheses mediated by 
the now widely-appreciated Grubbs type II catalyst Qa tended to proceed with superior 
reaction rates and overall conversions relative to Qb.167  Delaude and co-workers 
subsequently found that for favorable substrates the benzimidazolylidene complex Qc 
could give faster initial rates for ring-closing metathesis than Qa (Figure 4.2).168 
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Figure 4.2.  Comparing catalytic activity of Grubbs type II catalyst bearing imidazoline, 
Qa; imidazole, Qb and benzimidazole, Qc in certain RCM reactions. 
 
In total, the considerations above indicate there is no reliable way to extrapolate 
free ligand properties in the series a – c to catalytic performance of complexes, and that 
even small stereoelectronic differences in the carbenes could have significant effects.  
Consequently, we were curious to test the series 1a - c  (Figure 4.3) that include our 
carbene catalyst 1b.  Complex 1b, and similar chiral analogs of Crabtree’s catalyst, are 
suitable for hydrogenation of trisubstituted alkenes without functional groups that 
typically coordinate to the metal in these complexes (CFGs).16,17,169  Consequently, this 
study describes syntheses of the new complexes 1a and c, and use of these to 
hydrogenate some largely unfunctionalized alkenes.  Enantioselectivities were the 
critical end-point parameter that we wished to measure because the overriding 
application of 1b is in asymmetric catalysts.  
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Figure 4.3.  Structure of catalyst 1 bearing different carbenes. 
 
4.2       Results and discussion 
To obtain catalyst 1a, imidazoline R (Figure 4.4) was prepared via the known 
literature procedure.170  Benzimidazole S (Figure 4.4), required for catalyst 1c, is also a 
known compound,171 but we synthesized it using a different method, ie reaction of the 
corresponding 1,2-benzenediamine with trimethyl orthoformate under acidic conditions, 
p-TsOH in this case.  Removal of methanol from the reactions could promote the 
formation of product S in high yield.  
 
 
Figure 4.4.  Structure of imidazoline R and benzimidazole S. 
 
Both nucleophiles R and S were reacted with the appropriate iodo-oxazoline30 in 
DMF to give the corresponding carbene precursors as shown in Scheme 4.1.  Using 
identical conditions both carbene precursors were then deprotonated and reacted with 
[Ir(COD)Cl]2 followed by anion exchange to obtain the final iridium complexes. 
Complex 1b was prepared by following the known procedure developed in our group30 
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which can be scalable to obtain final complex around 5 grams.  Comparison on physical 
properties showed that complex 1a is yellow, whereas 1b and c are orange and the solids 
are very identical.  13C NMR chemical shifts of the coordinated carbene in this series 1a  
- c are very similar: 178.4, 179.5, and 187.2 ppm, respectively. 
Table 4.1 shows comparative data for a series of hydrogenations using catalysts 
1a – c.  The stilbene derivative in entry 1 was included because it is the most widely 
studied substrate for asymmetric hydrogenations using chiral Crabtree’s catalyst 
analogs.16  The endocyclic alkene in entry 2 was chosen because that kind of substrates 
are not reduced with high stereoselectivities using catalyst 1b.  The other substrates 
shown in Table 4.1 are relevant to our studies on hydrogenations to form fragments of 
polyketide-derived natural products and other useful chirons.33,132 
All the experiments summarized in Table 4.1 gave 100 % conversions under the 
conditions indicated.  Stereoselectivities in these reactions were almost identical in 
almost every case; variation of the catalyst carbene feature had no significant effect. 
We have previously reported evidence that the carbene-containing catalyst 1b is 
significantly less prone to generate protons in hydrogenation reactions than 
corresponding complexes that have phosphorus-based ligands in place of the carbene. 32  
Calculations in that work indicated that the carbene complexes gave intermediates that 
are of the order of 107 times less acidic than similar P-containing complexes.32  For the 
current study, similar calculations were undertaken for the series 1a – c, and the data 
obtained are outlined in Table 4.2.  Relative σ-donor and π-acceptor properties deduced 
from similar calculations are also shown.  In the event, calculated pKa values for the 
complexes are within a 2.2 unit range.  Similarly, the calculated σ-donor and π-acceptor 
potentials for the free carbenes were within relatively tight ranges: ±0.2 and ±0.7 eV, 
respectively.  These observations are consistent with Figure 4.5, which shows the 
HOMOs from these calculations are all relatively similar in shape. 
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Scheme 4.1.  Syntheses of iridium catalyst 1a and c. 
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Table 4.1.  Stereoselective hydrogenations using the featured catalysts.  
 
Entry  Stereoselectivity
a 
1a 1b 1c 
     
1 
 
93 99 95 
2 
 
12 5 15 
3 
 
57 63 55 
4 
 
77 83 75 
5 
 
70 65 66 
6 
 
93 96 95 
7 
 
91 93 93 
8 
 
94 95 94 
9 b, c 
syn:anti 
49:1.0 49:1.0 48:1.0 
a Enantioselectivity unless it stated. b Diastereoselectivity.           
c Reactions using 2 mol % of 1a – c. 
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Experimental validation of the calculated pKa trends discussed above was 
obtained by hydrogenation of 1,2-diphenylpropene using 1a – c as shown in Figure 4.6, 
then adding a pH indicator.  Whereas, we have shown previously that N,P-complexes 
tend to give red solutions (similar to the control in Figure 4.6a),32 all three complexes 1a 
– c gave light yellow solutions indicating the reaction medium is not acidic. 
 
Table 4.2.  σ-Donors, π-acceptor and pKa of intermediate in hydrogenation reaction of 
complexes 1a – c. 
 σ-donor (eV) 
π-acceptor 
(eV) 
pKa  
complex 1 
 
-4.690 -0.119 18.0 
 
-4.865 0.063 17.4 
 
-5.080 -1.337 15.8 
 
 
Figure 4.5.  HOMO of carbene electron from imidazoline, a; imidazole, b and 
benzimidazole, c. 
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Figure 4.6.  Hydrogenation with catalyst 1: a methyl red with acetic acid in CH2Cl2 
(control for acid); b methyl red with Et3N in CH2Cl2 (control for base); c catalyst 1a with 
methyl red; d catalyst 1b with methyl red; and e catalyst 1c with methyl red. 
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Our hypothesis regarding the mechanism of hydrogenation with 1b, based on 
calculations, indicated35 a strong trans-effect orients the alkene ligand opposite to the 
carbene in intermediate T as indicated in Figure 4.7.  These calculations also indicate 
transformation of T into the transition state U was predicted to be the rate-limiting step 
in the catalytic cycle.  We propose all the carbene ligands (abbreviated to C in Figure 
4.7) maintain that strong trans-effect in the catalysis, and there are insufficient steric 
differences to perturb the enantioselectivities. 
 
 
Figure 4.7.  Transformation of T to U is predicted to be rate-limiting in the catalytic 
hydrogenation of trans-1,2-diphenylpropene mediated by complex 1b. 
 
In order to explain the relatively poor performance for catalyst 1b with 
endocyclic substrates, as in entry 2 of Table 4.1, calculations were performed 
corresponding to use of catalyst 1b in entry 1, as reported previously, involved 
evaluating the energies of three species.  Specifically these were: (i) the intermediate T 
in Figure 4.7 before the turnover limiting step; (ii) the transition state that relates T and 
U; and, (iii) the energy of the intermediate U after the turnover limiting step.  These 
studies proved that the energy of that intermediate U is closely related to the transition 
state energy.35  Those studies also showed four pathways should be considered.  These 
are two for each enantio-face of the alkene, and, for each enantio-face, pathways 
corresponding to two different π-complex rotamers related by 180° rotation around the 
metal to π-bond in the starting intermediates T.  These correspond to putting each of the 
two inequivalent phenyl groups of the complexed alkene between the smaller pocket 
between the bulky 2,6-di-iso-propylphenyl and adamantly substituents.  The conclusion 
from this study is that the pathway from intermediate T to U (based on the relative 
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energies of these two intermediates) for hydrogenation of the alkene in Table 4.1, entry 
1, to give the (S)-product was 5.91 kcal/mol more stable than any of the two pathways 
leading to the (R)-enantiomer. 
  In the current study, calculations were preformed using exactly the same 
procedures as before to assess the energies of the same four types of pathways for the 
endocyclic substrate in entry 2.  Figure 4.8 shows the two of the four key intermediates 
(analogous to U), and their relative energy differences from the starting p-complexes 
(analogous to T); all the values are normalized relative to the most favorable pathway 
identified.  That most favorable pathway corresponds to production of the (R)-
enantiomer, but there is another calculated to be only 0.21 kcal/mol higher in energy that 
leads to the (S)-enantiomer.  Thus these calculations explain the poor enantioselectivities 
for endocyclic alkenes: in both intermediates shown the edge-fused ring system stacks 
above the (iPr)2C6H3 ligand aryl substituent. 
 
4.3      Conclusions 
New hydrogenation catalysts 1a and c were synthesized to compare the 
electronic effect of N-heterocyclic carbenes for asymmetric hydrogenation.  We cannot 
rule out the possibility that differences will emerge for these catalytic reactions mediated 
by complexes 1a – c, especially from stereoselectivity.  However, the current study 
demonstrates there are negligible differences between them in the asymmetric 
hydrogenation reactions shown in Table 4.1. Although the catalysts gave good 
performance in many substrates, poor enantioselectivities in the hydrogenations of 
endocyclic substrates seem to arise because hydrogenation pathways for the two 
enantiofaces of this substrate proceed through energetically similar turn-over limiting 
steps as illustrated in Figure 4.8. 
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Figure 4.8.  Intermediates in two most preferred pathways for hydrogenation of 
endocyclic substrate lead to different enantiomers have the same energies (within error 
limits for these calculations). 
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CHAPTER V 
METATHESIS FOR CATALYST DESIGN: METACATALYSIS 
 
5.1       Introduction  
During the past two decades, several chiral phosphorus compounds especially 
phosphines and phosphites were synthesized for many catalytic reactions as 
homogeneous and heterogeneous ligands.  To get effective catalysts with high 
stereoselectivities, ligands need suitable designs with high experience.  Moreover, 
influence of temperature, pressure, time, solvents and additives have to be evaluated 
until the best condition was discovered.  Less flexible ligands, such as bidentate or 
tridentate chelations are even harder to design and sometimes lead to very large library 
of ligands with many different substitutent combination.  All of these are time 
consuming that could lead to unpredictable results. 
In situ catalyst formation by mixing monodentate ligands with a reactive metal 
salt or complex (Figure 5.1) has been used extensively for rapid identification of 
superior catalysts by Reetz,172-175 Feringa/Vries,176-179 and by others.180-183   Those 
groundbreaking studies lead to several conclusions that were not appreciated before this 
approach was conceived.  First, even though it was known that high enantioselectivities 
could be obtained using certain monodentate ligands,184 formation of dynamic 
combinatorial mixtures of complexes in this way has proved to be an exceptionally 
efficient catalyst optimization strategy.   Second, mixtures of two ligands sometimes 
give higher enantioselectivities than experiments in which two equivalents of either of 
the two pure ligands are used.  Third, there are situations in which superior 
enantioselection has been achieved when one of the monodentate ligands is achiral.  
Fourth, time has shown that this approach is reasonably general, having been widely 
applied to asymmetric hydrogenations of alkenes with coordinating functional groups 
(CFGs),172-179 and to 1,4-additions to electron-deficient alkenes,185-188 allylic 
substitution,189-191 hydrovinylation,192,193 and cross coupling.194 
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Figure 5.1.  a Dynamic combinatorial catalysis is known; but, b can bidentate ligands be 
similarly formed via metathesis? 
 
In reality, mixtures in dynamic combinatorial catalysis usually are significantly 
more complicated than Figure 5.1a suggests.  For instance, it is possible that active 
complexes with one or three ligands might be involved.  Moreover, Hartwig has shown 
that ostensibly monodentate ligands in some reactions are, in fact, bidentate as a result of 
metalation processes.195-198  In short, dynamic combinatorial catalysis trades some 
control of the mixtures being screened for the ability to make potential catalysts quickly.   
Efficiency is possible in dynamic combinatorial catalysis by generating different 
combinations of monodentate ligands.  However, it would be highly desirable to produce 
bidentate ligands instead, without significantly compromising the efficiency.  This is 
because appropriately designed bidentate, chelating ligands have several attributes 
conducive to the design of stereoselective catalysts, mostly related to the fact that their 
complexes exist in fewer accessible low energy conformers.   A superior bidentate 
ligand may exist corresponding to each effective combination of monodentate ligands 
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identified in dynamic combinatorial chemistry; in practice the problem is finding this 
ligand. 
Research described in this manuscript was undertaken to obtain proof-of-
principle for the concept illustrated in Figure 5.1b.  We envisaged olefin metathesis199 
could be used to convert alkene-containing ligands with one P-center into mixtures of 
compounds with two.  In simple cases in which only the P-centers coordinate to the 
metal, this represents conversion of monodentate ligands to bidentate ones; metathesis to 
form catalysts is referred here as metacatalysis.  Thus, if the metathesis reactions are 
efficient enough that purification of the ligands before the test reaction is unnecessary, 
then metacatalysis could be almost as convenient as dynamic combinatorial processes 
featuring monodentate ligands, but have the distinction that bidentate “catalyst space” is 
covered. 
 
5.2       Results and discussion 
5.2.1 Selection of the metathesis substrates and test reactions   
Several considerations guided selection of the alkene chirons that were used as 
metathesis substrates in this work.  First, the alkenes should be conveniently assembled 
from commercial starting materials.  Second, carbene intermediates in the catalytic cycle 
should not permit a stable 5-ring chelate to be formed since this would tend to depress 
the catalytic activity.200  The third consideration follows because the previous one tends 
to impose design constraints that favor large-ring chelates, and because these would 
predominantly feature E-alkenes (assuming standard metathesis catalysts were used).  
Thus it was desirable to use monomers for which the anticipated macrocyclic chelates 
would be formed from large fragments; our hypothesis was that this would tend to 
decrease the number of accessible conformational states as a result of steric packing 
effects.   Finally, it was necessary to avoid situations in which the corresponding 
combinations of monodentate ligands for the featured catalytic reaction already gave 
high stereoselectivity.  In other words, the objective of this study was to see if 
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metacatalysis could give improved enantioselectivities, so it was logical to choose 
situations that allowed for substantial improvement.  
Based on the considerations outlined above, we elected to work with pseudo-
enantiomeric phosphite derivatives of quinidine and quinine, 27 and 28 respectively 
(Figure 5.2).  One monodentate ligand of this kind, 27e where (RO)2 = 1,2-diphenyl-1,2-
ethylenedioxy, has been reported previously and used for Pd-mediated allylation 
reactions; enantioselectivities up to 88% were obtained.201  In the event, ligands 27a – h 
and 28g – h were prepared in one-pot reactions and isolated in yields ranging from 30 - 
85 % after flash chromatography. 
 
 
Figure 5.2.  Alkene-phosphite chirons featured in this work.  Ultimately, the study 
focused on 27g – h, and 28g – h.  
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Hydrogenations of largely unfunctionalized alkenes were selected as the test 
reactions, for the following reasons.  Some of the most successful catalysts in these 
processes are iridium complexes with N,P-ligands;16,17,169 chirons 27 and 28 have the 
potential to use P- and N-atoms to coordinate in this way (Figure 5.3). Consequently, the 
archetypical hydrogenation of this kind was used to triage some of the monomers 
(reaction 5.1).  On the basis of the data shown, only the 2,2’-binaphthol-based ligands g 
and h were selected for further studies.  
 
 
Figure 5.3.  Chelating group in structure of cinchona alkaloids phosphite derivatives. 
 
 
reaction 5.1 
 
5.2.2 Metathesis of the alkene monomers    
Alkene metatheses of substrates 27 and 28, g and h, were studied as a prelude to 
the featured catalytic reactions.  It was not obvious that these metatheses reactions would 
proceed with high conversions because even monosubstituted alkenes tend to react 
slowly if the allylic site is bulky.202  Moreover, the alkenes featured here also contain 
phosphite centers that could similarly retard the catalysis.  Throughout, we restricted our 
studies to the more convenient Ru-based metathesis catalysts; the related Mo-centered 
catalysts were not explored. 
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In the event, the Grubbs-Hoveyda second generation system V gave good 
conversion of the monomers to the disubstituted alkenes 27’ – 27’ and 28’ – 28’ (Figure 
5.4).  This transformation was monitored by loss of the methylene 1H and 13C NMR 
signals while the vinylic CH shifted to the product resonance.   Only one vinylic CH 
NMR signal was observed in each case indicates that only the E-isomer of the alkene 
was formed in detectable amounts.  The 31P NMR resonances of the products were 
within 0.5 ppm (CDCl3) of the starting materials.  
 
 
 
Figure 5.4.  Alkene-phosphite chirons 27g – h, and 28g – h, could be joined via alkene 
metathesis.  
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Test reactions performed using mixtures of ligands 27 and 28 gave mixtures with 
complicated 1H and 13C NMR spectra. 31P NMR signals of the products in the crude 
reaction mixtures could not be resolved, and we were unable to separate the components 
of the mixture using either normal or reverse phase HPLC because they all had very 
similar polarities.  In retrospect it is clear that the polarity of products in these metathesis 
reactions are dominated by the amine-alkaloid parts; adding different hydrophobic 
fragments to the phosphite does not impart differences that are large enough even to see 
the isomers by analytical HPLC.  
 
5.2.3 Crude metathesis reactions do not give viable hydrogenation catalysts 
There have been reports of hydrogenation reactions mediated by Ru-based 
complexes for metathesis.203  However, these processes did not feature trisubstituted 
alkenes without coordinating functional groups (CFGs) for which exceptional 
hydrogenation catalysts are required,16 so it was necessary to test if complexes like V 
could mediate hydrogenation.  In the event, most of alkenes in these projects were tested 
hydrogenation mediate by V. The results indicated that in some substrates (Figure 5.5 
and 5.7), catalyst V did not hydrogenate the alkenes.  The same catalyst, however, did 
hydrogenate some of trisubstituted contains coordinating functional group (Figure 5.6 
and 5.8) giving only <2 % of products under the condition indicated.    
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Figure 5.5.  a Catalyst V did not mediate hydrogenation of E-1,2-diphenylpropene under 
the conditions shown.  b Catalyst V was used to mediate metathesis, then hydrogen and 
a trisubstituted alkene were introduced; the latter was not hydrogenated.  
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Figure 5.6.  a Catalyst V gave less than 2 % of product from hydrogenation of α-
cinnamic acid W under the conditions shown.  b Catalyst V was used to mediate 
metathesis, then hydrogen and a trisubstituted alkene were introduced; the latter was 
hydrogenated with less than 2 %.  
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Figure 5.7.  a Catalyst V did not mediate hydrogenation of hydroxy-ester X under the 
conditions shown.  b Catalyst V was used to mediate metathesis, then hydrogen and a 
trisubstituted alkene were introduced; the latter was not hydrogenated.  
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Figure 5.8.  a Catalyst V gave less than 1 % of product from hydrogenation of acetoxy-
acid Z under the conditions shown.  b Catalyst V was used to mediate metathesis, then 
hydrogen and a trisubstituted alkene were introduced; the latter was hydrogenated with 
less than 1 %.  
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5.2.4 Hydrogenations of cinnamic acids derivatives with monodentate 
ligands   
Hydrogenations of α,β-unsaturated acids and esters (see below) can be used to 
make chirons for polyketide-derived natural products and other materials,33,90 but these 
reactions with simple substrates are difficult to perform with high enantioselectivities.11  
Consequently we decided to test combinations of our ligands in these reactions, 
beginning with a substrate that is relatively easy to hydrogenate with significant 
enantioselectivity, α-methylcinnamic acid W. 
The first step in probing the featured hydrogenation reactions was to establish 
“baseline data” representing enantioselectivities obtained using the monodentate ligands, 
ie precursors to the fragments to be connected via metathesis.  Figure 5.9 showed that 
catalysts formed in situ from Ir(COD)2 BARF and ligand 27g in a ratio of approximately 
1:2 gave complete conversion to product with an ee of 60 %.   
At this stage we choose to check the effects of adding an achiral ligand.  Figure 
5.9 (right side) shows data for the experiment in which the reaction described above was 
repeated using a mixture of Ir(COD)2 BARF, 27g, and PPh3 in a ratio of approximately 
1:2:1 complete conversion and 64 % ee was observed.   On the basis of these 
observations, no more tests were performed with the achiral PPh3 additive because no 
significant enhancement in ee was obtained when it was added.  Curiously, when the 
same reaction was run using a ~1:1:1 ratio of Ir(COD)2 BARF, 27g, and PPh3 the 
product was again formed exclusively, but it was racemic (Figure 5.9, center); this 
observation gave more support to the decision not to investigate PPh3 as an additive 
more extensively. 
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Figure 5.9.  Hydrogenation of α-methylcinnamic acid W using catalysts formed from 
27g with and without PPh3. 
 
 Another series of experiments was performed to compare rhodium- and iridium-
based catalyst precursors in reactions using mixtures of the monodentate ligands 27g, 
27h, 28g, and 28h; these data are shown in Figure 5.10.  Throughout, 100 % conversion 
to the product was obtained under the conditions indicated.  The data in Figure 6 clearly 
shows that the iridium complexes featured in part a generally gave superior 
enantioselectivities when compared to their rhodium analogs (b).  For the Ir-data in part 
a, all the homo-combinations gave superior enantioselectivities than the 
heterocombinations (eg experiments with ~2 equivalents of ligand 27g, and with ~2 
equivalents of ligand 27h, both gave better enantioselectivities than when 27g and 27h 
were used together in a 1:1 ratio; top of part a).   In the Rh-series (part b) there are 
heterocombinations that proved to be more enantioselective than one of the homo-
combinations, but never both. 
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a  M = Ir 
 
Figure 5.10.  Hydrogenation of α-methylcinnamic acid W using catalysts formed from 
the monodentate ligands 27g, 27h, 28g, and 28h with: a Ir(COD)2+; and, b Rh(COD)2+. 
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b  M = Rh 
 
Figure 5.10.  Continued. 
 
5.2.5 Hydrogenations of α ,β-unsaturated ester derivatives with monodentate 
ligands 
From the perspective of potential users, reduction of α-methylcinnamic acid W is 
probably less interesting than the corresponding reactions of α,ω-functionalized 
substrates like the alcohol X shown in Figure 5.11a, or the acetate Y shown in Figure 
5.11b.  Data were collected only for the Ir-based complexes because such catalysts tend 
to be more suitable for this type of substrate (ie where the catalyst can be ligated by N,P-
ligands and the substrate has functional groups that are only weakly coordinating),11 and 
because Ir-based complexes were superior to the Rh-based ones for substrate W.   
For alcohol X, Figure 5.11a shows that homocombinations of ligand 27g (blue 
bars) gave the best enantioselectivities.  Just as in Figure 5.10, enantioselectivities for 
some heterocombinations (yellow bars) are superior to one homocombination, but there 
was no heterocombination that was superior to both the corresponding 
homocombinations.  
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Figure 5.11.  Hydrogenation of: a hydroxyester X; and b acetoxyester Y using catalysts 
formed from the monodentate ligands 27g, 27h, 28g, and 28h with: Ir(COD)2+. 
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Figure 5.11.  continued. 
 
5.2.6 Hydrogenations of α ,β-unsaturated ester derivatives with bidentate 
ligands formed via metathesis   
Having established enantioselectivities for the hydroxyester X and the 
acetoxyester Y using monodentate ligands, we then used metathesis to form bivalent 
ligands from the same quinidine- and quinine-based phosphites in situ and tested these.  
For example, in Figure 5.11, 27g + 27h refers to the combination of monodentate 
ligands, whereas in Figure 5.12, where these same monodentate ligands are subjected to 
metathesis as in Figure 5.4, 27g’ - 27h’ refers to that heterocombination (which contains 
two homodimers and one heterodimer; see above).  The bars in Figure 5.12 show the 
enantioselectivity differences obtained relative to the corresponding hydrogenations 
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with the corresponding combinations of monodentate ligands; positive values indicate 
the dimer combinations gave superior enantioselectivities.  Throughout, the sense of the 
enantioselection is governed by the binaphthyl chirality, series g gives the S-enantiomer 
while the R-enantiomer is consistently formed from the h series. Enantioselectivity 
values (as opposed to differences) are indicated by the numbers on the bars themselves.  
Thus an improvement of up to 37 % ee was observed under the metacatalysis for the 
hydroxyester X (Figure 5.12a), and up to 34 % for the acetoxyester (5.12b).  
Interestingly, the same metacatalysis combination, 27h’ – 28g’, gave the maximum 
improvement for the hydroxyester X and the acetoxyester Y.  However, the overall best 
selectivities for these reactions were in the monomer combination series (27g + 27g in 
Figure 5.11a and b) and not for the dimers formed via metacatalysis.  
Finally, we decided to test one of the carboxylic acid substrates that correspond 
to one of Figure 5.12.  For these experiments the acetoxy acid Z was selected because 
acetates gave marginally higher enantiosectivities than the alcohols for the esters in 
Figure 5.11 with monodentate ligands.  Data for hydrogenation of the acetoxy acid Z 
(Figure 5.13) show a maximum improvement of 32 % ee (for 28g’ – 28g’). The best 
overall selectivity for the carboxylic acid hydrogenations in Figure 5.11 is for 28g + 28g 
and 28g’ – 28g’, ie the same combination in the monomer (a) and dimer (b) series.  The 
optimal enantioselectivity was superior for the dimers (b) from metacatalysis relative to 
the monomers (a) (92 vs 60 % ee for the combinations involving 28g). 
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Figure 5.12.  Hydrogenation of hydroxyester X (a) and acetoxyester Y (b) using 
catalysts from the monodentate ligands 27g, 27h, 28g, and 28h after metathesis (as in 
Figure 5.4) then addition of Ir(COD)2+.  The bars are calibrated to the corresponding 
combination of monodentate ligands, and the overall enantioselectivities are indicated by 
the numbers on the bars. 
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Figure 5.12.  continued. 
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Figure 5.13.  Hydrogenation of the acetoxy acid Z using: a catalysts from the 
monodentate ligands 27g, 27h, 28g, and 28h; and b from the same ligands after 
metathesis (as in Figure 5.4).  The bars in part b are calibrated to the corresponding 
combination of monodentate ligands, and the enantioselectivities are indicated by the 
numbers on the bars. 
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Figure 5.13.  continued. 
 
Data was also collected for hydrogenation of the acetoxy acid Z with and without 
metacatalysis using Rh(COD)2+ {rather than Ir(COD)2+ as in Figure 5.13}.  Some of the 
reactions with metacatalysis showed improvements relative to the ones without, but the 
best overall enantioselectivity (75 %) was observed for a monomer combination.  This 
data is shown in the supporting materials. 
 
5.3      Conclusions 
These studies have shown that ligands can be formed via metathesis reactions, 
then used in hydrogenation catalysts formed in situ, thus the concept of metathesis then 
catalysts, metacatalysis, is validated.  Residual ruthenium complexes from the 
metathesis steps do not mediate hydrogenations of the substrates studied here.  Relative 
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to controls with monomeric starting materials (series 27 and 28), metacatalysis can have 
positive and negative effects on the enantioselectivities (see Figure 5.9 and 5.10b).  Only 
four monomeric starting materials were used (27g and h, 28g and h) to explore 
metacatalysis here, but in general for n ligands there would be n(n + 1)/2 possible 
combinations; if n is a larger number many combinations can be generated (eg for n = 
10, the number of possibilities is 55)204 so, just like mixing monodentate ligands, this is 
an effective form of combinatorial catalysis.205-208  Overall enantioselectivities observed 
(up to 92 %) were good but not excellent, and there are several obvious reasons why this 
might be so.  Throughout, the bisphosphites formed in this study would form huge 
chelates if they complexed in the MPP form, so they are likely to be somewhat flexible.  
Moreover, the alkene formed between the two monomeric fragments is almost certainly 
reduced in these reactions, and rapidly compared with the more substituted alkene 
substrates, hence the ligands change early in the hydrogenation.  On the other hand, one 
of the objectives we had at the onset of this study was to see if we could find ligands via 
metacatalysis that were effective despite these factors, and indeed enantioselectivities of 
up to 92 % ee were obtained.  Rational design is most effective for relatively simple 
systems for which some parameters can be predicted with certainty, whereas 
combinatorial methods tend to be relatively more effective as the opportunities for 
rational design diminish.   
This research has shown that the dominant parameter governing 
stereodifferentiation by ligands 27 and 28 is the alkoxy P-substituent, and binaphthyl 
was the best studied here.  The alkaloid fragment in the ligands has much less impact 
than the binaphthyl.  Metathesis coupling of the alkaloid fragments is relatively slow, 
requiring 12 h in refluxing dichloromethane, though, given time, conversion to the 
dimeric forms 27’ and 28’, was near complete.   
The most enantioselective catalyst found in this study was from the metathesis 
coupling product 2g’ – 2g’ (92 % ee, Figure 8b, third entry).  This ligand, 2g’ – 2g’, is a 
homo-combination so it was not necessary to deconvolute mixtures from hetero-
combinations to find the best ligand-metathesis products: we were able to demonstrate 
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proof of concept without doing that.  This is fortunate because, as alluded to above, the 
polarities of these particular molecules are dominated by the huge and similar alkaloid 
parts, hence we were unable to separate the various metathesis combinations even by 
analytical HPLC.  There is an important conclusion to be drawn from this: separations in 
metacatalysis can be problematic, so the “end game” in the method is likely to be easiest 
to implement if the alkenes combined have different polarities or other features that 
make homo- and hetero-combinations separable. 
Based on observations from this work, further studies of metacatalysis might 
focus on ligand fragments that give more distinct differences between homo- and hetero-
dimeric products.  That strategy would be desirable because mixture analyses would be 
easier, and the diversity of ligands created would be greater.  Another obvious 
modification would be to use alkene-monomers with potential complexing atoms that are 
closer to the metathesis site.  This strategy would produce smaller chelates, but it is 
somewhat limited by the undesirable potential for deactivation of the metathesis catalyst 
by association of the complexing atom to the ruthenium carbene center.  For this reason, 
the design of the alkene-monomers requires careful consideration. 
Metacatalysis need not be restricted to hydrogenation reactions.  Indeed, one intriguing 
possibility for alkaloid-based ligands would be to explore oxidation processes including, 
and related to, Sharpless’ dihydroxylations, for which cinchona alkaloids are known to 
be highly effective.209  Moreover, there are possibilities for using other transformations 
to join monomeric fragments in situ, the only obvious restrictions being that they should 
be efficient and generate no by-products that adversely effect the subsequent reactions.  
We suggest metacatalysis is an option for expanding the combinatorial methodology 
established by Reetz and others, and it has the advantage of generating diverse, 
potentially chelating ligands. On a broader level, our method complements others that 
allow generation of diverse libraries of bidentate ligands by combining monodentate 
ones;204,210-237 notably, those include dynamic combinatorial libraries formed from 
fragments having complementary H-bonding topologies.238-244 
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CHAPTER VI 
LIGHT ACTIVATED LIGANDS FOR CATALYTIC REACTIONS  
 
6.1       Introduction  
Most of catalytic reactions are usually driven by thermal energy or microwave 
irradiation.  These sources of energy mostly eliminated dangerous byproducts; for 
example, CO2 from burned charcoal is pollutants leading to global warming.  Moreover, 
both thermal energy and microwave irradiation, at present, use electricity that needs to 
be produced and hard to be stored.  Light, however, is a natural abundance source and 
excellent green energy that can reduce the use or generation of hazardous chemicals.   
Many applications using light mostly involved radical reactions, chemosensors or 
photosensitizers that generated electron transfer in reactions to be potential ligands for 
REDOX chemistry (example shown in Figure 6.1).  In most cases, especially radical 
reactions, the purpose of use light as energy is to avoid harsh conditions to overcome 
activation energy in limiting step; for instance, Heck reaction, one of typical carbon–
carbon bond formation, need at least 60 oC to get good conversion. 
Carbon–carbon bond formation using metal catalyzed reaction is useful with 
widely application in organic synthesis.  Instead of using thermal conditions, light can be 
used to start catalytic cycle via radical reactions.  Simple starting materials, however, 
require high energy to generate radicals; for example, C-H bond requires far UV (l <220 
nm) to reach excited state.  Improving by lower the energy requirement could be 
accessible by using photosensitizers to transfer electron or energy to reagents in catalytic 
cycle (Figure 6.2).   Electron transfer in catalysis has usually been studied for reduction 
of CO2,245 but intermolecular processes,246,247 usually featuring (bipyridyl)3Ru(2+),248,249 
have been known for some time, even featuring organocatalysis.250 
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Figure 6.1.  Examples of light absorption substrates and their applications. 
 
 
Figure 6.2.  Using photosensitizers to transfer electron or energy to reagents in catalytic 
cycle. 
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For energy transfer, there are very few examples of photo-driven catalytic 
reactions.251 Konig’s work is the best one in literature reported about Suzuki/Stille 
mediated by Pd(PAr3)4, Ar = pyrene, to couple phenyl boronic acid with 4-BrC6H4Me 
under irradiation at 361 – 375 nm from a UV diode array (Figure 6.3b).252  The results 
indicated reactions gave selectivity for heterocoupling products. Furthermore, reactions 
did not proceed in the dark, but proceed again when light was irradiated.  Other 
examples feature ruthenium complexes in which ruthenium is in electronic 
communication with palladium.253,254  This complex has been shown to mediate head-to-
tail coupling of 2-phenylpropene (Figure 6.3c). 
 
 
 
Figure 6.3.  a Energy transfer diagram for catalytic reactions and examples of catalysts;  
b Pd catalyst for Suzuki/Stille reactions and c Ru /Pd for polymerization. 
 
Our group has been interested in the energy transfer, but not electron transfer, 
and has synthesized many dyes for cell-imaging works.  We, however, never use those 
dyes in light activated catalytic reaction because they lack of ability to become ligand to 
metal. 
As a result, we proposed to synthesize ligands that could be effective and suitable 
for photo-driven catalysis.  The desired ligands were considered to have chromophores 
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that absorb UV visible light with high absorptivities, and would otherwise fluoresce.  
Moreover, these chromophores should be connected to metal by electronic conjugation 
(Figure 6.4), so that energy transfer to the metal can take place through bonds, as well as 
through space.  By using direct conjugation, we hypothesized that energy transfer will be 
similarly efficient to cell-imaging dyes and could be applied to ligands in photo-driven 
catalysis. 
 
 
Figure 6.4.  Energy transfer from donor to metal by through space energy transfer a; and 
through bond energy transfer b. 
 
To get the best advantage, we proposed to use Heck reaction.  In general, this 
reaction using phosphine ligands usually requires high temperature and high catalyst 
loading.  Carbene ligands, however, could help decrease catalyst loading to about 0.1 – 1 
%.  There, we desired to synthesize the carbenes attached with chromophores and 
studied the Heck reaction using low temperature. 
 
6.2       Results and discussion 
We proposed to synthesize ligands that could be effective and suitable for photo-
driven catalysis.  The desired ligands were considered to have chromophores that absorb 
UV visible light with high absorptivities, and would otherwise fluoresce.  Carbenes 
ligands were suitable in this case because they conjugate directly to the metal and 
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catalysts could be used in many catalytic reactions.  Moreover, pyrene was selected as 
chromophore due to it strong absorbance under UV-visible (Figure 6.5). 
 
 
Figure 6.5.  N-Heterocyclic carbenes containing pyrene as chromophore. 
 
Precursors of carbenes, imidazolium and imidazolinium salts were synthesized 
from same diimine starting materials that was obtained from condensation of 1-
aminopyrene with glyoxal under acidic condition.   Reaction of diimine with 
formaldehyde gave imidazolium salt about 85 % (Scheme 6.1).  To obtain another 
carbine precursor, diimine was reduced to corresponding diamine followed by 
condensation with trimethyl orthoformate yield imidazolinium salt about 78 % (Scheme 
6.2).   
 
 
 
Scheme 6.1. Synthesis of imidazolium salt 30. 
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Scheme 6.2. Synthesis of imidazolinium salt 32. 
 
Table 6.1 shows the results of Heck reactions using ethyl acrylate and 2-
bromotoluene. Pd sources, catalyst loading, bases, and solvent varied to obtain 
optimization condition.  Unfortunately, the highest conversion of the reaction was only 3 
% conversion when imidazolium salt was used as precursor of carbene combined with 
0.05 Pd2(dba)3 and tBuOK.  The rest of conditions gave only trace amount of product.  
Same results were obtained when imidazolinium salt was used as a carbene precursor as 
shown in Table 6.2.   
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Table 6.1. Heck reactions using imidazolium salt 30 as light activated ligands. 
 
Pd Pd (eq) Base 
Alkene 
(eq) Solvent 
Conversion 
(%)a 
      
Pd(OAc)2 0.01 tBuOK 1 DMF trace 
Pd(OAc)2 0.01 tBuOK 1 THF trace 
Pd(OAc)2 0.01 tBuOK 1 EtOH trace 
PdCl2 0.01 tBuOK 1 THF trace 
Pd2(dba)3 0.01 tBuOK 1 THF <1% 
Pd2(dba)3 0.01 tBuOK 10 THF 2% 
Pd2(dba)3 0.05 tBuOK 10 THF 3% 
Pd2(dba)3 0.01 K2CO3 10 THF <1% 
Pd2(dba)3 0.01 Cs2CO3 10 THF <1% 
 aConversion determined by GC 
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Table 6.2. Heck reactions using imidazolinium salt 32 as light activated ligands. 
 
Pd Pd (eq) Base 
Alkene 
(eq) Solvent 
Conversion 
(%)a 
      
Pd(OAc)2 0.01 tBuOK 1 DMF trace 
Pd(OAc)2 0.01 tBuOK 1 THF trace 
Pd2(dba)3 0.01 tBuOK 1 EtOH trace 
Pd2(dba)3 0.05 tBuOK 5 THF 2% 
Pd2(dba)3 0.05 tBuOK 10 THF 3% 
 
After all results in Table 6.1 and 6.2, we were curious that the ligands were 
suitable for Heck reaction.  Therefore, we performed the standard thermal Heck coupling 
conditions using the imidazolium salt as light activated ligand (reaction 6.1).  The results 
indicated that 60 % conversion was obtained in 30 min using 60 °C in DMF and reaction 
reached 100 % conversion at 80 °C in 1 h.  
 
 
 reaction 6.1 
 
All results indicated that the new light absorbing carbenes were excellent ligands 
for Heck coupling under thermal condition but unable to perform as the catalyst using 
light activation.  Considered of both precursors of carbene, there is possibility that 
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pyrene is big and forms perpendicular with core of imidazole.  Therefore, the pyrene 
would possibly not conjugate with imidazole leading to only through space energy 
transfer in the reaction that was not the proposed of our study. 
Therefore, we designed a new carbene ligand 33 (Figure 6.6) to obtain good 
conjugation; it has strong absorption and fluorescence.   As a result, fluorene, the 
precursor of many dyes, was chosen as the best choice because of its absorption and 
commercially available. 
 
 
Figure 6.6.  Structure of compound 33. 
 
2-Iodofluorene was synthesized by the known method255 followed by alkylation 
under basic condition yielded 9,9-dimethyl-2-iodofluorene.  Nitration followed by SNAr 
with 2,6-diisopropylaniline gave 2-amino-9,9-dimethyl-3-nitrofluorene derivative. The 
product, then, was reduced to give 2,3-diamine derivatives. Finally, reduction product 
was reacted with trimethyl orthoformate under acid condition give fluorene-2,3-
imidazole 37 (Scheme 6.3). 
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Scheme 6.3. Synthesis of imidazole 37 from fluorene derivatives. 
 
The final imidazole was investigated in two ways.  First, reaction of resulting 
imidazole with methyliodide yielded imidazolium salt as carbene precursor to study 
Heck reactions as previously mentioned above (reaction 6.4).  Second, the same 
imidazole was reacted with iodo-oxazoline30 to give the corresponding carbene 
precursors that were converted to the iridium complexes (Scheme 6.4). The final 
complex was used for studying hydrogenation of unfunctionalized alkenes or alkenes 
without coordinating functional groups. 
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reaction 6.2 
 
 
reaction 6.3 
 
 
Scheme 6.4. Synthesis of hydrogenation catalyst 39 containing chromophore derived 
from fluorene. 
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Using the same conditions for Heck reaction previously mentioned above, 
imidazolium ligand (33) derived from fluorene, unfortunately, could not be able to give 
the product under both thermal and light activated conditions (reaction 6.4).  Therefore, 
we moved our attention to the asymmetric hydrogenation reaction.  First, α-
methylstilbene was tested to confirm that catalyst was effective and excellent conversion 
was obtained with good stereoselectivity.  Other substrates, then, were tested using 
Burgess’ oxazoline-imidazole iridium catalyst to confirm that they cannot be 
hydrogenated under 1 bar of H2.  Methyl tiglate (reaction 6.5), tiglic alcohol (reaction 
6.6), and cyclic compounds were chosen to investigate hydrogenation.  The new light 
activated catalyst, however, cannot perform any hydrogenation.   
 
 
reaction 6.4 
 
 
reaction 6.5 
 
 
reaction 6.6 
 
To explain this situation, we tested UV and fluorescence to the new catalyst.  The 
results indicated that the new catalyst absorbed at the new wavelength compared to 
precursor ligand and fluorescence at another wavelength.  As a result, a wavelength used 
for activation would excite the new catalyst without energy transfer to metal and the 
activated catalysts might not be suitable for any reaction due to their excited state. 
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The results from Heck reaction could be explained using thermal condition.  We 
believed that the activated catalyst released the fluorescence acted as new source of 
energy for reaction.  As a result, the solution mixture was little heated up cause the Heck 
reaction to yield the products up to only 3 %. 
 
6.3       Conclusions 
The new carbene precursors with chromophore for light absorption catalytic 
reaction, N,N’-dipyrenyl-imidazolium salt, N,N’-dipyrenyl-imidazolinium salt and 
fluorene-2,3-imidazole, were synthesized and used to investigate Heck reactions and 
asymmetric hydrogenations.  The carbene ligands with chromophores were excellent 
catalyst under thermal conditions as shown in Heck reactions. The catalysts, however, 
could not perform as light activated catalysts under room temperature.  Moreover, the 
new fluorene-2,3-imidazole ligand also could not be used in asymmetric hydrogenation 
because whole molecule of catalysts were probably excited without energy transfer.  To 
investigate performance of catalysts further, REDOX reactions probably gave some 
results that could be suitable for the energy and electron transfer in catalytic reactions. 
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CHAPTER VII 
SYNTHESIS AND INVESTIGATION OF NEW P,N-LIGANDS DERIVED FROM 
2-OXO-IMIDAZOLINE FOR ASYMMETRIC HYDROGENATION 
 
7.1       Introduction  
During the past decades, stereoselective hydrogenations have gained attention by 
several chemists because it is an attractive methodology used for synthesizing natural 
products.  Many chiral analogs of Crabtree’s catalysts were synthesized and studied 
hydrogenation of unfunctionalized alkenes. Moreover, they were applied to hydrogenate 
alkenes without coordinating functional groups, such as ester, silyl ether, enol ethers, 
etc.11,16,21,84   Even though several catalysts have been introduced, none of these catalysts 
is perfect for hydrogenation every substrate.  Design of the new ligands is one possible 
method to screen and discover new excellent catalysts.   
Imidazoles and imidazolines were often used as sources of N-heterocyclic 
carbene ligands.  The 2-substituted-imidazoles and -imidazolines, however, cannot be 
used for this purpose.  The compounds can be used as ligands for asymmetric catalysis 
because they have two nitrogens to serve as coordination sites.  Figure 7.1 shows 
examples of ligands derived from imidazole that use nitrogen as chelation part.  Using 
this new designed complexes were able to perform as promising candidates for 
application in a wide range of asymmetric reactions such as the Henry reaction,256 
conjugate addition,257 addition of dialkylzinc to aldehydes,258 allylation,259 epoxidation 
and cyclopropanation, 260 oxidation261 or transfer hydrogenation.262 
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Figure 7.1. Examples of imidazoles derivatives served as N-chelation ligands. 
 
To the best of my knowledge, most of catalysts synthesized so far using N-
chelation from oxazolines, pyridines, primary amines, and thiazoles.  In this project, I 
would like to introduce the first chiral analogs of Crabtree’s catalyst 40 derived from 
phosphine and 2-oxo-imidazoline derived from (R),(R)-1,2-diphenylethylenediamine 
(Figure 7.2).  Different commercially available phosphines have been used to synthesize 
a small library of ligand in this set for comparison resulting to finding high 
stereoselective ligands for unfunctionalized and non-coordination functional group 
alkenes. 
 
 
Figure 7.2. Structure of new hydrogenation P,N-iridium catalysts derived from 2-oxo-
imidazoles. 
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7.2       Results and discussion 
Syntheses of catalysts were divided into two parts, 2-chloro-imidazoline 
derivatives and 2-dialkylphosphino-phenol.  The former was synthesized by using BOC 
protected (R),(R)-1,2-diphenyl-ethylenediamine, prepared using a known literature 
procedure,263 reacted with iodomethane to form N,N’-di(BOC)-N-methyl-(R),(R)-1,2-
diphenyl-ethylenediamine.  Deprotection of the BOC group gave mono-N-alkylated 
product 41, N-methyl-(R),(R)-1,2-diphenyl-ethylenediamine,  in moderate yield.  
Compound 41 was reacted with 1,1-carbodiimidazole to obtain N-methyl-4,5-
diphenylimidazolidin-2-one which was converted to 2-chlro-N-methyl-4,5-
diphenylimidazolidine using phosphorus oxychloride (Scheme 6.1). 
 
 
 
Scheme 7.1. Synthesis of 2-chloro-N-methyl-4,5-diphenylimidazolidine. 
 
The phosphine parts were synthesized strarting from MOM-protected phenol.  
Directing group ortho-deprotonation compounds using n-butyllithium were reacted with 
corresponding electrophiles, chlorodisubstitutedphosphine, to obtain 2-dialklphosphino-
MOM-protected phenol.264  MOM-Deprotection under acid condition gave 2-
dialkylphosphino phenols (Scheme 6.2) in good yield.  Three different phosphines, e.g. 
phenyl, cyclohexyl and isopropyl, were chosen to study steric and electronic properties  
of the catalysts 40. 
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Scheme 7.2. Syntheses of 2-dialkylphosphino-phenol. 
 
After getting two parts in-hand, phenol derivatives were reacted with 2-chloro-N-
methyl-4,5-diphenylimidazolidine under basic condition to obtain the corresponding 
ligands.  Reaction of the appropriated ligands with [Ir(COD)Cl]2 followed by anion 
exchange with NaBARF gave the corresponding catalysts 40 in moderate yield (Scheme 
6.3).   According to this procedure, all catalysts were obtained by using cheap starting 
material except the chiral  (R),(R)-1,2-diphenyl-ethylenediamine.  Even though the 
procedure is easy, the product of many reactions need to be purified by flash 
chromatography under a harsh condition such as CH2Cl2, CHCl3 and MeOH.  
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Scheme 7.3. Syntheses the P,N-iridium catalyst 40 for asymmetric hydrogenation. 
 
Table 7.1 shows the hydrogenation results using catalysts 40a – c.  
Hydrogenation of unfunctionalized alkene, 1,2-diphenylpropane, was first investigated 
using these catalysts because it is the most widely studied substrate for asymmetric 
hydrogenations using chiral Crabtree’s catalyst analogs.16  The results indicated that 
these catalysts were effective as hydrogenation catalyst with good enantioselectivities.  
Substrates without coordinating functional group, especially acyclic and cyclic esters, 
were then hydrogenated to obtain the moderate selectivities.  The results showed that 
catalyst 40c, the diisopropylphosphino phenol derivative, was the best catalyst in most 
cases.  The only case that catalyst 40b give better result than 40c is the hydrogenation of 
lactone that 40b can give 28 % ee.  Only one olefin with coordinating functional group, 
carboxylic acid, was tested in this study. The results, however, indicated that all catalysts 
were not suitable for both lactone and carboxylic acid substrates. 
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Table 7.1.  Hydrogenation result using Ir-catalyst 40. 
 
Alkenes 
40 
a b c 
 
91 93 94 
 
55 58 60 
 
50 55 75 
 
10 28 15 
 
18 28 30 
 
According to data obtained from Table 7.1, further study can be possible 
achieved by synthesizing more catalysts using many commercially available phosphines 
to make a larger library and then investigate the asymmetric hydrogenation to obtain 
better selectivities.  Moreover, only one chiral, (R),(R)-1,2-diphenyl-ethylenediamine, 
was used in this study.   Other chiral ethylenediamines can be used to prepare 2-chloro-
imidazolines to compare different chiral environment for asymmetric reactions. Another 
investigation of this research can be obtained from different alkene substrates because it 
is possible that the catalysts were suitable for substrates that were not included in this 
study. 
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7.3       Conclusions 
The new chiral analogs of Crabtree’s catalyst derived from 2-oxo-imidazoline 
were introduced and proved to be effective for hydrogenation reactions with 
unfunctionalized alkenes.  In addition, the catalysts were also used to hydrogenate olefin 
without coordinating functional group provided moderate enantioselectivities for acyclic 
ester derivatives and poor stereoselectivity for cyclic ester.  In order to gain higher 
selectivity, synthesis of larger library should be obtained to find the best catalyst in this 
structure. Moreover, the catalyst might not be suitable for the compounds tested in this 
study.  Varying the substrates might provide suitable structures that can be hydrogenated 
with high stereoselectivities. 
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CHAPTER VIII 
CONCLUSIONS AND OUTLOOK 
  
8.1 Conclusions 
8.1.1 Syntheses useful chirons using chiral Crabtree’s catalyst 
Asymmetric hydrogenations of non- or weakly-coordinating functional group 
alkenes have been used to prepared useful chirons for syntheses many natural products.  
Chiral analogs of Crabtree’s catalyst have privilege to this type of alkenes yielded high 
stereoselectivities.  Several substrate vectors were used to obtain the highest 
stereoselectivities by manipulating: (i) protecting groups; (ii) functional groups; and (iii) 
alkene geometry. 
We have demonstrated the application of Chiral Crabtree’s catalysts, especially 
catalyst 1, for hydrogenation allylic amines as new approaches to α,γ-amino acid 
derivatives.  The excellent diastereoselectivities of hydrogenation provided an 
opportunity to apply this method to chiral natural products with different substituents 
varying from α-amino acids. 
 
 
Figure 8.1. Useful compounds from chirons prepared via stereoselective hydrogenation. 
 
Catalyst 1 has also been applied to scalable synthesis of homo-Roche ester which 
could give more than ten grams of product.  The catalyst, however, gave only good but 
not excellent selectivity up to 94 % ee.  Fortunately, the homo-Roche ester could be 
converted to five-membered lactone and then recrystallized under cold condition to 
provide enantioenriched homo-Roche ester.  Modification of this compound to generate 
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α-substituted homo-Roche ester derivatives via organocatalysis has provided useful 
compound such as γ-hydroxyvaline. 
 
8.1.2 Varying electronic effect using different carbenes as new catalysts for 
hydrogenation 
Structure of catalyst 1 can be easily modified using different N-heterocyclic 
carbenes, imidazolinylidene and benzimidazolylidene.  Three different N-heterocyclic 
carbenes provided different electronic effect to the iridium catalysts.  New iridium 
catalysts have performed as good asymmetric hydrogenation catalysts.  The results 
indicated that small electronic effect could be negligible and catalysts provided no 
different catalytic activity in term of stereselectivity. 
 
8.1.3 Syntheses new ligands with N,P and P,P-iridium catalysts for 
asymmetric hydrogenation  
Many new ligands were synthesized using to investigate asymmetric 
hydrogenation of largely unfunctionalized alkenes such as esters, alcohols and 
carboxylic acids.  First, the new ligands contained cinchona alkaloid phosphite 
derivatives to give monodentate ligands.  The results indicated that the phosphite 
containing quinidine, or quinine, and binaphthol (Figure 8.2) gave the best 
stereoselectivity in this series.  This study also showed that combination of metathesis to 
convert mono-dentate into bi-dentate ligands with catalysis (in here refer to 
“metacatalysis”) could give the better selectivity in some cases.  
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Figure 8.2. Example of new ligands derived from quinidine and binaphthol. 
 
Second, another ligands were redesigned to use different N-chelating site 
synthesized from 2-oxo-imidazoline to give new phosphine-2-oxo-imidazoline ligands 
(Figure 8.3).  The new P,N-iridium catalysts were proved to be effective as asymmetric 
hydrogenation catalyst on certain substrates. 
 
 
Figure 8.3. New ligands derived from 2-oxo-imidazoline. 
 
Finally, N-heterocyclic carbenes were modified to have chromophores (Figure 
8.4).  These gave new ligands that have an ability to absorb UV-Visible light and 
possibly used light to activate the catalysts.  Even though, the ligands were effective in 
Heck reactions under thermal condition. They, unfortunately, were ineffective under 
light absorption condition.  Moreover, the same results were obtained from 
hydrogenation reaction. 
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Figure 8.4. New ligands with chromophores for light absorption reactions. 
 
8.2 Outlook 
8.2.1 Syntheses of natural products via hydrogenations 
During my research studies, our group has developed many methodologies for 
the syntheses of many chiral building blocks.  One of my research studies was involved 
with syntheses of γ-amino acid derivatives that could be used to synthesize part of 
tubulysins, potential anticancer natural products isolated from a strain of myxobacteria 
(Figure 8.5). 
 
 
Figure 8.5. Tubulysins, natural products containing γ-amino acid derivatives. 
 
According to the structure, tubulysins contained another γ-amino acid derivatives 
but not the one in my research.  Previous data from Dr. Ye Zhu in our group indicated 
that catalyst 1 could hydrogenate enol ethers without isomerization.  Combination of 
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both data gave possible opportunity to hydrogenate alkene in Figure 8.6 in order to 
obtain another fragment then connected with the other amino acids to obtain tubulysins. 
 
 
Figure 8.6. Other alkene fragment that possibly be hydrogenated with catalyst 1. 
 
8.2.2 Syntheses of new energy transfer ligand for light activation reaction 
Due to the energy transfer problems, the next investigation of the project might 
be using the longer conjugation with some connections that allow direct through-bond 
energy transfer; for examples, triazole synthesized from click chemistry and alkyne 
could be used to extend the conjugation (Figure 8.7).  Using this method, the absorption 
energy would be only at the chromophores then energy could transfer to the metal 
catalytic site to activate the catalytic reaction. 
 
 
Figure 8.7.  N-Heterocyclic carbenes containing pyrene as chromophore. 
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APPENDIX A 
GENERAL EXPERIMENTAL PROCEDURES 
 
 A. General Methods 
All reactions were carried out under an atmosphere of dry nitrogen or argon. 
Glassware was oven-dried prior to use. Unless otherwise indicted, common reagents or 
materials were obtained from commercial source and used without further purification. 
All the solvents were used after appropriate distillation or purification. 
Flash column chromatography was performed using silica gel 60 (230-400 
mesh). Analytical thin layer chromatography (TLC) was carried out on Merck silica gel 
plates with QF-254 indicator and visualized by UV. IR spectra were recorded on a 
Bruker Tensor 27 spectrometer. Optical rotations were measured on Jasco DIP-360 
digital polarimeter. 1H and 13C spectra were recorded on Varian 300 (300 MHz 1H; 75 
MHz 13C), Avance 400 (400 MHz 1H; 100 MHz 13C) or Varian 500 (500 MHz 1H; 125 
MHz 13C) spectrometer at room temperature. Chemical shifts were reported in ppm 
relative to the residual CDCl3 (δ 7.28 ppm 1H; δ 77.0 ppm 13C), CD3OD (δ 3.31 ppm 1H; 
δ 49.0 ppm 13C) or d6-DMSO (δ 2.49 ppm 1H; δ 39.5 ppm 13C). Coupling constants (J) 
were reported in Hertz (Hz). The following abbreviations were used to explain the 
multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, dd = double doublet, dq = 
double quartet m = multiplet, br = broad. 
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APPENDIX B 
EXPERIMENTAL FOR CHAPTER II 
 
A. Preparation of compounds 3 – 11. 
 
Synthesis Of α-Methyl-γ-Amino Acid Derivatives 3. 
α-Methyl-γ-amino acid alkene-derivatives (E-3) and (Z-3) were synthesized via a 
known procedure.122,124,265-268 
 
(S)-E-Methyl 4-((tert-butoxycarbonyl)amino)-2-methyl-5-phenylpent-2-enoate (E-
3a).  1H NMR (300 MHz, CDCl3) δ 7.28-7.08 (5H, m), 6.56 (1H, d, J = 12 Hz), 4.72-
4.54 (2H, br), 3.75 (3H, s), 2.98 (1H, dd, J = 6.0, 14 Hz), 2.79 (1H, dd, J = 12, 18 Hz), 
1.71 (3H, d, J = 1.1 Hz), 1.43 (9H, s); 13C NMR (75 MHz, CDCl3) δ 155.4, 138.0, 137.9, 
129.9, 128.5, 126.6, 125.0, 79.9, 52.2, 50.4, 41.4, 28.6, 12.9. HRMS (ESI): Exact mass 
calcd for C18H25LiNO4 ie [M+Li]+ 326.1944. Found 326.2052. 
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General Procedure For Syntheses Of Compounds (E)-4, Illustrated For 4a 
 
 
 
The phenylalanine derivative 3a (0.9 g, 2.7 mmol) was dissolved in CH2Cl2 (20 
mL) and the solution was cooled to -50 oC.  A DIBAL solution (1M in hexane) (8.1 mL, 
8.1 mmol) was added slowly, then the reaction was stirred at -50 oC for 5 h and then 
quenched by addition of EtOAc (0.5 mL).  Saturated potassium sodium tartrate solution 
(20 mL) was added, and the mixture was warmed to 25 oC and stirred for 1 h.  The layers 
were separated, and the aqueous layer was extracted with CH2Cl2 (3 × 30 mL).  The 
combined organic extracts were dried over Na2SO4 and concentrated in vacuo.  The 
residue was purified by column chromatography using 30% EtOAc/hexanes as eluent 
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giving (S)-E-tert-butyl (5-hydroxy-4-methyl-1-phenylpent-3-en-2-yl)carbamate (4a) 
as a colorless oil (0.7 g, 2.4 mmol, 90%). 1H NMR (300 MHz, CDCl3) δ 7.32-7.18 (5H, 
m), 5.31 (1H, dq, J = 1.5, 9.0 Hz), 4.55 (2H, br), 3.97 (2H, s), 2.94 (1H, dd, J = 6.0, 13 
Hz), 2.73 (1H, dd, J = 7.2, 13 Hz), 1.51 (3H, d, J = 1.5 Hz), 1.43 (9H, s); 13C NMR (75 
MHz, CDCl3) δ 155.4, 138.0, 137.9, 129.9, 128.5, 126.6, 125.0, 79.6, 76.9, 68.1, 50.0, 
42.3, 28.7, 14.2. HRMS (ESI): Exact mass calcd for C17H25NNaO3 ie [M+Na]+ 314.1732. 
Found 314.1768. 
 
Synthesis Of The Phenylalanine Derivative (E)-5a 
 
 
 
The Boc-protected allylamine 4a (1.4 g, 4.9 mmol) was dissolved in 30 mL 
CH2Cl2  and cooled to 0 oC.  Trifluoroacetic acid (25 mL) was added in one portion, then 
the mixture was warmed to 25 °C and stirred for 3 h.  Solvent was evaporated under a 
stream of nitrogen, and the residue was dissolved in 20 mL CH2Cl2 and washed with 20 
mL saturated NaHCO3.  The aqueous layer was extracted with CH2Cl2 (2  × 10 mL).  
The combined organic layers were dried over Na2SO4 and solvent was removed in vacuo.  
The residue 5a was used without further purification.   
Allylic amine 5a was dissolved in CH2Cl2 (20 mL) and imidazole (1.2 eq) was 
then added.  tert-Butyldiphenylsilyl chloride (1.1 eq) was then added slowly and the 
resulting mixture was stirred for 1 h at 25 oC.  The reaction was quenched with saturated 
NaHCO3 20 mL and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL).   The 
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combined organic extracts were dried over Na2SO4 and concentrated in vacuo.  The 
residue was purified by column chromatography using 5% MeOH/CH2Cl2 to give 25% 
of compound 6a as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.69-7.65 (4H, m), 
7.43-7.34 (5H, m), 7.30-7.18 (6H, m), 5.43 (1H, dd, J = 1.2, 8.8 Hz), 5.30 (1H, s), 4.01 
(2H, s), 3.06 (1H, m), 2.69 (2H, t, J = 6.3 Hz), 1.48 (3H, d, J = 0.9 Hz), 1.05 (9H, s); 13C 
NMR (75 MHz, CDCl3) δ 139.2, 135.8, 135.2, 134.0, 129.9, 129.8, 128.6, 128.3, 127.9, 
126.4, 68.6, 50.8, 44.8, 27.1, 19.6, 14.0. HRMS (ESI): Exact mass calcd for C28H36NOSi 
ie [M+H]+ 430.2566. Found 430.2502. 
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General Procedure For Syntheses Of Compounds (E)-8, Illustrated For 8a 
 
Imidazole (0.7 g, 10 mmol) was added to a stirred solution of Boc-protected 
allylic amine 4a (2.7 g, 9.4 mmol) in CH2Cl2 (20 mL).  tert-Butyldiphenylsilyl chloride 
(2.5 mL, 9.9 mmol) was then added slowly and the resulting mixture was stirred for 24 
h.  Water (30 mL) was added to the reaction and the layers were separated. The aqueous 
layer was extracted using CH2Cl2 (3 × 20 mL).  The combined organic extracts were 
dried over Na2SO4 and concentrated in vacuo.  The residue was purified by column 
chromatography using 10% EtOAc/hexanes as eluent giving (S)-E-tert-butyl (5-((tert-
butyldiphenylsilyl)oxy)-4-methyl-1-phenylpent-3-en-2-yl)carbamate (8a) (4.1 g, 
82%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.68-7.66 (4H, m), 7.48-7.37 (6H, 
R = Bn, a; Me, b; iPr, c;
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m), 7.29-7.19 (5H, m), 5.41 (1H, d, J = 9.3 Hz), 4.72-4.50 (1H, br), 4.50-4.39 (1H, br), 
4.01 (2H, s), 3.05-2.90 (1H, m), 2.75 (1H, dd, J = 7.5, 13 Hz), 1.47 (9H, s), 1.44 (3H, s), 
1.09 (9H, s); 13C NMR (75 MHz, CDCl3) δ 155.1, 137.8, 137.2, 135.6, 135.5, 133.6 (2 
peaks), 129.8, 129.7, 128.2, 127.7, 126.2, 123.0, 79.2, 67.8, 49.6, 42.2, 28.5, 26.9, 19.3, 
13.8.  HRMS (ESI): Exact mass calcd for C33H43LiNO3Si ie [M+Li]+ 536.3172. Found 
536.3175. 
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General Procedure For Syntheses Of Compounds (E)-6, Illustrated For 6a 
 
A dioxane solution of 4M HCl (3.0 mL, 12 mmol) was added to the Boc-
protected amine 8a (0.5 g, 1.0 mmol) in Et2O 30 mL, and stirred at 25 oC for 4 h.  The 
mixture was made basic by additioning of a 10% NaOH solution and the layers were 
separated.  The aqueous layer was extracted with Et2O (3 × 20 mL).  The combined 
organic extracts were dried over Na2SO4 and concentrated in vacuo.  The product 9a was 
used without further purification. 1H NMR (300 MHz, CDCl3) δ 7.69-7.65 (4H, m), 
7.43-7.34 (6H, m), 7.30-7.18 (5H, m), 5.43 (1H, dd, J = 1.2, 8.8 Hz), 5.30 (1H, s), 4.01 
(2H, s), 3.87 (1H, q), 2.69 (2H, t, J = 6.3 Hz), 1.52-1.31 (1H, br), 1.48 (3H, d, J = 0.9 
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Hz), 1.05 (9H, s); 13C NMR (75 MHz, CDCl3) δ 140.4, 136.6, 135.8, 135.7, 133.7, 133.6, 
130.1, 129.9, 128.8, 128.0, 127.1, 120.4, 68.6, 50.8, 44.8, 27.1, 19.6, 14.0.  HRMS (ESI): 
Exact mass calcd for C28H36NOSi ie [M+H]+ 430.2566. Found 430.2502. 
 
General Procedure For Syntheses Of Allylic Acetates (E)-9 
 
Allylic amine 6 was dissolved in CH2Cl2 (0.1M) and pyridine (1.5 eq) was added 
to the solution.  Acetic anhydride (1.1 eq) was added and the mixture was stirred at 25 
oC for 1 h.  The solution was washed with 1M HCl(aq) (10 mL), saturated NaHCO3(aq) 
(10 mL) and water (10 mL).  The organic layers were dried over Na2SO4 and 
concentrated in vacuo.  The residue was purified by column chromatography using 50% 
EtOAc/hexanes as eluent. 
 
 
(S)-E-N-(5-((tert-Butyldiphenylsilyl)oxy)-4-methyl-1-phenylpent-3-en-2-
yl)acetamide (E-9a).  Product was obtained as a colorless oil (95%). 1H NMR (300 
MHz, CDCl3) δ 7.67-7.63 (4H, m), 7.48-7.36 (6H, m), 7.30-7.17 (5H, m), 5.44 (1H, dd, 
J = 1.5, 9.0 Hz), 5.26 (1H, d), 5.01-4.90 (1H, m), 4.01 (2H, s), 2.96 (1H, dd, J = 4.8, 13 
Hz), 2.79 (1H, dd, J = 7.5, 13 Hz), 1.97 (3H, s), 1.28 (3H, s), 1.08 (9H, s); 13C NMR (75 
MHz, CDCl3) δ 169.2, 138.3, 137.8, 135.7, 133.9, 133.7, 130.1, 129.9, 128.5, 127.9, 
126.5, 122.2, 67.8, 48.2, 41.7, 27.1, 23.7, 19.5, 14.1.  HRMS (ESI): Exact mass calcd for 
C30H38NO2Si ie [M+H]+ 472.2672. Found 472.2666.  
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(S)-E-N-(5-((tert-Butyldiphenylsilyl)oxy)-4-methylpent-3-en-2-yl)acetamide (E-9b).  
Product was obtained as a colorless oil (89%). 1H NMR (300 MHz, CDCl3) 
δ 7.72-7.68 (4H, m), 7.47-7.39 (6H, m), 5.40-5.38 (2H, m), 4.82-4.72 (1H, m), 4.08 (2H, 
s), 1.97 (3H, s), 1.66 (3H, s), 1.22 (3H, d, J = 6.6 Hz), 1.11 (9H, s); 13C NMR (75 MHz, 
CDCl3) δ 168.8, 136.9, 135.6, 133.7, 133.6, 129.7, 127.7, 125.1, 68.0, 43.1, 26.9, 23.6, 
21.9, 19.3, 13.9.  HRMS (ESI): Exact mass calcd for C24H34NO2Si ie [M+H]+ 396.2359. 
Found 396.2570.  
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(S)-E-N-(6-((tert-Butyldiphenylsilyl)oxy)-2,5-dimethylhex-4-en-3-yl)acetamide (E-
9c).  Product was obtained as a colorless oil (71%). 1H NMR (300 MHz, CDCl3) δ 7.70-
7.63 (4H, m), 7.42-7.28 (6H, m), 5.42 (1H, d, J = 6.0 Hz), 5.22 (1H, d, J = 6.0 Hz), 4.59-
4.45 (1H, m), 4.07 (2H, s), 1.97 (3H, s), 1.83-1.70 (1H, m), 1.63 (3H, s), 1.07 (9H, s) 
0.89 (6H, dd, J = 6.3, 6.6 Hz); 13C NMR (75 MHz, CDCl3) δ 168.9, 138.3, 135.5 (2 
peaks), 133.7, 133.6, 129.7, 127.7, 121.5, 67.9, 51.9, 32.9, 26.8, 23.6, 19.3, 18.7, 18.1, 
14.2.  HRMS (ESI): Exact mass calcd for C26H38NO2Si ie [M+H]+ 424.2672. Found 
424.2682.  
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(R)-E-N-(1-(Benzyloxy)-5-((tert-butyldiphenylsilyl)oxy)-4-methylpent-3-en-2-
yl)acetamide (E-9d).  Product was obtained as a colorless oil (78%). 1H NMR (300 
MHz, CDCl3) δ 7.73-7.70 (4H, m), 7.44-7.36 (11H, m), 5.82 (1H, d, J = 7.5 Hz), 5.69 
(1H, dd, J = 3.0, 15 Hz), 5.05-4.92 (1H, m), 4.58 (2H, d, J = 2.7 Hz), 4.11 (2H, s), 3.60 
(1H, dd, J = 5.0, 7.5 Hz), 3.52 (1H, dd, J = 5.0, 8.4 Hz), 2.00 (3H, s), 1.70 (3H, s), 1.12 
(9H, s); 13C NMR (75 MHz, CDCl3) δ 169.1, 138.4, 138.1, 135.6, 133.7, 133.6, 129.7, 
128.5, 128.2, 127.7, 73.3, 72.5, 68.0, 46.9, 26.9, 23.5, 19.3, 14.0.  HRMS (ESI): Exact 
mass calcd for C31H40NO3Si ie [M+H]+ 502.2777. Found 502.2801. 
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(S)-E-N-(1-(4-(Benzyloxy)phenyl)-5-((tert-butyldiphenylsilyl)oxy)-4-methylpent-3-
en-2-yl)acetamide (E-9e).  Product was obtained as a colorless oil (83%). 1H NMR (300 
MHz, CDCl3) δ 7.70-7.67 (4H, m), 7.48-7.40 (11H, m), 7.12 (2H, dd, J = 13 Hz), 6.92 
(2H, d, J = 8.0 Hz), 5.47 (1H, d, J = 0.9 Hz), 5.39 (1H, d, J = 6.0 Hz), 5.07 (2H, s), 5.01-
4.89 (1H, m), 4.05 (2H, s), 2.92 (1H, dd, J = 3.0, 12 Hz), 2.85 (1H, dd, J = 0.9, 9.0 Hz), 
2.00 (3H, s), 1.49 (3H, s), 1.12 (9H, s); 13C NMR (75 MHz, CDCl3) δ 169.0, 157.4, 
138.0, 137.2, 135.6, 133.7, 133.5, 130.8, 130.0, 129.7, 128.6, 128.0, 127.7, 127.5, 122.2, 
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114.7, 70.0, 67.7, 48.2, 40.7, 26.9, 23.5, 19.3, 14.0.  HRMS (ESI): Exact mass calcd for 
C37H44NO3Si ie [M+H]+ 578.3090.  Found 578.3075. 
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Synthesis Of (Z)-9 
(Z)-9 was synthesized from (Z)-2 by using the same procedure for synthesis of 
compounds (E)-9. 
 
 
 
 
(S)-Z-N-(5-((tert-Butyldiphenylsilyl)oxy)-4-methyl-1-phenylpent-3-en-2-
yl)acetamide (Z-9a).  Product was obtained as a colorless oil (83%). 1H NMR (300 
MHz, CDCl3) δ 7.67-7.63 (4H, m), 7.45-7.37 (6H, m), 7.25-7.17 (3H, m), 7.08-7.05 (2H, 
m), 5.23 (1H, d, J = 6.0 Hz), 5.08 (1H, d, J = 15 Hz), 4.74-4.62 (1H, m), 4.14 (1H, d, J = 
7.2 Hz), 3.97 (1H, d, J = 13 Hz), 2.82 (1H, dd, J = 0.6, 3.0 Hz), 2.69 (1H, dd, J = 6.9, 13 
Hz), 1.87 (3H, s), 1.80 (3H, s), 1.05 (9H, s); 13C NMR (75 MHz, CDCl3) δ 168.9, 138.4, 
137.4, 135.6, 135.6, 133.5, 129.7, 129.6, 128.2, 127.8, 127.7, 126.3, 125.1, 62.5, 48.2, 
41.4, 26.8, 23.4, 21.1, 19.3.  HRMS (ESI): Exact mass calcd for C30H38NO2Si ie [M+H]+ 
472.2672. Found 472.2723.  
R = Bn, a; Me, b; iPr, c;
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(S)-Z-N-(5-((tert-Butyldiphenylsilyl)oxy)-4-methylpent-3-en-2-yl)acetamide (Z-9b).  
Product was obtained as a colorless oil (70%). 1H NMR (300 MHz, CDCl3) 
δ 7.71-7.69 (4H, m), 7.46-7.41 (6H, m), 5.28-5.26 (1H, m), 5.12-5.09 (1H, m), 4.59-4.50 
(1H, m), 4.30 (2H, dd, J = 12, 39 Hz), 1.88 (3H, s), 1.83 (3H, s), 1.08 (9H, s), 0.90 (3H, 
d, J = 7.5 Hz); 13C NMR (75 MHz, CDCl3) δ 168.8, 135.6, 135.5, 134.8, 133.9, 129.6, 
127.7, 63.2, 53.9, 43.6, 29.2, 26.8, 22.5, 21.8. HRMS (ESI): Exact mass calcd for 
C24H34NO2Si ie [M+H]+ 396.2359. Found 396.2570. 
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(S)-Z-N-(6-((tert-Butyldiphenylsilyl)oxy)-2,5-dimethylhex-4-en-3-yl)acetamide (Z-
9c).  Product was obtained as a colorless oil (71%). 1H NMR (300 MHz, CDCl3) δ 7.72-
7.69 (4H, m), 7.48-7.38 (6H, m), 5.28 (1H, d, J = 8.7 Hz), 5.09 (1H, dd, J = 1.2, 9.4 Hz), 
4.39-4.36 (1H, m), 4.34 (1H, s), 4.28 (1H, d, J = 12 Hz), 1.91 (3H, s), 1.86 (3H, d, J = 
1.2 Hz), 1.79-1.69 (1H, m), 1.09 (9H, s), 0.85 (3H, d, J = 3.9 Hz), 0.83 (3H, d, J = 3.9 
Hz); 13C NMR (75 MHz, CDCl3) δ 168.8, 138.7, 135.7, 133.7 (2 peaks), 129.6, 127.7, 
124.6, 62.8, 52.0, 32.7, 26.9, 23.5, 21.4, 19.4, 18.6, 18.3.  HRMS (ESI): Exact mass 
calcd for C26H38NO2Si ie [M+H]+ 424.2672. Found 424.2689. 
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(R)-Z-N-(1-(Benzyloxy)-5-((tert-butyldiphenylsilyl)oxy)-4-methylpent-3-en-2-
yl)acetamide (Z-9d).  Product was obtained as a colorless oil (83%). 1H NMR (300 
MHz, CDCl3) δ 7.73-7.68 (4H, m), 7.47-7.30 (11H, m), 5.69 (1H, d, J = 6.9 Hz), 5.30 
(1H, dd, J = 1.5, 9 Hz), 4.71-4.66 (1H, m), 4.48 (2H, d, J = 2.1 Hz), 4.39 (1H, dd, J = 0.9, 
12 Hz), 4.24 (1H, d, J = 13 Hz), 3.48-3.35 (2H, m), 1.89 (3H, s), 1.85 (3H, s), 1.08 (9H, 
s); 13C NMR (75 MHz, CDCl3) δ 169.0, 138.8, 138.0, 135.6, 133.6 (2 peaks), 129.7, 
128.5, 127.8, 127.7, 123.8, 73.2, 72.4, 62.8, 46.9, 26.9, 23.4, 21.4, 19.3.  HRMS (ESI): 
Exact mass calcd for C31H40NO3Si ie [M+H]+ 502.2777. Found 502.2758. 
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(S)-Z-N-(1-(4-(Benzyloxy)phenyl)-5-((tert-butyldiphenylsilyl)oxy)-4-methylpent-3-
en-2-yl)acetamide (Z-9e).  Product was obtained as a colorless oil (75%). 1H NMR (300 
MHz, CDCl3) δ 7.70-7.67 (4H, m), 7.48-7.40 (11H, m), 7.12 (2H, d, J = 13 Hz), 6.92 
(2H, d, J = 8.0 Hz), 5.47 (1H, d, J = 0.9 Hz), 5.39 (1H, d, J = 6.0 Hz), 5.07 (2H, s), 5.01-
4.89 (1H, m), 4.05 (2H, s), 2.92 (1H, dd, J = 3.0, 12 Hz), 2.85 (1H, dd, J = 0.9, 9.0 Hz), 
2.00 (3H, s), 1.49 (3H, s), 1.12 (9H, s); 13C NMR (75 MHz, CDCl3) δ 169.4, 157.6, 
138.1, 135.2 (2 peaks), 134.2, 134.0, 131.4, 129.7, 128.4, 127.4, 126.9, 126.3, 114.2, 
70.1, 62.3, 48.7, 40.6, 26.2, 23.3, 20.9, 19.2.  HRMS (ESI): Exact mass calcd for 
C37H44NO3Si ie [M+H]+ 578.3090. Found 578.3077. 
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Synthesis Of (S)-E-N-(5-((tert-Butyldiphenylsilyl)oxy)-4-methyl-1-phenylpent-3-en-
2-yl)formamide (10a).  
 
Formic acid (0.2 g, 5 mmol) in CH2Cl2 (2.5 mL) was added dropwise to a 
solution of DCC (0.5 g, 2.5 mmol) in 3 mL CH2Cl2 at 0 oC.  The mixture was stirred for 
5 min then added to an ice-bath cooled solution of O-TBDPS-allylic amine 8a (0.4 g, 1 
mmol) in 3 mL pyridine.  The mixture was then stirred in ice-bath for 4 h.  The solid was 
removed via filtration, and washed with Et2O (10 mL).  The combined extracts were 
evaporated and purified by flash chromatography using 40% EtOAc/hexanes giving 
formamide 10a as a colorless oil (0.4 g, 78%). 1H NMR (300 MHz, CDCl3) δ 7.18-7.63 
(4H, m), 7.48-7.31 (6H, m), 7.29-7.19 (5H, m), 5.45 (1H, dd, J = 1.2, 9.1 Hz), 5.31 (1H, 
d, J = 6.0 Hz), 5.10-5.00 (1H, m), 4.02 (1H, s), 2.98 (1H, dd, J = 5.4, 13 Hz), 2.82 (1H, 
dd, J = 7.5, 13 Hz), 1.59 (2H, s), 1.47 (3H, d , J = 0.6 Hz), 1.08 (9H, s); 13C NMR (75 
MHz, CDCl3) δ 163.6, 160.0, 138.4, 138.0, 137.2, 136.5, 135.5 (2 peaks), 133.6, 133.5, 
129.8, 129.7 (2 peaks), 126.9, 126.5, 122.3, 121.7, 67.5 (2 peaks), 61.3, 46.8, 43.4, 41.5, 
26.8, 19.3, 13.8 (2 peaks).  HRMS (ESI): Exact mass calcd for C29H36NO2Si ie [M+H]+ 
458.2515. Found 458.2577. 
 
Synthesis Of (S)-E-N-(5-((tert-Butyldiphenylsilyl)oxy)-4-methyl-1-phenylpent-3-en-
2-yl)-2,2,2-trifluoroacetamide (11a).  
 
O-TBDPS-allylic amine 8a (0.2 g, 0.5 mmol) was dissolved in 2 mL CH2Cl2 and 
cooled to 0 oC.  Trifluoroacetic anhydride (76 µL, 0.6 mmol) was added dropwise to this 
solution followed by pyridine (61 µL, 0.8 mmol).  The mixture was stirred for 2 h at 25 
oC, then another aliquot of trifluoroacetic anhydride (38 µL, 0.3 mmol) and pyridine (30 
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µL, 0.4 mmol) were added to this solution and stirred for an additional 1 h.  The solvent 
was removed in vacuo and the residue was purified by flash chromatography using 10% 
EtOAc/hexanes giving acetamide 11a as a colorless oil (0.3 g, 96%). 1H NMR (300 
MHz, CDCl3) δ 7.70-7.65 (4H, m), 7.49-7.37 (6H, m), 7.34-7.18 (5H, m), 6.30 (1H, d, J 
= 8.0 Hz), 5.56-5.52 (1H, m), 5.02-4.97 (1H, m), 4.05 (2H, s), 3.01 (1H, dd, J = 5.4, 13 
Hz), 2.88 (1H, dd, J = 7.8, 13 Hz), 1.48 (3H, d, J = 1.2 Hz), 1.12 (9H, s); 13C NMR (75 
MHz, CDCl3) δ 156.4, 155.9, 140.1, 136.4, 135.5 (2 peaks), 133.5, 133.4, 129.8, 129.7, 
128.6, 128.1, 127.8, 126.8, 120.2, 117.8, 114.0, 67.4, 48.9, 41.0, 26.9, 19.3, 13.9.  
HRMS (ESI): Exact mass calcd for C30H34F3LiNO2Si ie [M+H]+ 532.2471. Found 
532.2474. 
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B. General Procedure for Catalytic Hydrogenation. 
 
The corresponding alkenes (0.1 mmol) and (S)-1 (2 mol %) were dissolved in 
CH2Cl2 (0.5 M).  The resulting mixture was degassed by three cycles of freeze-pump-
thaw and then transferred to a Parr Bomb.  The bomb was pressurized to 50 bar with 
hydrogen and the mixture was stirred at 300 rpm for 16 h.  The bomb was then vented 
and solvent was evaporated.  The crude product was passed through a short silica plug 
using 50% EtOAc/hexanes as the eluent.  The diastereomeric ratio was then measured 
through HPLC analysis using unbonded silica 300 Å column. 
 
 
50 bar H2, 0.02 (S)-1
CH2Cl2, 25 °C, 16 h
alkene alkane
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N-((2R,4R)-5-((tert-Butyldiphenylsilyl)oxy)-4-methyl-1-phenylpentan-2-
yl)acetamide (syn-2a).  1H NMR (300 MHz, CDCl3) δ 7.67-7.62 (4H, m), 7.46-7.35 (6H, 
m), 7.33-7.17 (5H, m), 5.17 (1H, d, J = 9.0 Hz), 4.39-4.21 (1H, m), 3.52-3.40 (2H, m), 
2.83-2.80 (2H, m), 1.89 (3H, s), 1.78-1.64 (1H, m), 1.55 (1H, s), 1.30-1.21 (1H, s), 1.07 
(9H, s), 0.89 (3H, d, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 169.6, 137.8, 135.6, 
135.5, 133.9, 133.7, 129.6, 128.3, 127.8, 126.4, 69.2, 47.8, 41.4, 37.4, 32.7, 26.9, 23.4, 
19.3, 16.4.  HRMS (ESI): Exact mass calcd for C30H40NO2Si ie [M+H]+ 474.2828. 
Found 474.2832.  
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N-(2S,4R)-5-((tert-Butyldiphenylsilyl)oxy)-4-methylpentan-2-yl)acetamide (syn-2b).  
1H NMR (300 MHz, CDCl3) δ 7.67-7.63 (4H, m), 7.43-7.36 (6H, m), 5.12 (1H, d, J = 
8.7 Hz), 4.13-3.97 (1H, m), 4.06-4.01 (1H, m), 1.88 (3H, s), 1.79-1.60 (1H, m), 1.62 (1H, 
s), 1.25-1.13 (2H, m), 1.11 (3H, d, J = 3.3 Hz), 1.08 (9H, s), 0.91 (3H, d, J = 6.5 Hz); 
13C NMR (75 MHz, CDCl3) δ 135.6, 134.8, 129.6 (2 peaks), 127.7 (2 peaks), 68.1, 28.5, 
26.9, 26.6, 22.0, 19.3, 13.7.  HRMS (ESI): Exact mass calcd for C24H36NO2Si ie [M+H]+ 
398.2515 Found 398.2552. 
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N-((3R,5R)-6-((tert-Butyldiphenylsilyl)oxy)-2,5-dimethylhexan-3-yl)acetamide (syn-
2c).  1H NMR (300 MHz, CDCl3) δ 7.67-7.63 (4H, m), 7.41-7.38 (6H, m), 5.00 (1H, d, J 
= 9.9 Hz), 3.91-3.88 (1H, m), 3.53-3.39 (2H, m), 1.91 (3H, s), 1.78-1.55 (1H, m), 1.56 
(1H, s), 1.52-1.45 (1H, m), 1.19-1.10 (1H, m), 1.06 (9H, s), 0.91-0.84 (9H, m); 13C NMR 
(75 MHz, CDCl3) δ 135.6 (2 peaks), 129.6, 127.6 (2 peaks), 69.8, 51.9, 37.4, 33.1, 33.0, 
26.9, 23.7, 19.8, 19.3, 19.1, 16.2.  HRMS (ESI): Exact mass calcd for C26H40NO2Si ie 
[M+H]+ 426.2828. Found 426.2851. 
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N-((2R,4R)-1-(Benzyloxy)-5-((tert-butyldiphenylsilyl)oxy)-4-methylpentan-2-
yl)acetamide (syn-2d).  1H NMR (300 MHz, CDCl3) δ 7.67-7.63 (4H, m), 7.40-7.32 
(11H, m), 5.47 (1H, d, J = 9.0 Hz), 4.50 (2H, dd, J = 12, 17 Hz), 4.24-4.12 (1H, m), 
3.50-3.43 (4H, m), 1.89 (3H, s), 1.80-1.76 (1H, m), 1.73-1.59 (1H, m), 1.27-1.20 (1H, 
m), 1.16 (9H, s), 0.93 (3H, d, J = 6.6Hz); 13C NMR (75 MHz, CDCl3) δ 135.6, 129.6, 
128.4, 127.6 (2 peaks), 73.5, 72.8, 69.9, 47.0, 36.1, 33.2, 27.0, 23.8, 19.2, 18.0.  HRMS 
(ESI): Exact mass calcd for C31H42NO3Si ie [M+H]+ 504.2934. Found 504.2952. 
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N-((2R,4R)-1-(4-(Benzyloxy)phenyl)-5-((tert-butyldiphenylsilyl)oxy)-4-
methylpentan-2-yl)acetamide (syn-2e).  1H NMR (300 MHz, CDCl3) δ 7.67-7.62 (4H, 
m), 7.45-7.37 (11H, m), 7.09 (2H, d, J = 8.4 Hz), 6.94 (2H, d, J = 8.4 Hz), 5.07 (2H, s), 
4.32-4.19 (1H, m), 3.53-3.40 (2H, m), 2.76 (1H, s), 2.74 (1H, d, J = 2.1 Hz), 1.89 (3H, s), 
1.78-1.60 (1H, m), 1.62 (1H, s), 1.59-1.46 (1H, m), 1.30-1.19 (1H, m), 1.06 (9H, s), 0.89 
(3H, d, J = 6.6 Hz); 13C NMR (75 MHz, CDCl3) δ 169.6, 157.5, 137.1, 135.6 (2 peaks), 
130.6, 130.2, 129.7, 128.6, 128.0, 127.7, 127.5, 114.7, 70.0, 69.2, 47.9, 40.0, 37.4, 32.7, 
26.9, 23.5, 19.3, 16.5.  HRMS (ESI): Exact mass calcd for C37H46NO3Si ie [M+H]+ 
580.3247. Found 580.3253. 
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N-((2R,4S)-5-((tert-Butyldiphenylsilyl)oxy)-4-methyl-1-phenylpentan-2-
yl)acetamide (anti-2a).  1H NMR (300 MHz, CDCl3) δ 7.72-7.65 (4H, m), 7.48-7.38 
(6H, m), 7.33-7.11 (5H, m), 5.40 (1H, d, J = 8.7 Hz), 4.38-4.22 (1H, m), 3.59 (1H, dd, J 
= 5.4, 10 Hz), 3.49 (1H, dd, J = 5.6, 10 Hz), 2.85-2.75 (2H, m), 1.90 (3H, s), 1.88-1.70 
(2H, m), 1.29-1.24 (1H, m), 1.08 (9H, s), 0.96 (3H, d, J = 6.6 Hz); 13C NMR (75 MHz, 
CDCl3) δ 169.3, 137.9, 137.8, 136.3, 135.6, 135.4, 135.3, 133.8, 133.7, 130.0 (2 peaks), 
129.6, 129.5, 128.3 (2 peaks), 127.9, 127.8, 127.7, 127.6, 126.4, 126.3, 113.7, 68.2, 48.0 
(2 peaks), 40.2, 41.0, 38.0, 37.1, 32.8, 26.9, 26.5, 23.5, 23.4, 19.3, 19.2, 17.2, 12.9.  
HRMS (ESI): Exact mass calcd for C30H40NO2Si ie [M+H]+ 474.2828. Found 474.2833.  
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N-((2S,4S)-5-((tert-Butyldiphenylsilyl)oxy)-4-methylpentan-2-yl)acetamide (anti-
2b).  1H NMR (300 MHz, CDCl3) δ 7.71-7.63 (4H, m), 7.53-7.13 (6H, m), 4.10-3.95 
(1H, m), 3.49-3.44 (2H, m), 2.60-2.51 (1H, m), 2.35 (3H, s), 1.97-1.62 (1H, m), 1.53 
(3H, d,  J = 6.0 Hz), 1.21 (3H, d, J = 9.0 Hz), 1.08 (9H, s), 0.97-0.79 (2H, m); 13C NMR 
(75 MHz, CDCl3) δ 135.6, 134.8, 129.7, 129.0, 128.2, 124.6, 95.4, 29.7, 26.8, 17.8.  
HRMS (ESI): Exact mass calcd for C24H36NO2Si ie [M+H]+ 398.2515 Found 398.2571. 
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N-((3R,5S)-6-((tert-Butyldiphenylsilyl)oxy)-2,5-dimethylhexan-3-yl)acetamide (anti-
2c).  1H NMR (300 MHz, CDCl3) δ 7.72-7.69 (4H, m), 7.48-7.38 (6H, m), 4.92 (1H, d, J 
= 9.0 Hz), 3.98-3.91 (2H, m), 3.62-3.49 (2H, m), 1.96 (3H, s), 1.80-1.53 (2H, m), 1.40-
1.20 (1H, m), 1.09 (9H, s), 0.96-0.81 (9H, m);13C NMR (75 MHz, CDCl3) δ 135.6, 
133.8, 133.6, 132.3, 129.9, 127.8, 122.0, 67.9, 51.7, 35.2, 32.1, 26.3, 24.5, 21.8, 20.7, 
19.8, 18.0.  HRMS (ESI): Exact mass calcd for C26H40NO2Si ie [M+H]+ 426.2828. 
Found 426.2842. 
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N-((2R,4S)-1-(Benzyloxy)-5-((tert-butyldiphenylsilyl)oxy)-4-methylpentan-2-
yl)acetamide (anti-2d).  1H NMR (300 MHz, CDCl3) δ 7.76-7.63 (4H, m), 7.47-7.30 
(11H, m), 5.73 (1H, d, J = 8.1 Hz), 4.52 (2H, s), 4.17-4.14 (1H, m), 3.60-3.44 (4H, m), 
1.94 (3H, s), 1.89-1.55 (2H, m), 1.37-1.32 (1H, m), 1.08 (9H, s), 0.97 (3H, d, J = 6.9 Hz); 
13C NMR (75 MHz, CDCl3) δ 158.7, 137.2, 135.1, 134.5, 132.7, 128.5, 127.7, 127.3, 
71.3, 68.1, 42.7, 34.7, 32.8, 26.0, 22.5, 19.8, 17.2.  HRMS (ESI): Exact mass calcd for 
C31H42NO3Si ie [M+H]+ 504.2934. Found 504.2971. 
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N-((2R,4S)-1-(4-(Benzyloxy)phenyl)-5-((tert-butyldiphenylsilyl)oxy)-4-
methylpentan-2-yl)acetamide (anti-2e).  1H NMR (300 MHz, CDCl3) δ 7.78-7.66 (4H, 
m), 7.65-7.36 (11H, m), 7.08 (2H, dd, J = 9.0 Hz), 6.91 (2H, d, J = 8.7 Hz), 5.05 (2H, s), 
4.25-4.18 (1H, m), 3.58-3.45 (1H, m), 2.78-2.72 (2H, m), 2.28 (2H, br), 1.89 (3H, s), 
1.68-1.59 (1H, br), 1.11 (9H, s), 1.10 (2H, s), 0.95 (3H, d, J = 6.6 Hz); 13C NMR (75 
MHz, CDCl3) δ 169.3, 137.1, 135.6, 135.3, 135.2, 134.8, 133.7, 130.0, 129.7, 128.6, 
127.9, 127.8, 127.5, 121.1, 116.5, 114.7, 68.2, 53.5, 48.1, 39.2, 37.0, 32.8, 26.6, 23.5, 
19.4, 17.2.  HRMS (ESI): Exact mass calcd for C37H46NO3Si ie [M+H]+ 580.3247. 
Found 580.3272.  
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APPENDIX C 
EXPERIMENTAL FOR CHAPTER III 
 
A. Preparation of compounds 15 
 
Preparation of (E)-Methyl 4-Hydroxy-3-methylbut-2-enoate 15.  
 
 
 (E)-4-Methoxy-3-methyl-4-oxobut-2-enoic acid (J)139; 
To a solution of (1-methoxy-1-oxopropan-2-yl)triphenylphosphonium bromide 
(42.9  g, 100 mmol, 1 equiv) in dry MeCN (300 mL) was added triethylamine (13.2 mL, 
95 mmol, 0.95 equiv) and glyoxylic acid monohydrate (8.74 g, 95 mmol, 0.95 equiv) at 
0 °C.  The solution was further stirred at 0 °C for 2 h and at room temperature overnight.  
Half of the solvent was removed under reduced pressure, and ethyl acetate (100 mL) was 
added.  The resulting solution was washed with saturated aqueous NaHCO3 (3 × 50 mL).  
The combined aqueous layers were extracted with ethyl acetate (2 × 50 mL), acidified 
(pH 1 - 2) at 0 °C with concentrated HCl (50 mL) and extracted with ethyl acetate (3 × 
50 mL).  The combined organic layers were evaporated to dryness, yielding a clear oil J 
(10.5 g, 73 %) which was used for the next reaction without further purification.  
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(E)-4-Hydroxy-3-methylbut-2-enoic acid (14)140; 
LiBH4 (2 equiv) was added to (E)-4-methoxy-3-methyl-4-oxobut-2-enoic acid J 
(200 mmol) in THF (200 mL) at 0 °C.  The reaction mixture was then allowed to 
ambient temperature and stirred for 12 h.  The mixture was poured into 1N HCl and 
extracted with ethyl acetate (3 × 50 mL).  The combined organic layers were dried over 
Na2SO4 and solvent was removed under reduced pressure to yield the product 14 as a 
white solid (16 g, 69 %) which was used for the next reaction without further 
purification.  
 
(E)-Methyl 4-Hydroxy-3-methylbut-2-enoate (15); 
To a solution of H2SO4 in 50 mL of MeOH, (E)-4-hydroxy-3-methylbut-2-enoic 
acid 14 was added at room temperature.  The mixture was stirred and refluxed for 4 h. 
After cooling to ambient temperature, solvent was removed under reduced pressure.  The 
residue was dissolved in CH2Cl2.  The organic layer was washed with NaHCO3, brine 
and dried over Na2SO4.  Solvent was removed under reduced pressure to obtain product 
15 as a clear oil (62 %). 1H NMR (400 MHz, CDCl3) δ 6.48 (1H, d, J = 4.7 Hz), 3.96 
(2H, s), 3.63 (3H, s), 1.89 (3H, d, J = 6.6 Hz); 13C NMR (100 MHz, CDCl3) δ 167.2, 
132.3, 119.7, 67.2, 58.3, 26.2. HRMS (ESI): Exact mass calcd for C6H11O3 ie [M+H]+ 
131.0708. Found 131.0711. 
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B. Catalytic Hydrogenation conditions 
 
The (E)-Methyl 4-hydroxy-3-methylbut-2-enoate 15 (100 mmol) and (S)-1 (1 
mol %) were dissolved in CH2Cl2 (0.5 M).  The resulting mixture was degassed by three 
cycles of freeze-pump-thaw and then transferred to a Parr Bomb.  The bomb was 
pressurized to 50 bar with hydrogen and the mixture was stirred at 300 rpm for 24 h.  
The bomb was then vented and solvent was evaporated.  The crude product was passed 
through a short silica plug using 10 - 30% EtOAc/hexanes as the eluent.  The 
enantiomeric ratio was then measured through chiral GC analysis. 
 
Methyl (S)-4-Hydroxy-3-methylbutanoate (16); 
Colorless oil; 1H NMR (400 MHz, CDCl3) δ 4.05 (3H, s), 3.35 (2H, dd, J = 6.6, 12 Hz), 
2.48 (2H, m), 2.07 (1H, m), 0.92 (3H, d, J = 6.6 Hz); 13C NMR (100 MHz, CDCl3) δ 
171.0, 68.5, 62,1, 37.8, 32.5, 14.7. HRMS (ESI): Exact mass calcd for C6H13O3 ie 
[M+H]+ 133.0865. Found 133.0864. 
OMe
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C. Preparation of (S)-4-Methyldihydrofuran-2(3H)-one (17). 
 
To a solution of methyl (S)-4-hydroxy-3-methylbutanoate 16 in 30 mL of CH2Cl2, 
TsOH  (0.95 equiv) was added at room temperature.  The mixture was stirred for 6 h, 
then the organic layer was washed with H2O (3 × 30 mL), brine and dried over Na2SO4.  
Solvent was removed under reduced pressure to yield product as colorless oil (98 %). 
 
D. Recrystallization conditions 
 
(S)-4-Methyldihydrofuran-2(3H)-one 17 was dissolved in EtOAc and hexane and 
the mixture was cooled to -20 °C.  After getting precipitation, solvent was decanted in 
low temperature and washed with cold hexane. 
 
E. Preparation of compounds 18 
 
Preparation of Methyl (S)-4-((tert-Butyldiphenylsilyl)oxy)-3-methylbutanoate (18). 
 
To a solution of methyl (S)-4-hydroxy-3-methylbutanoate 3 in 30 mL of DMF, 
TBDPSCl  (0.95 equiv) was added at room temperature.  The mixture was stirred for 4 h, 
then solvent was removed under reduced pressure.  The residue was dissolved in CH2Cl2.  
The organic layer was washed with H2O (3 × 30 mL), brine and dried over Na2SO4.  
Solvent was removed under reduced pressure and the crude was purified by 
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chromatography using 5 % EtOAc/hexane as eluent to obtain product 5 as a clear oil (15 
g, 99 %). 1H NMR (400 MHz, CDCl3) δ 7.79 – 7.30 (10H, m), 3.69 (3H, s), 3.59 (2H, dd, 
J = 3.3, 12 Hz), 2.63-2.60 (2H, m), 2.32-2.20 (1H, m), 1.09 (9H, s), 1.02 (3H, d, J = 6.6 
Hz); 13C NMR (100 MHz, CDCl3) δ 173.5, 137.8, 133.8, 129.7, 126.9, 68.7, 51.9, 38.7, 
26.8, 19.7, 16.1. HRMS (ESI): Exact mass calcd for C22H31O3Si ie [M+H]+ 371.0242. 
Found 371.0222. 
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F. Preparation of (S)-4-(tert-Butyldiphenylsilyloxy)-3-methylbutanal (19). 
 
A modification of reported procedure144 was used.  Under an atmosphere of 
argon, to an oven dried flask was added [Ir(COD)Cl]2 (10.1 mg, 0.015 mmol) and 1.5 
mL of CH2Cl2.  Then diethyl silane (529 mg, 6 mmol) was added and the resulting 
mixture was stirred at 23 °C for 1 minute.  After addition of methyl (S)-4-((tert-
butyldiphenylsilyl)oxy)-3-methylbutanoate 18 (3 mmol), the mixture was stirred at 23 
°C for 1 h.  Then add another portion of [Ir(COD)Cl]2 (10.1 mg, 0.015 mmol) and 
diethyl silane (265 mg, 3 mmol) to the mixture and allow it to stir  23 °C for 2 h.  The 
reaction was diluted with diethyl ether and quenched by 0.1 M HCl.  After stirring for 20 
minutes, the layers were separated and the aqueous layer was extracted with CH2Cl2. 
0.01 [Ir(COD)Cl]2
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The combined organic layers were dried with MgSO4, and concentrated under vacuum. 
Purification of the residue by flash chromatography on silica gel using 10 % ~ 15 % 
CH2Cl2/hexanes as eluents gave the desired aldehyde 19 as colorless oil (766 mg, 75 %). 
1H NMR (400 MHz, CDCl3) δ 9.86 (1H, t, J = 2.1 Hz), 7.81 – 7.74 (4H, m), 7.54 – 7.47 
(6H, m), 3.70 (1H, dd, J = 9.9, 5.1 Hz), 3.57 (1H, dd, J = 9.9, 6.9 Hz), 2.69 (1H, ddd, J = 
15.9, 5.7, 2.1 Hz), 2.48 – 2.39 (1H, m), 2.35 (1H, ddd, J = 15.9, 7.2, 2.1 Hz), 1.18 (9H, 
s), 1.05 (3H, d, J = 6.7 Hz); 13C NMR (100 MHz, CDCl3) δ 202.5, 135.6, 135.6, 133.6, 
133.5 129.8, 127.8, 68.5, 48.2, 31.3, 27.0, 19.3, 16.9.  IR (CH2Cl2) n (cm-1) 3070, 2931, 
2858, 2360, 1724, 1469, 1427, 1111, 806.3, 740.7, 702.1.  HRMS (ESI): Exact mass 
calcd for C21H28O2SiLi ie [M+Li]+ 347.2019. Found 347.2021. 
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G. Typical Procedure for α-Chlorination of the Aldehyde.  
 
A modification of reported procedure150 was used.  5-Benzyl-2,2,3,-
trimethylimidazolidin-4-one trifluoroacetic acid salt (13.5 mg, 0.05 mmol) in chloroform 
(1 mL) is cooled to -30 °C for five minutes prior to addition of 2,3,4,5,6,6-hexachloro-
2,4-cyclohexadien-1-one (181 mg, 0.6 mmol).  The aldehyde 19 (170 mg, 0.5 mmol) 
was added to the yellow mixture.  The resulting mixture was stirred at -30 °C for 8 h.  
The reaction was then warmed to 0 °C and MeOH (1 mL) was added to the mixture, 
followed by NaBH4 (80 mg, 2 mmol).  After stirring at 0 °C for 5 minutes, the reaction 
was quenched by 1 M KHSO4.  The aqueous solution was extracted with EtOAc three 
times. The combined organic layers were dried with MgSO4, and concentrated in vacuo.  
(i) 0.05 M•TFA 
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Purification of the residue by flash chromatography on silica gel, eluting with 2.5 % ~ 
5.0 % EtOAc/hexanes gave the desired alcohol as colorless oil. 
 
H. Typical Procedure for Preparation Epoxides. 
 
Under Ar, to a solution of 20 (75.4 mg, 0.2 mmol) in anhydrous THF was added NaH 
(10.0 mg, 0.4 mmol) and the mixture was stirred at 60 °C for 4 h.  The reaction was 
quenched by 1 M KHSO4.  The aqueous solution was extracted with CH2Cl2 three times.  
The combined organic layers were dried with MgSO4, and concentrated in vacuo.  
Purification of the residue by flash chromatography on silica gel, eluting with 
CH2Cl2/hexanes (20 %) gave the desired epoxide as a colorless oil. 
 
 
(2S,3R)-4-((tert-Butyldiphenylsilyl)oxy)-2-chloro-3-methylbutan-1-ol (syn-20); 
The compound was prepared according to the typical α-chlorination procedure 
catalysed by (S)-5-benzyl-2,2,3,-trimethylimidazolidin-4-one trifluoroacetic acid salt.  
Purification by flash chromatography afforded syn-20 as a colorless oil (147 mg, 78 % 
isolated yield).  1H NMR (400 MHz, CDCl3) δ 7.81 – 7.75 (4H, m), 7.54 – 7.44 (6H, m), 
4.49 – 4.45 (1H, m), 3.88 – 3.86 (2H, m), 3.71 – 3.62 (2H, m), 2.34 (1H, br), 2.22 – 2.16 
(1H, m), 1.12 (9H, s), 1.05 (3H, d, J = 6.7 Hz); 13C NMR (100 MHz, CDCl3) δ 135.6, 
135.6, 133.2, 129.8, 127.8, 66.5, 65.7, 65.7, 38.8, 26.9, 19.3, 11.8.  IR (CH2Cl2) n (cm-1) 
3356, 3071, 2932, 2859, 2361, 1470, 1427, 1377, 1111, 822.  HRMS (ESI): Exact mass 
calcd for C21H30ClO2Si ie [M+H]+ 377.1704. Found 377.1718. The diastereoselectivity 
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was 18:1.0, determined by Chiral HPLC (Chiralcel OD, Hex/iPrOH 99:1, 1 mL/min, 
25 °C), tr 11.7 min (major diastereomer), tr 12.7 min (minor diastereomer).      
The product was converted to the epoxide according to the typical procedure for 
preparation epoxides.  Purification by flash chromatography afforded (2R,3R)-4-tert-
butyldiphenylsilyloxy-1,3-epoxy-3-methylbutane (anti-23) as a colorless oil (67.5 mg, 
95 % isolated yield).  1H NMR (400 MHz, CDCl3) δ 7.70 – 7.67 (4H, m), 7.49 – 7.38 
(6H, m), 3.66 (2H, dd, J = 6.3, 1.6 Hz), 2.90 – 2.87 (1H, m), 2.79 (1H, dd, J = 4.9, 4.1 
Hz), 2.63 (1H, dd, J = 5.0, 2.8 Hz), 1.65 – 1.56 (1H, m), 1.09 (9H, s), 1.03 (3H, d, J = 
6.8 Hz); 13C NMR (100 MHz, CDCl3) δ 135.6, 133.6, 129.7, 127.7, 66.4, 55.1, 46.8, 
39.1, 26.8, 19.2, 13.3.  IR (CH2Cl2) n (cm-1) 3070, 2927, 2859, 2338, 1462, 1427, 1389, 
1362, 1111, 933.6, 887.3, 821.7.  HRMS (ESI): Exact mass calcd for C21H28O2SiLi ie 
[M+Li]+ 347.2019. Found 347.2020.  
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(2R,3R)-4-((tert-Butyldiphenylsilyl)oxy)-2-chloro-3-methylbutan-1-ol (anti-20); 
The compound was prepared according to the typical chlorination procedure 
catalysed by (R)-5-benzyl-2,2,3,-trimethylimidazolidin-4-one trifluoroacetic acid salt.  
Purification by flash chromatography afforded anti-7 as a colorless oil (141 mg, 75 % 
isolated yield).  1H NMR (400 MHz, CDCl3) δ 7.74 – 7.68 (4H, m), 7.51 – 7.39 (6H, m), 
4.26 – 4.22 (1H, m), 3.95 (1H, dd, J = 12.2, 4.5 Hz), 3.87 (1H, dd, J = 12.2, 6.5 Hz), 
3.78 (1H, dd, J = 10.4, 5.9 Hz), 3.72 (1H, dd, J = 10.4, 4.3 Hz), 2.54 (1H, br), 2.27 – 
2.16 (1H, m), 1.10 (2H, s), 1.06 (1H, d, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) δ 
135.6, 133.1, 129.8, 127.8, 67.4, 65.5, 65.1, 39.4, 26.9, 19.2, 14.6. IR (CH2Cl2) n (cm-1) 
3383, 3071, 2932, 2859, 2361, 1470, 1427, 1389, 1111.  HRMS (ESI): Exact mass calcd 
for C21H30ClO2Si ie [M+H]+ 377.1704. Found 377.1710.  The diastereoselectivity was 
1.0:10 determined by Chiral HPLC (Chiralcel OD, Hex/iPrOH 99:1, 1 mL/min, 25 °C), 
tr 11.8 min (minor diastereomer), tr 12.8 min (major diastereomer).   
The product was then converted to the epoxide according to the typical procedure 
for preparation epoxides.  Purification by flash chromatography afforded (2S,3R)-4-tert-
butyldiphenylsilyloxy-1,3-epoxy-3-methylbutane (syn-23) as a colorless oil (61.3 mg, 
90 % isolated yield).  The relative stereochemistry was determined by comparing with a 
known epoxide, which was reported previously.153  1H NMR (400 MHz, CDCl3) δ 7.74 – 
7.66 (4H, m), 7.48 – 7.38 (6H, m), 3.75 (2H, qd, J = 9.9, 5.1 Hz), 3.02 – 2.99 (1H, m), 
2.81 – 2.75 (1H, m), 2.57 (1H, dd, J = 5.0, 2.8 Hz), 1.68 – 1.60 (1H, m), 1.10 (9H, s), 
1.03 (3H, d, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) δ 135.6, 133.8, 129.6, 127.6, 
66.2, 54.0, 45.6, 38.5, 26.9, 19.3, 12.6.  IR (CH2Cl2) n (cm-1) 3071, 2928, 2859, 1470, 
1427, 1389, 1362, 1111, 933.6, 875.7, 821.7.  HRMS (ESI): Exact mass calcd for 
C21H28O2SiLi ie [M+Li]+ 347.2019. Found 347.2003. 
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Relative stereochemistry determination of 20: the 1H NMR data of syn-23 
matched with reported data153 and differs from that of anti-23.  Therefore, the relative 
stereochemistry assignment was confirmed. 
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I. Typical Procedure for α-Fluorination of the Aldehyde:  
 
A modification of reported procedure148 was used.  5-Benzyl-2,2,3,-
trimethylimidazolidin-4-one dichloroacetic acid salt (38 mg, 0.1 mmol) and N-
fluorobenzenesulfonimide (315 mg, 1.0 mmol) was dissolved in THF (4.5 mL) and 
iPrOH (0.5 mL).  The mixture was cooled to -10 °C prior to addition of the aldehyde 
(170 mg, 0.5 mmol).  The resulting mixture was stirred at -10 °C for 16 h and was then 
warmed to 0 °C.  To the mixture at 0 °C was added 1 mL MeOH and NaBH4 (200 mg, 5 
(i) 0.1 M•Cl2HCCO2- 
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mmol).  After stirring at 0 °C for 5 minutes, the reaction was quenched by 1 M KHSO4.  
The mixture was diluted with water and the aqueous solution was extracted with EtOAc 
three times.  The combined organic layers were dried with MgSO4, and concentrated in 
vacuo.  The residue was redissolved in dichloromethane and the solid was filtered off on 
a small silica pad.  The mixture was concentrated again in vacuo.  Purification of the 
residue by flash chromatography on silica gel, eluting with 5 % ~ 10 % EtOAc/hexanes 
gave the desired alcohol as colorless oil. 
 
 
(2S,3R)-4-((tert-Butyldiphenylsilyl)oxy)-2-fluoro-3-methylbutan-1-ol (syn-21); 
The compound was prepared according to the typical α-fluorination procedure 
catalysed by (S)-5-benzyl-2,2,3,-trimethylimidazolidin-4-one dichloroacetic acid salt.  
Purification by flash chromatography afforded syn-21 as a colorless oil (162 mg, 90 % 
isolated yield).  1H NMR (400 MHz, CDCl3) δ 7.72 – 7.69 (4H, m), 7.51 – 7.39 (6H, m), 
4.75 – 4.59 (1H, m), 3.96 – 3.68 (4H, m), 2.22 – 2.01 (2H, m), 1.11 (9H, s), 1.04 (3H, d, 
J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) δ 135.6 (d, J = 2.3 Hz), 133.5 (d, J = 3.1 Hz), 
129.7 (d, J = 1.3 Hz), 127.7 (s), 95.4 (d, J = 170.3 Hz), 64.5 (d, J = 6.1 Hz), 63.3 (d, J = 
22.2 Hz), 37.1 (d, J = 18.9 Hz), 26.9 (s), 19.3 (s), 13.0 (d, J = 6.8 Hz); 19F NMR (282 
MHz, CDCl3) δ -194.48 (dtd, J = 40.0, 25.3, 14.5 Hz).  IR (CH2Cl2) n (cm-1) 3364, 3071, 
2928, 2855, 2361, 1470, 1427, 1393, 1362, 1111, 1049.  HRMS (ESI): Exact mass calcd 
for C21H30FO2Si ie [M+H]+ 361.1999. Found 361.2021.  The diastereoselectivity was 
22:1.0 determined by Chiral HPLC (Chiralcel OD, Hex/iPrOH 99:1, 1 mL/min, 25 °C), 
tr 16.05 min (major diastereomer), tr 23.68 min (minor diastereomer). 
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(2R,3R)-4-((tert-Butyldiphenylsilyl)oxy)-2-fluoro-3-methylbutan-1-ol (anti-21); 
The compound was prepared according to the typical α-fluorination procedure 
catalysed by (R)-5-benzyl-2,2,3,-trimethylimidazolidin-4-one dichloroacetic acid salt.  
Purification by flash chromatography afforded anti-21 as a colorless oil (153 mg, 85 % 
isolated yield).  1H NMR (400 MHz, CDCl3) δ 7.74 – 7.69 (4H, m), 7.51 – 7.41 (6H, m), 
4.82 – 4.63 (1H, m), 3.97 – 3.75 (2H, m), 3.67 – 3.64 (2H, m), 2.28 (1H, br), 2.11– 2.00 
(1H, m), 1.12 (9H, s), 0.99 (3H, dd, J = 7.0, 0.8 Hz);  13C NMR (100 MHz, CDCl3) δ 
135.6 (d, J = 4.5 Hz), 133.3 (d, J = 8.2 Hz), 129.8 (s), 127.8 (d, J = 1.6 Hz), 95.4 (d, J = 
171.0 Hz), 65.2 (d, J = 6.0 Hz), 63.7 (d, J = 22.6 Hz), 37.4 (d, J = 19.6 Hz), 26.9 (s), 
11.7 (d, J = 5.8 Hz); 19F NMR (282 MHz, CDCl3) δ -198.46 – -198.93 (m).  IR (CH2Cl2) 
n (cm-1) 3356, 3071, 2932, 2859, 2361, 1470, 1427, 1389, 1362, 1111, 1034.  HRMS 
(ESI): Exact mass calcd for C21H30FO2Si ie [M+H]+ 361.1999. Found 361.2035.  The 
diastereoselectivity was 1.0:58, determined by Chiral HPLC (Chiralcel OD, Hex/iPrOH 
99:1, 1 mL/min, 25 °C), tr 16.05 min (minor diastereomer), tr 23.68 min (major 
diastereomer).  
Relative stereochemistry determination of 21: since both catalyst and reaction 
condition are identical to what has been reported, and the reaction is catalyst controlled; 
the stereochemistry was assigned according to MacMillan’s fluorinated product. The 
product cannot be easily converted to any known structure. 
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J. Typical Procedure for the α-Amination of the Aldehyde: 
 
A modification of reported procedure269 was used.  Dibenzyl azodicarboxylate 
(90 %, 1.29 g, 3.9 mmol) and proline (70 mg, 0.6 mmol) in MeCN (10 mL) were cooled 
down to -3 °C.  The aldehyde (1.02 g 3.0 mmol) was then added and the mixture was 
stirred at -3 °C for 2 h.  The reaction was gradually warmed to 20 °C within ca. 1 h.  The 
mixture was then cooled to 0 °C, treated with MeOH (3 mL) and NaBH4 (240 mg, 6 
mmol) and was stirred for 5 min at 0 °C.  The reaction was quenched by 1 M KHSO4.  
The aqueous solution was extracted with EtOAc three times.  The combined organic 
layers were dried with MgSO4, and concentrated in vacuo.  Purification of the residue by 
flash chromatography on silica gel, eluting with 15 % EtOAc/hexanes gave the desired 
alcohol as white foamy solid.  
 
 
Dibenzyl 1-((2R,3S)-4-((tert-Butyldiphenylsilyl)oxy)-1-hydroxy-3-methylbutan-2-
yl)hydrazine-1,2-dicarboxylate (anti-22); 
The compound was prepared according to the typical α-amination procedure 
catalysed by (R)-Proline.  Purification by flash chromatography afforded anti-22 as a 
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white foamy solid (1.54 g, 80 % isolated yield).  1H NMR (400 MHz, CDCl3) δ 7.70 – 
7.67 (4H, m), 7.50 – 7.27 (16H, m), 6.85 (1H, d, J = 31.1 Hz), 5.37 – 5.10 (4H, m), 4.45 
– 4.12 (2H, m), 3.80 – 3.41 (4H, m), 1.95 – 1.66 (1H, m), 1.12 – 1.09 (9H, m), 0.99 – 
0.88 (3H, m); 13C NMR (100 MHz, CDCl3) δ 159.1, 157.4, 135.6, 133.3, 133.2, 129.6, 
129.8, 128.7, 128.6, 128.2, 127.9, 127.8, 127.7, 68.6, 65.9, 65.6, 60.4, 35.6, 26.9, 19.3, 
15.1.  IR (CH2Cl2) n (cm-1) 3356, 3032, 2928, 1717, 1454, 1408, 1265, 1227, 1111, 1057.  
HRMS (ESI): Exact mass calcd for C37H45N2O6Si ie [M+H]+ 641.3047. Found 
641.3078.  The diastereoselectivity was 1.0:13, determined by Chiral HPLC (Chiralcel 
OD, Hex/iPrOH 93:7, 1 mL/min, 25 °C), tr 10.3 min (minor diastereomer), tr 14.4 min 
(major diastereomer). 
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Dibenzyl 1-((2S,3S)-4-((tert-Butyldiphenylsilyl)oxy)-1-hydroxy-3-methylbutan-2-
yl)hydrazine-1,2-dicarboxylate (syn-22); 
The compound was prepared according to the typical α-amidation procedure 
catalysed by (S)-Proline.  Purification by flash chromatography afforded syn-22 as a 
white foamy solid (1.63 g, 85 % isolated yield).  1H NMR (400 MHz, CDCl3) δ 7.69 – 
7.62 (4H, m, J = 13.5, 6.6 Hz), 7.50 – 7.24 (16H, m), 6.96 (1H, s), 5.30 – 5.22 (3H, m), 
5.13 (1H, dd, J = 12.1, 9.6 Hz), 4.36 – 4.16 (2H, m), 3.86 – 3.70 (2H, m), 3.59 – 3.44 
(2H, m), 1.80 (1H, br), 1.11 – 1.08 (9H, m), 0.93 – 0.90 (3H, m); 13C NMR (100 MHz, 
CDCl3) δ 158.6 (d, J = 65.9 Hz), 156.6 (d, J = 27.3 Hz), 135.8, 135.6, 135.5, 135.4, 
133.0, 130.1, 129.9, 128.6, 128.5, 128.1, 127.9, 127.8, 68.3, 64.0, 63.2, 60.6, 35.5, 27.0, 
19.2, 14.9.  IR (CH2Cl2) n (cm-1) 3356, 3032, 2959, 1724, 1470, 1408, 1261, 1223, 1111, 
1053.  HRMS (ESI): Exact mass calcd for C37H45N2O6Si ie [M+H]+ 641.3047. Found 
641.3063. The diastereoselectivity was 62:1.0, determined by Chiral HPLC (Chiralcel 
OD, Hex/iPrOH 93:7, 1 mL/min, 25 °C), tr 10.2 min (minor diastereomer), tr 14.3 min 
(major diastereomer). 
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K. Typical Procedure for the Hydrogenolysis and Benzylation of the Alcohol. 
 
To Raney–Nickel (~0.3 g, prewashed with dry MeOH) in MeOH (1 mL), was 
added AcOH (0.3 mL) and a solution of 9 (0.1 mmol) in MeOH (1 mL).  The solution 
was degassed and stirred under a slightly positive pressure of hydrogen (balloon) at 
23 °C for 16 h.  The reaction was then filtered through a short pad of Celite, and washed 
with CH2Cl2.  The mixture was concentrated in vacuo and the residue was redissolved in 
CH2Cl2 and was neutralized by anhydrous Na2CO3.  The solvent was removed by 
vacuum and the crude product was subjected to benzyl protection without further 
purification.  Under Ar atmosphere, to a solution of the hydrogenated crude product 
(0.15 mmol) in anhydrous THF was added NaH (4.8 mg, 0.4 mmol).  After stirring for 5 
min, BnBr (19 mL, 0.15 mmol) and nBu4NI (11.1 mg, 0.03 mmol) was added and the 
mixture was stirred at 23 °C for 16 h.  The reaction was quenched by 1 M KHSO4.  The 
aqueous solution was extracted with EtOAc (three times).  The combined organic layers 
were dried with MgSO4, and concentrated in vacuo.  Purification of the residue by flash 
chromatography on silica gel, eluting with 1.0 % ~ 2.5 % MeOH/CH2Cl2 gave the 
desired product as a white foamy solid. 
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(2S,3S)-1-(Benzyloxy)-4-((tert-butyldiphenylsilyl)oxy)-3-methylbutan-2-amine (syn-
48); 
The compound was prepared according to the typical hydrogenolysis and 
benzylation procedure.  Purification by flash chromatography afforded syn-48 as a white 
foamy solid (22.2 mg, 50 % yield in two steps).  1H NMR (400 MHz, CDCl3) δ 7.71 – 
7.65 (4H, m), 7.48 – 7.28 (11H, m), 4.55 (2H, d, J = 4.8 Hz), 3.77 – 3.60 (3H, m), 3.47 
(1H, dd, J = 9.3, 7.6 Hz), 3.18 (1H, td, J = 7.2, 3.4 Hz), 2.80 (2H, br), 1.90 – 1.79 (1H, 
m), 1.08 (9H, s), 0.94 (3H, d, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) δ 138.1, 135.6, 
133.4, 133.3, 129.7, 128.4, 127.8, 127.7, 73.3, 72.8, 66.8, 53.9, 38.1, 27.0, 19.2, 13.9.  
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(2R,3S)-1-(Benzyloxy)-4-((tert-butyldiphenylsilyl)oxy)-3-methylbutan-2-amine (anti-
48); 
The compound was prepared according to the typical hydrogenolysis and 
benzylation procedure.  Purification by flash chromatography afforded anti-48 as a white 
foamy solid (22.3 mg, 50 % yield in two steps).  1H NMR (400 MHz, CDCl3) δ 7.70 – 
7.67 (4H, m), 7.49 – 7.28 (11H, m), 4.54 (2H, s), 3.68 – 3.58 (2H, m), 3.56 – 3.49 (1H, 
m), 3.38 (1H, dd, J = 10.2, 6.5 Hz), 3.26 (1H, br), 1.83 (1H, br), 1.51 (2H, br), 1.08 (9H, 
s), 0.92 (3H, d, J = 6.9 Hz); 13C NMR (100 MHz, CDCl3) δ 138.5, 135.6, 133.8, 133.7, 
129.6, 128.4, 127.7, 127.6, 74.3, 73.2, 66.8, 29.7, 26.9, 19.3, 11.7.  
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Relative stereochemistry determination of 22: the 13C NMR data of syn-48 
matched with reported data270 and differ from that of anti-48.  Therefore, the relative 
stereochemistry assignment was confirmed. 
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L. Typical Procedure for the Preparation of α-Amino Acid. 
 
To Raney–Nickel (~1.5 g, prewashed with dry MeOH) in MeOH (10 mL), was 
added AcOH (3 mL) and a solution of 22 (2.25 mmol) in MeOH (10 mL).  The solution 
was degassed and stirred under a slightly positive pressure of hydrogen (balloon) at 
23 °C for 16 h.  The reaction was then filtered through a short pad of Celite, and washed 
with CH2Cl2.  The mixture was concentrated in vacuo and the residue was redissolved in 
CH2Cl2 and was neutralized by anhydrous Na2CO3.  The solvent was removed by 
vacuum and the crude product was subjected to Fmoc-protection without further 
purification.  To a solution of the above crude product in H2O (10 mL) and acetone (10 
mL) was added FmocOSu (830 mg, 2.5 mmol) and Na2CO3 (715 mg, 6.7 mmol).  The 
reaction was stirred at 23 °C for 16 h.  The mixture was extracted with EtOAc three 
times. The combined organic layers were dried with MgSO4, and concentrated in vacuo.  
Purification of the residue by flash chromatography on silica gel, eluting with 10 % ~ 20 % 
EtOAc/hexanes gave 24 as a white foamy solid.  To a solution of RuCl3 (29 mg, 0.14 
mmol) and NaIO4 (2.95 g, 13.8 mmol) in water was added 12 (800 mg, 1.38 mmol).  The 
mixture was stirred at 23 °C for 2 h, and then added MeOH (2 mL).  The reaction was 
stirred until solid precipitation occurred.  The solid was filtered on Celite and washed it 
with EtOAc.  1 M KHSO4 (3 mL) was added to the filtrate.  Then, the aqueous phase 
was extracted by EtOAc.  The combined organic layers were dried with MgSO4, and 
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concentrated in vacuo.  Purification of the residue by flash chromatography on silica gel, 
eluting with 15 % ~ 50 % EtOAc/hexanes gave the desired acid as a white foamy solid. 
 
 
(9H-Fluoren-9-yl)methyl ((2S,3S)-4-((tert-Butyldiphenylsilyl)oxy)-1-hydroxy-3-
methylbutan-2-yl)carbamate (syn-24); 
Purification by flash chromatography afforded syn-24 as a white foamy solid 
(1.28 g, 98 % yield in two steps).  1H NMR (400 MHz, CDCl3) δ 7.86 – 7.74 (6H, m), 
7.66 (2H, dd, J = 7.3, 3.6 Hz), 7.55 – 7.40 (8H, m), 7.34 (2H, t, J = 7.4 Hz), 6.05 (1H, d, 
J = 6.7 Hz), 4.50 (2H, d, J = 6.5 Hz), 4.28 (1H, t, J = 6.8 Hz), 3.93 – 3.74 (4H, m), 3.69 
(1H, dd, J = 10.4, 4.5 Hz), 3.31 (1H, br), 2.05 (1H, br), 1.19 (9H, s), 1.13 (3H, d, J = 6.7 
Hz); 13C NMR (100 MHz, CDCl3) δ 157.4, 144.1, 141.4, 135.7, 132.9, 130.0, 127.9, 
127.7, 127.1, 125.2, 120.0, 66.9, 66.0, 64.6, 56.7, 47.4, 35.7, 27.0, 19.2, 15.3.  IR 
(CH2Cl2) n (cm-1) 3402, 3067, 2928, 1701, 1508, 1450, 1327, 1227, 1111, 1042.  HRMS 
(ESI): Exact mass calcd for C36H42NO4Si ie [M+H]+ 580.2883. Found 580.2874.  
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(9H-Fluoren-9-yl)methyl ((2R,3S)-4-((tert-Butyldiphenylsilyl)oxy)-1-hydroxy-3-
methylbutan-2-yl)carbamate (anti-24); 
Purification by flash chromatography afforded anti-24 as a white foamy solid 
(1.24 g, 95 % yield in two steps).  1H NMR (500 MHz, CDCl3) δ 7.84 – 7.77 (2H, m), 
7.74 (4H, dd, J = 7.7, 6.7 Hz), 7.64 (2H, d, J = 7.4 Hz), 7.55 – 7.39 (8H, m), 7.33 (2H, 
td, J = 7.5, 1.0 Hz), 5.85 (1H, d, J = 8.3 Hz), 4.51 – 4.43 (2H, m), 4.26 (1H, t, J = 6.9 
Hz), 3.90 (1H, dd, J = 11.2, 4.2 Hz), 3.83 – 3.80 (1H, m), 3.78 – 3.69 (2H, m), 3.63 (1H, 
dd, J = 10.7, 7.2 Hz), 3.34 (1H, br), 2.11 – 2.10 (1H, m), 1.15 (9H, s), 0.97 (3H, d, J = 
7.2 Hz); 13C NMR (125 MHz, CDCl3) δ 156.9, 144.0, 141.4, 135.7, 132.8, 130.1, 127.9, 
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127.7, 127.1, 125.1, 120.0, 66.8, 66.1, 63.0, 56.3, 47.4, 37.2, 27.0, 19.2, 14.1.  IR 
(CH2Cl2) n (cm-1) 3368, 3067, 2928, 1701, 1512, 1450, 1242, 1111.  HRMS (ESI): Exact 
mass calcd for C36H42NO4Si ie [M+H]+ 580.2883. Found 580.2865. 
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(2S,3S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-((tert-butyldiphenyl-
silyl)oxy)-3-methylbutanoic acid (syn-25); 
Purification by flash chromatography afforded syn-25 as a white foamy solid 
(0.42 g, 49 % yield).  1H NMR (400 MHz, CDCl3) δ 7.89 – 7.60 (8H, m), 7.55 – 7.29 
(10H, m), 6.41 (1H, d, J = 8.4 Hz), 4.61 – 4.51 (7H, m), 4.34 (1H, t, J = 6.9 Hz), 3.88 
(1H, d, J = 8.5 Hz), 3.62 (1H, dd, J = 10.7, 5.1 Hz), 2.49 (1H, m), 1.25 – 1.09 (12H, m); 
13C NMR (100 MHz, CDCl3) δ 177.1, 156.9, 143.9, 141.3, 135.7, 132.6, 130.0, 127.9, 
127.7, 127.1, 125.3, 120.0, 67.4, 66.1, 58.1, 47.1, 36.4, 26.9, 19.2, 14.7.  IR (CH2Cl2) 
n (cm-1) 3399, 3067, 2928, 1717, 1508, 1450, 1427, 1219, 1111, 1034.  HRMS (ESI): 
Exact mass calcd for C36H39NaNO5Si ie [M+Na]+ 616.2495. Found 616.2552. 
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(2R,3S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-((tert-butyldiphenyl-
silyl)oxy)-3-methylbutanoic acid (anti-25); 
Purification by flash chromatography afforded anti-25 as a white foamy solid 
(0.34 g, 40 % yield).  1H NMR (400 MHz, CDCl3) δ 7.81 – 7.56 (8H, m), 7.49 – 7.27 
(10H, m), 5.90 (1H, d, J = 8.2 Hz), 4.69 (2H, d, J = 6.2 Hz), 4.51 – 4.34 (2H, m), 4.24 
(1H, t, J = 6.5 Hz), 3.70 – 3.57 (2H, m), 2.43 (1H, br), 1.09 (9H, s), 0.95 (3H, d, J = 6.7 
Hz);  13C NMR (100 MHz, CDCl3) δ 156.4, 143.8, 141.3, 135.6, 133.0, 129.8, 127.8, 
127.7, 127.1, 125.1, 119.9, 67.3, 66.1, 56.1, 47.2, 37.9, 29.7, 26.8, 19.1.  HRMS (ESI): 
Exact mass calcd for C36H40NO5Si ie [M+H]+ 594.2676. Found 594.2752. 
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APPENDIX D 
EXPERIMENTAL FOR CHAPTER IV 
 
A. Preparation of compounds R – S, 26a and c and 1a and c. 
 
Calculations were performed as previously described.32,35 
 
Preparation of 1-(2,6-Diisopropylphenyl)-4,5-dihydro-imidazole R.  
 
N-(2,6-Diisopropylphenyl)ethane-1,2-diamine (2.20 g, 10 mmol) was dissolved 
in 10 mL of trimethyl orthoformate.  Catalytic amount of p-toluenesulfonic acid (0.10 g, 
0.5 mmol) was added to solution then the mixture was refluxed using an air condenser to 
allowed methanol to escape until completion (18 h).  Solvent was removed under reduce 
pressure and the residue was purified by recrystallization (CH2Cl2/hexane) to obtained R 
(1.04 g, 4.5 mmol, 45%) as a yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.33-7.16 (3H, 
m) 6.82 (1H, s), 4.06 (2H, t, J = 8.7 Hz), 3.58 (2H, t, J = 10.2 Hz), 3.11-3.04 (2H, m), 
1.23 (6H, d, J = 6.9 Hz), 1.18 (6H, d, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) 
δ 163.0, 156.2, 155.9, 148.2, 134.1, 128.6, 124.1, 55.0, 51.6, 28.3, 28.0, 25.3, 24.5, 23.9, 
23.5.  IR (Thin film, cm-1) 3364, 3206, 3063, 3024, 2963, 2928, 2866, 1678, 1605, 1585, 
1458, 1381, 1366, 1327, 1265, 1204, 1180, 1107, 1053, 961, 933, 887. HRMS (ESI, 
TOF): Exact mass calcd for C15H22N2 ie [M+H]+ 231.1861. Found. 231.1835. 
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Preparation of (S)-3-(2-(2-(Adamantan-1-yl)-4,5-dihydrooxazol-4-yl)ethyl)-1-(2,6-
diisopropylphenyl)-4,5-dihydro-imidazolium Iodide 26a.  
 
(S)-2-(Adamantan-1-yl)-4-(2-iodoethyl)-4,5-dihydrooxazole (1.80 g, 5 mmol) 
and 1-(2,6-diisopropylphenyl)-4,5-dihydro-imidazole R (1.15 g, 5 mmol) was dissolved 
in 10 mL of DMF under Ar atmosphere.  The mixture was heated to 80 oC for 12 h.  The 
solvent was removed under reduced pressure and the residue was washed with Et2O (5 × 
5 mL) to yield compound 26a (2.89 g, 4.9 mmol, 98%) as a yellow solid.  1H NMR (300 
MHz, CDCl3) δ 9.0 (1H, s), 8.05-8.01 (1H, m), 7.49-7.40 (2H, m), 7.31-7.20 (1H, m), 
3.79 (2H, m), 3.57-3.46 (3H, m), 3.45-3.23 (1H, m), 2.92-2.70 (3H, m), 2.37 (1H, s), 
1.91-1.54 (15H, m), 1.27-1.00 (14H, m); 13C NMR (75 MHz, CDCl3) δ. 183.6, 166.1, 
162.8, 161.9, 147.0, 144.5, 143.9, 142.7, 142.3, 129.6, 124.4, 123.4, 122.5, 73.4, 50.7, 
47.2, 20.3, 38.9, 38.6, 37.3, 36.4, 28.2, 28.0, 27.4, 25.1, 24.1, 23.5, 22.3. IR (Thin film, 
cm-1) 3066, 2978, 2922, 2844, 1610, 1602, 1458, 1352, 1268, 1161, 1131, 998, 931.  
HRMS (ESI, TOF): Exact mass calcd for C30H44N3O+ ie [M]+ 462.3479. Found 462.3487.  
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Synthesis of (η4-1,5-Cyclooctadiene)(1-[(4S)-(2-(1-adamantyl) -4-5-
dihydrooxazolyl)-ethyl]-3-(2,6-diisopropylphenyl)-4,5-dihydro-imidazolin-2-
ylidene)iridium(I) Tetrakis(3,5- bis(trifluoromethyl)phenyl)borate 1a.  
 
(S)-3-(2-(2-(Adamantan-1-yl)-4,5-dihydrooxazol-4-yl)ethyl)-1-(2,6-diisopropyl-
phenyl)-4,5-dihydro-imidazolium iodide 26a (1 mmol) was added to a round bottom 
flask along with 1.5 equivalents lithium tert-butoxide and 0.5 equivalents of 
[Ir(COD)Cl]2 under Ar.  THF was syringed in to make the solution 0.03 M in 
imidazolinium salt.  The mixture was heated to 70 oC in an oil bath and stirred for 16 h.  
After cooling to room temperature, the volatiles were removed under reduced pressure 
and 1.5 equivalents of NaBARF in 5 mL CH2Cl2 was added.  Water (5 mL) was added 
and the mixture was stirred vigorously for 15 min.  The organic layer was removed and 
the aqueous layer was washed with an additional 5 mL CH2Cl2.  The organic layers were 
combined, dried (Na2SO4) and the volatiles were removed in vacuo.  The residue was 
chromatographed using a short silica column and 10 % hexane/CH2Cl2 as the eluent to 
obtain compound 1a (55 %). mp. 79.8-80.4 (decompose).  1H NMR (300 MHz, CDCl3) δ 
7.74 (8H, s), 7.57 (4H, s), 7.41-7.39 (1H, m), 7.28-7.20 (2H, m), 4.73-4.68 (1H, m), 
4.41-4.29 (2H, m), 4.16-4.12 (1H, m), 3.97-3.58 (6H, m), 3.46-3.38 (1H, m), 3.25-3.21 
(1H, m), 2.95-2.89 (1H, m), 2.68-2.59 (1H, m), 2.17-1.59 (20H, m), 1.45-1.15 (16H, m), 
0.95-0.84 (2H, m); 13C NMR (75 MHz, CDCl3) δ. 178.4, 177.5, 174.5, 163.6, 162.7, 
162.0, 161.3, 160.7, 146.7, 136.3, 134,9, 134.8, 130.0, 129.2, 129.1, 128.7 (2 peaks), 
128.6, 126.4, 124.8, 122.7, 117.5, 85.5, 62.1, 55.7, 39.3, 36.1, 29.1, 28.7, 27.4, 26.9, 
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25.4, 23.9, 22.9. IR (Thin film, cm-1) 3067, 2967, 2916, 2851, 1609, 1606, 1458, 1354, 
1277, 1161, 1126, 999, 929, 887. HRMS (ESI, TOF): Exact mass calcd for 
C38H55IrN3O+ ie [M]+ 762.3969. Found 762.3954 and C32H12BF24- ie [M]- 863.0654.  
Found 863.0632. 
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Preparation of 2,6-Diisopropyl-N-(2-nitrophenyl)aniline 49.  
2-Fluoronitrobenzene (1.41 g, 10 mmol) was added into solution of K2CO3 (2.76 
g, 20 mmol) and 2,6-diisopropylaniline (4.43 g, 20 mmol) in 30 mL of ethanol.  The 
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mixture was refluxed until completion (36 h).  The mixture was allowed to cool to 
ambient temperature then filtered through celite.  Solvent was removed under reduced 
pressure, and the crude products were chromatographed using 5% CH2Cl2/hexane to 
yield 49 (2.27 g, 7.6 mmol, 76%) as yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.10 (2H, 
d, J = 7.8 Hz), 6.98 (1H, t, J = 7.5 Hz), 6.70-6.45 (4H, m), 3.65 (1H, br), 3.05-2.96 (2H, 
m), 1.34 (12H, d, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ. 145.6, 143.0, 141.3, 126.3, 
124.5, 123.8, 120.4, 118.6, 118.0, 116.6, 115.8, 114.3, 79.6, 29.1. HRMS (ESI, TOF): 
Exact mass calcd for C18H22N2O2 ie [M+H]+ 299.1760. Found 299.1733. 
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Preparation of N-(2,6-Diisopropylphenyl)benzene-1,2-diamine 50.  
10 % Pd/C (0.02 g, 0.02 mmol) was added to solution of 2,6-diisopropyl-N-(2-
nitrophenyl)aniline 49 (0.65 g, 2 mmol) in 15 mL of EtOH.  The mixture was then 
placed into steel pressure bomb and then flushed with H2.  The reaction was stirred 
under 20 bar of H2 for 12 h.  The mixture was passed through celite and the solvent was 
removed under reduced pressure to yield compound 50 (0.52 g, 1.96 mmol, 98%) as a 
yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.36-7.29 (3H, m), 6.88-6.76 (3H, m), 6.29-
6.26 (1H, m), 5.01 (1H, br), 3.60 (2H, br), 3.21-3.12 (2H, m), 1.37-1.23 (12H, m); 13C 
NMR (75 MHz, CDCl3) δ 145.6, 137.2, 136.5, 134.4, 126.2, 123.8, 120.4,119.6, 116.5, 
114.2, 28.0, 14.2. HRMS (ESI, TOF): Exact mass calcd for C18H24N2 ie [M+2H]2+ 
135.1043. Found 135.1054. 
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Preparation of 1-(2,6-Diisopropylphenyl)-benzo[d]-imidazole S.  
N-(2,6-Diisopropylphenyl)benzene-1,2-diamine 50 (0.60 g, 2.3 mmol) was 
dissolved in 5 mL of trimethyl orthoformate.  Catalytic amount of p-toluenesulfonic acid 
(0.002 g, 0.01 mmol) was added to solution then the mixture was refluxed using air 
condenser to allow methanol to escape until completion (18 h).  Solvent was removed 
under reduce pressure and the residue was purified by recrystallization (CH2Cl2/hexane) 
to obtained S (0.19 g, 0.69 mmol, 30%) as a brown solid. 1H NMR (300 MHz, CDCl3) δ 
7.93 (1H, s), 7.55-7.53 (1H, m), 7.38-7.24 (5H, m), 7.08-7.05 (1H, m), 2.34-2.25 (2H, 
m), 1.13 (6H, d, J = 6.9 Hz), 1.06 (6H, d, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) 
δ 147.5, 143.7, 143.1, 130.6, 130.2, 124.2, 123.6, 122.4, 120.3,  110.3,  28.3, 24.7,  23.9. 
IR (Thin film, cm-1) 3429, 3075, 2963, 2928, 2870, 1643, 1612, 1593, 1485, 1462, 1385, 
1366, 1308, 1281, 1223, 1142, 1057, 1007, 976, 934, 887.  HRMS (ESI, TOF): Exact 
mass calcd for C19H22N2 ie [M+H]+ 279.1861. Found 279.1863. 
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Preparation of (S)-3-(2-(2-(Adamantan-1-yl)-4,5-dihydrooxazol-4-yl)ethyl)-1-(2,6-
diisopropylphenyl)benzo[d]imidazolium Iodide 26c.  
 
(S)-2-(Adamantan-1-yl)-4-(2-iodoethyl)-4,5-dihydrooxazole (1.80 g, 5 mmol) 
and 1-(2,6-diisopropylphenyl)-benzo[d]imidazole S (1.39 g, 5 mmol) was dissolved in 
10 mL of DMF under Ar atmosphere.  The mixture was heated to 80 oC for 12 h.  The 
solvent was removed under reduced pressure and the residue was washed with Et2O (5 × 
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5 mL) to yield compound 26c (2.39 g, 3.8 mmol, 75%) as a brown solid. 1H NMR (300 
MHz, CDCl3) δ 8.06 (1H, s), 8.06-7.99 (1H, m) 7.57-7.22 (5H, m), 7.06-7.03 (1H, m), 
4.15-4.08 (1H, m), 2.97-2.90 (2H, m), 2.29-1.74 (14H, m), 1.37-1.21 (5H, m), 1.12 (6H, 
d, J = 6.9 Hz), 1.04 (6H, d, J = 6.9 Hz), 0.94-0.84 (2H, m); 13C NMR (75 MHz, CDCl3) 
δ 182.9,  147.4,  146.7,  143.9, 135.6,  132.8,  130.4, 124.2, 123.9, 122.9, 120.1,  117.7, 
110.5, 60.0, 51.8, 49.6, 49.1, 46.3, 40.5, 38.8, 36.5, 28.3, 27.9,  24.7,  23.9,  22.5, 22.4. 
IR (Thin film, cm-1) 3065, 2977, 2915, 2853, 1615, 1605, 1454, 1352, 1267, 1161, 998, 
934, 889. HRMS (ESI, TOF): Exact mass calcd for C34H44N3O+ ie [M]+ 510.3479. Found 
510.3499. 
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Synthesis of (η4-1,5-Cyclooctadiene)(1-[(4S)-(2-(1-adamantyl)-4-5-
dihydrooxazolyl)-ethyl]-3-(2,6-diisopropylphenyl)benzo[d]imidazol-2-ylidene)-
iridium(I) Tetrakis(3,5- bis(trifluoromethyl)phenyl)borate 1c.  
 
3
i) [IrCl(COD)]2, LiOtBu, THF    
  70 oC, 16 h
ii) NaBARF, CH2Cl2 : H2O (1:1)
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(S)-3-(2-(2-(Adamantan-1-yl)-4,5-dihydrooxazol-4-yl)ethyl)-1-(2,6-diisopropyl-
phenyl)-benzo[d]imidazol-3-ium iodide 26c (1 mmol) was added to a round bottom flask 
along with 1.5 equivalents lithium tert-butoxide and 0.5 equivalents of [Ir(COD)Cl]2 
under Ar.  THF was syringed in to make the solution 0.03 M in imidazolinium salt.  The 
mixture was heated to 70 oC in an oil bath and stirred for 16 h.  After cooling to room 
temperature, the volatiles were removed under reduced pressure and 1.5 equivalents of 
NaBARF in 5 mL CH2Cl2 was added.  Water (5 mL) was added and the mixture was 
stirred vigorously for 15 min.  The organic layer was removed and the aqueous layer was 
washed with an additional 5 mL CH2Cl2.  The organic layers were combined, dried 
(Na2SO4) and the volatiles were removed in vacuo.  The residue was chromatographed 
using a short silica column and 10 % hexane/CH2Cl2 as the eluent to obtain 1c (43 %). 
mp. 145.5-146.4 (decompose). 1H NMR (300 MHz, CDCl3) δ 7.72 (8H, s), 7.52 (4H, s), 
7.46-7.40 (3H, m), 7.28-7.26 (2H, m), 7.18-7.10 (1H, m), 6.92-6.89 (1H, m), 4.65-4.50 
(1H, m), 4.38 (2H, s), 3.78-3.71 (3H, m), 3.39-3.25 (2H, m), 2.87-2.70 (1H, m), 2.30-
1.60 (7H, m), 1.56-1.17 (18H, m), 1.17-1.11 (2H, m), 0.95 (6H, d, J = 6.9 Hz), 0.90 (6H, 
d, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 187.2, 162.7, 162.0, 161.3, 160.7, 146.4, 
142.5, 139.1, 134.8, 134.5, 131.7, 129.1, 129.0 (2 peaks), 128.6, 128.5, 128.3, 126.5, 
126.3, 125.1, 124.8, 122.7, 117.9, 117.5, 117.4, 112.1, 70.5, 61.8, 36.2, 31.7, 29.7, 28.6, 
24.3, 23.4, 22.7, 14.1. IR (Thin film, cm-1) 3067, 2967, 2916, 2851, 1609, 1458, 1354, 
1277, 1161, 1126, 995, 949, 934, 887, 837. HRMS (ESI, TOF): Exact mass calcd for 
C42H55IrN3O ie [M]+ 810.3974. Found 810.3998 and C32H12BF24- ie [M]- 863.0654.  
Found 863.0634. 
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B. Catalytic Hydrogenation Conditions 
 
The corresponding alkenes (0.25 mmol) and Ir-catalyst (1-2 mol %) were 
dissolved in CH2Cl2 (0.5 M).  The resulting mixture was degassed by three cycles of 
freeze-pump-thaw and then transferred to a Parr Bomb.  The bomb was pressurized to 50 
bar with hydrogen and the mixture was stirred at 300 rpm for 16 h.  The bomb was then 
vented and solvent was evaporated.  The crude product was passed through a short silica 
plug using 10 - 30% EtOAc/hexanes as the eluent.  The enantiomeric ratio was then 
measured through chiral GC or HPLC analysis. 
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APPENDIX E 
EXPERIMENTAL FOR CHAPTER V 
 
A. General Procedure for Preparation of Compounds 27 and 28.201 
 
 
A solution of appropriate alcohol (2 equiv) or diol (1 equiv) in THF was added 
dropwise to phosphorus trichloride (0.42 g, 3 mmol) under nitrogen.  The mixture was 
stirred at room temperature until completion (TLC).  Subsequently, selected cinchona 
alkaloids (3 mmol) were added to the mixture followed by triethylamine (3 mL).  The 
reaction was stirred and heated to 60 °C for 24 h, then the suspension was filtered and 
the mother liquor was concentrated to give a light yellow solid.  This solid was dissolved 
in water and extracted with CH2Cl2 (3 × 50 mL).  The combined organic layers were 
dried over anhydrous Na2SO4.  Solvent was removed under reduced pressure to give 
light yellow crude product.  The product purified by flash column chromatography on 
silica gel using n-hexane/acetone/triethylamine (3:3:1) as the eluent. 
 
PCl3, THF
25 oC, 6 h
Et3N, THF, 60 oC, 24 h
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(1S,2R,4S,5R)-2-((S)-(Benzo[d][1,3,2]dioxaphosphol-2-yloxy)(6-methoxyquinolin-4-
yl)methyl)-5-vinylquinuclidine; 27a (0.85 g, 72 %). 1H NMR (300 MHz, CDCl3) δ 8.55 
(1H, d, J = 4.5 Hz), 7.90 (1H, d, J = 9.3 Hz), 7.52 (1H, d, J = 4.5 Hz), 7.24 (1H, dd, J = 
2.4, 6.0 Hz), 7.16 (1H, d, J = 2.7 Hz), 6.12-6.00 (2H, m), 5.72 (1H, d, J = 3.3 Hz), 5.31 
(1H, s), 5.10-5.08 (1H, m), 5.06-5.04 (1H, m), 3.82 (3H, s), 3.54-3.46 (1H, m), 3.08-2.76 
(4H, m) 2.27-2.22 (1H, m), 2.16-2.07 (2H, m), 1.77 (1H, b), 1.57-1.47 (1H, m) 1.26 (1H, 
s), 1.13-1.04 (1H, m), 0.90-0.87 (1H. m); 13C NMR (75 MHz, CDCl3) δ 
158.5, 147.2, 145.3, 144.3, 141.8, 136.4, 131.7, 125.5, 122.8, 122.5, 122.2, 121.6, 119.9, 
118.9, 118.0, 116.5, 100.0, 70.6, 59.4, 55.3, 48.9, 45.8, 37.5, 27.8, 23.6, 18.5; 31P NMR 
(121 MHz, CDCl3) δ 143.5.  HRMS (ESI): Exact mass calcd for C26H27N2O4P ie [M+H]+ 
463.1787. Found 463.1762. 
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bis(Adamantan-1-ylmethyl) ((S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-
vinylquinuclidin-2-yl)methyl) phosphite; 27b (0.5 g, 48%). 1H NMR (300 MHz, CDCl3) 
δ 8.55 (1H, d, J = 4.5 Hz), 7.90 (1H, d, J = 9.3 Hz), 7.52 (1H, d, J = 4.5 Hz), 7.24 (1H, 
dd, J = 2.4, 6.0 Hz), 7.16 (1H, d, J = 2.7 Hz), 6.12-6.00 (2H, m), 5.72 (1H, d, J = 3.3 Hz), 
5.31 (1H, s), 5.10-5.08 (1H, m), 5.06-5.04 (1H, m), 3.82 (3H, s), 3.54-3.46 (1H, m), 
3.08-2.76 (4H, m) 2.27-2.22 (1H, m), 2.16-2.07 (2H, m), 1.77 (1H, b), 1.57-1.47 (1H, m) 
1.26 (1H, s), 1.13-1.04 (1H, m), 0.90-0.87 (1H. m); 13C NMR (75 MHz, CDCl3) δ 
158.5, 147.2, 145.3, 144.3, 141.8, 136.4, 131.7, 125.5, 122.8, 122.5, 122.2, 121.6, 119.9, 
118.9, 118.0, 116.5, 100.0, 70.6, 59.4, 55.3, 48.9, 45.8, 37.5, 27.8, 23.6, 18.5; 31P NMR 
(121 MHz, CDCl3) δ 145.2.  HRMS (ESI): Exact mass calcd for C42H57N2O4P ie [M+H]+ 
685.4134. Found 685.4198. 
 
 
 
 
N
N
OP
O
OAda
Ada
OMe
  216 
 
l 
c + d + k + m + 
n + o + r 
a
b
c
d
e
f
g
hj i
l
o
k
m
n
p
q
r N
N
OP
O
OAda
Ada
OMes
s p i h f 
e + g 
a
b
c
d
e
f
g
hj i
l
o
k
m
n
p
q
N
N
OP
O
OAda
Ada
OMe
l 
k m + n + c 
d 
j 
p 
b + i + h 
e + q 
f 
g 
  217 
 
bis(Adamantan-1-yl) ((S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-
yl)methyl) phosphite; 27c (0.6 g, 32%). 1H NMR (300 MHz, CDCl3) δ 8.73 (1H, d, J = 
4.5 Hz), 7.98 (1H, d, J = 9.3 Hz), 7.61 (1H, d, J = 4.5 Hz), 7.33-7.29 (1H, m), 7.20-7.19 
(1H, m), 6.06 (1H, dd, J = 9.6, 12.9 Hz), 5.99-5.92 (1H, b), 5.14 (2H, s), 5.12-5.08 (1H, 
m), 3.86 (3H, s), 3.64-3.59 (1H, m), 3.51, (10H, b), 3.17-3.00 (6H, m), 2.94-2.86 (4H, 
m), 2.39-2.30 (4H, m), 2.20-2.08 (3H, m) 2.19-1.84 (4H, m), 1.71-1.09 (8H, m); 13C 
NMR (75 MHz, CDCl3) δ 157.9, 147.6, 146.5, 144.1, 139.4, 131.7, 126.3, 121.7, 118.5, 
115.5, 100.9, 70.5, 70.4, 59.7, 55.9, 50.8, 49.8, 49.2, 39.3, 280, 27.9, 25.5, 20.1; 31P 
NMR (121 MHz, CDCl3) δ 140.8.  HRMS (ESI): Exact mass calcd for C40H53N2O4P ie 
[M+H]+ 657.3821. Found 657.3797. 
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bis(2,6-Diisopropylphenyl)-((S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-
vinylquinuclidin-2-yl)methyl) phosphite; 27d (0.6 g, 30%). 1H NMR (300 MHz, CDCl3) 
δ 8.51-8.50 (1H, m), 8.15-8.13 (1H, m), 8.02-7.95 (2H, m), 7.33-7.29 (1H, m), 7.85-7.82 
(1H, m), 7.42-6.97 (5H, m), 6.74-6.73 (1H, m), 5.93-5.69 (2H, m), 5.11-4.92 (4H, m), 
3.48-3.142 (2H, m), 3.27-3.15 (1H, m), 2.97-2.46, (10H, m), 2.14-2.07 (2H, m), 1.59-
1.55 (3H, m), 1.45-1.32 (3H, m), 1.29-1.26 (6H, m) 1.17-1.15 (6H, m), 1.00-0.88 (6H, 
m); 13C NMR (75 MHz, CDCl3) δ 157.5, 147.3, 147.2, 147.0, 146.9, 144.4, 140.5, 140.1, 
133.6, 131.9 (2 peaks), 131.8, 126.3, 124.6, 123.8, 123.4, 121.2 (2 peaks), 121.1 (2 
peaks), 120.6, 114.6, 101.0, 55.3, 50.0, 49.9, 49.7 (2 peaks), 49.6, 49.4, 49.3, 40.2, 39.9, 
28.1, 28.0, 27.9, 27.5, 27.1, 26.3, 23.8, 23.6, 23.4, 23.1, 22.8; 31P NMR (121 MHz, 
CDCl3) δ 143.5.  HRMS (ESI): Exact mass calcd for C44H57N2O4P ie [M+H]+ 709.4134. 
Found 709.4202. 
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(1S,2R,4S,5R)-2-((S)-(((4S,5S)-4,5-Diphenyl-1,3,2-dioxaphospholan-2-yl)oxy)(6-
methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine; 27e (0.3 g, 52%).  1H NMR (300 
MHz, CDCl3) δ 8.62 (1H, d, J = 4.4 Hz), 7.92 (1H, d, J = 9.3 Hz), 7.50 (1H, d, J = 4.5 
Hz), 7.15-7.03 (5H, m), 6.95-6.76 (7H, m), 6.18-6.05 (2H, m), 5.80 (1H, d, J = 3.3 Hz), 
5.31 (1H, s), 5.10-5.02 (2H, m), 4.02 (3H, s), 3.62-3.47 (4H, m), 3.28-3.15 (2H, m) 2.27-
2.22 (1H, m), 2.10-2.03 (2H, m), 1.73-1.68 (1H, m), 0.90-0.87 (1H. m); 13C NMR (75 
MHz, CDCl3) δ 158.3, 147.0, 145.1, 144.3, 141.0, 135.9, 131.8 (2 peaks), 130.2 (2 
peaks), 129.7, 125.4, 122.8, 122.6, 122.2, 120.2, 119.3, 118.5, 117.9, 117.0, 100.1, 70.6, 
64.8, 63.4, 59.4, 55.3, 48.3, 45.8, 37.3, 27.8, 23.5; 31P NMR (121 MHz, CDCl3) δ 144.1.  
HRMS (ESI): Exact mass calcd for C34H35N2O4P ie [M+H]+ 567.2413. Found 567.2467. 
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(1S,2R,4S,5R)-2-((S)-(((4R,5R)-4,5-Diphenyl-1,3,2-dioxaphospholan-2-yl)oxy)(6-
methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine; 27f (0.4 g, 50%).  1H NMR (300 
MHz, CDCl3) δ 8.75 (1H, d, J = 4.5 Hz), 8.03 (1H, d, J = 9.2 Hz), 7.61 (1H, d, J = 4.5 
Hz), 7.38-7.30 (5H, m), 7.11-6.94 (6H, m), 6.06-5.95 (2H, m), 5.15 (1H, s), 5.11 (2H, d, 
J = 8 Hz), 3.91 (3H, s), 3.86-3.70 (1H, m), 3.27-2.85 (5H, m) 2.34-2.31 (1H, m), 2.22-
2.16 (1H, m), 1.86 (1H, m), 1.69-1.59 (2H, m), 1.12-1.10 (1H, m); 13C NMR (75 MHz, 
CDCl3) δ 158.0, 148.2, 145.4, 144.8, 141.7, 136.5, 130.8 (2 peaks), 130.2 (2 peaks), 
129.5, 124.5, 122.8, 122.6, 122.3, 120.1, 119.5, 118.1, 117.0, 100.0, 71.2, 64.5, 63.7, 
59.5, 49.0, 47.5, 46.0, 37.8, 27.8, 18.8; 31P NMR (121 MHz, CDCl3) δ 144.2.  HRMS 
(ESI): Exact mass calcd for C34H35N2O4P ie [M+H]+ 567.2413 Found 567.2471. 
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(1S,2R,4S,5R)-2-((1S)-(Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yloxy)(6-
methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine; 27g (0.5 g, 31%).  1H NMR (300 
MHz, CDCl3) δ 8.70 (1H, d, J = 4.5 Hz), 8.05 (1H, d, J = 9.3 Hz), 7.96-7.78 (2H, m), 
7.70-7.51 (4H, m), 7.51-7.03 (9H, m), 6.24-6.06 (2H, m), 5.85-5.70 (1H, m), 5.29 (1H, 
s), 3.98 (3H, s), 3.25-3.16 (1H, m) 2.90-2.53 (2H, m), 2.05-1.90 (1H, m), 1.81-1.75 (1H, 
m), 1.52-1.27 (3H, m), 0.92-0.85 (3H. m); 13C NMR (75 MHz, CDCl3) δ 157.6, 147.9, 
145.8, 145.3, 142.1, 135.7, 135.5, 132.7, 132.6, 132.5, 132.4, 132.2, 131.6, 131.5 (2 
peaks), 131.3, 131.2 (2 peaks), 130.9, 130.7, 130.0, 129.5, 129.1, 128.8, 127.5, 127.3, 
123.5, 119.3, 102.1, 80.1, 62.1, 55.8, 52.1, 50.9, 37.3, 27.8, 27.0, 26.1, 12.1; 31P NMR 
(121 MHz, CDCl3) δ 148.6.  HRMS (ESI): Exact mass calcd for C40H35N2O4P ie [M+H]+ 
639.2413. Found 639.2477. 
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(1S,2R,4S,5R)-2-((1S)-((11bS)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-
yloxy)(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine; 27h (0.5 g,35%).  1H NMR 
(300 MHz, CDCl3) δ 8.67 (1H, d, J = 4.5 Hz), 8.10 (1H, d, J = 9.3 Hz), 8.05-7.82 (2H, 
m), 7.78-7.70 (4H, m), 7.65-7.08 (9H, m), 6.32-6.25 (2H, m), 5.80-5.70 (1H, m), 5.29 
(1H, s), 3.96 (3H, s), 3.28-3.19 (1H, m), 2.92-2.53 (2H, m), 2.05-1.90 (1H, m), 1.78-1.75 
(1H, m), 1.51-1.27 (3H, m), 0.92-0.85 (3H. m); 13C NMR (75 MHz, CDCl3) δ 158.1, 
153.0, 147.5, 147.2, 147.1, 144.6, 144.2, 140.1, 139.9, 133.8, 131.9, 131.8, 131.7, 130.6, 
129.2, 128.5, 128.2, 126.9, 126.0, 125.8, 124.6, 123.5, 121.7, 121.0, 118.7, 118.2, 115.0, 
114.8, 112.6, 100.8, 679, 59.8, 55.8, 55.6, 55.5, 49.7, 49.1, 48.5, 46.0, 39.7, 39.6, 29.7, 
27.9, 27.7, 27.6, 26.3, 26.2, 25.6; 31P NMR (121 MHz, CDCl3) δ 148.6.  HRMS (ESI): 
Exact mass calcd for C40H35N2O4P ie [M+H]+ 639.2413. Found 639.2437. 
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(1S,2S,4S,5R)-2-((1R)-((11bR)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-
yloxy)(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine; 28g (0.4 g, 80 %).  1H 
NMR (300 MHz, CDCl3) δ 8.63 (1H, d, J = 4.5 Hz), 7.97-7.80 (5H, m), 7.53 (2H, d, J = 
3.3 Hz), 7.48-7.40 (1H, m), 7.29-7.04 (8H, m), 6.45-6.40 (2H, m), 5.65-5.48 (1H, m), 
5.03 (1H, d, J = 3.6 Hz), 4.98 (1H, s), 4.38-4.30 (1H, m), 3.63(3H, s), 3.34-3.29 (1H, m), 
3.03-2.98 (1H, m), 2.75-2.50 (1H, m), 2.04-1.97 (1H, m), 1.77-1.46 (1H, m), 1.32-1.15 
(2H, m), 0.92-0.85 (2H, m); 13C NMR (75 MHz, CDCl3) δ 158.3, 153.2, 148.1, 145.5, 
145.0, 139.5, 135.8, 135.3, 132.8, 132.6 (2 peaks), 132.4 (2 peaks), 132.2, 131.8 (2 
peaks), 131.5, 130.0 (2 peaks), 128.9, 128.8, 125.8, 123.3, 119.5, 101.3, 79.8, 62.4, 55.3, 
52.1, 50.8, 39.1, 27.8, 27.3, 26.3, 12.5; 31P NMR (121 MHz, CDCl3) δ 148.7.  HRMS 
(ESI): Exact mass calcd for C40H35N2O4P ie [M+H]+ 639.2413. Found 639.2437. 
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(1S,2S,4S,5R)-2-((1R)-((11bS)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-
yloxy)(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine; 28h (0.3 g, 72 %).  1H 
NMR (300 MHz, CDCl3) δ 8.79 (1H, d, J = 4.8 Hz), 8.05-7.87 (5H, m), 7.80-7.66 (2H, 
m), 7.54-7.52 (1H, m), 7.42-7.16 (8H, m), 6.95-6.79 (2H, m), 5.60-5.49 (1H, m), 5.03-
4.95 (1H, m), 4.41-4.37 (1H, m), 4.33-3.56 (4H, m), 3.30-3.23 (1H, m), 2.65-2.64 (1H, 
m), 2.31-1.78 (5H, m), 1.55-1.01(3H, m); 13C NMR (75 MHz, CDCl3) δ 158.6, 152.3, 
149.5, 149.4, 147.0, 144.3, 141.6, 141.5, 138.0 (2 peaks), 137.8, 137.7, 137.5, 134.4, 
132.6, 131.7, 131.6, 131.1, 130.1, 128.2, 127.8, 127.0, 125.9 (2 peaks), 125.5, 125.0, 
124.6, 122.8, 122.3 (2 peaks), 122.2 (2 peaks), 122.1, 122.0 (2 peaks), 118.9 (2 peaks), 
59.4, 54.3, 37.1, 26.8, 24.2, 18.7; 31P NMR (121 MHz, CDCl3) δ 148.7.  HRMS (ESI): 
Exact mass calcd for C40H35N2O4P ie [M+H]+ 639.2413. Found 639.2437. 
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B. General Procedure for Metathesis of Cinchona Alkaloid Ligands.  
Appropriate cinchona alkaloid was added to 2nd Generation Hoveyda-Grubb’s 
catalyst (5 mol %) in CH2Cl2 in schlenk tube under Ar (Balloon).  The mixture was 
stirred and heated to 40 oC for 12 h. Ar (balloon) was changed every 4 - 6 h.  Solvent 
was removed under reduced pressure and the crude metathesis was used in the next step 
without further purification.  
The following purification was used only for characterized the homodimer to 
check the disappearance of monomer starting material. The product was purified by flash 
column chromatography on silica gel using n-hexane/CH2Cl2/triethylamine (6:3:1) as the 
eluent. 
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m), 1.51-1.27 (2H, m), 0.95-0.87 (2H, m); 13C NMR (75 MHz, CDCl3) δ 158.3, 153.2, 
148.1, 145.5, 145.0, 139.5, 135.8, 135.3, 132.8, 132.6 (2 peaks), 132.4 (2 peaks), 132.2, 
131.8 (2 peaks), 131.5, 130.0 (2 peaks), 128.9, 128.8, 125.8, 123.3, 119.5, 101.3, 79.8, 
62.4, 55.3, 52.1, 50.8, 39.1, 27.8, 27.3, 26.3, 12.5; 31P NMR (121 MHz, CDCl3) δ 148.6.   
 
(1S,2R,4S,5R)-2-((1S)-((11bS)-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-
yloxy)(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine dimer; 27h’ – 27h’. 31 % 
isolated yield.  1H NMR (300 MHz, CDCl3) δ 8.65 (1H, d, J = 4.5 Hz), 7.94-7.80 (5H, 
m), 7.56 (2H, d, J = 3.3 Hz), 7.45-7.40 (1H, m), 7.31-7.03 (8H, m), 6.02-5.98 (1H, m), 
5.60-5.48 (1H, m), 5.03 (1H, d, J = 3.6 Hz), 4.95 (1H, s), 4.41-4.30 (1H, m), 3.62 (3H, 
s), 3.34-3.29 (1H, m), 3.03-2.98 (1H, m), 2.94-2.54 (2H, m), 2.09-1.93 (1H, m), 1.76-
1.47 (1H, m), 1.51-1.27 (2H, m), 0.95-0.87 (2H, m); 13C NMR (75 MHz, CDCl3) δ 158.3, 
153.2, 148.1, 145.5, 145.0, 139.5, 135.8, 135.3, 132.8, 132.6 (2 peaks), 132.4 (2 peaks), 
132.2, 131.8 (2 peaks), 131.5, 130.0 (2 peaks), 128.9, 128.8, 125.8, 123.3, 119.5, 101.3, 
79.8, 62.4, 55.3, 52.1, 50.8, 39.1, 27.8, 27.3, 26.3, 12.5; 31P NMR (121 MHz, CDCl3) δ 
148.6.   
2
O
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(1S,2S,4S,5R)-2-((1R)-((11bR)-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-
yloxy)(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine dimer; 28g’ – 28g’. 40 % 
isolated yield. 1H NMR (300 MHz, CDCl3) δ 8.65 (1H, d, J = 4.5 Hz), 7.94-7.80 (5H, 
m), 7.56 (2H, d, J = 3.3 Hz), 7.45-7.40 (1H, m), 7.31-7.03 (8H, m), 6.02-5.98 (1H, m), 
5.60-5.48 (1H, m), 5.03 (1H, d, J = 3.6 Hz), 4.95 (1H, s), 4.41-4.30 (1H, m), 3.62 (3H, 
s), 3.34-3.29 (1H, m), 3.03-2.98 (1H, m), 2.94-2.54 (2H, m), 2.09-1.93 (1H, m), 1.76-
1.47 (1H, m), 1.51-1.27 (2H, m), 0.95-0.87 (2H, m); 13C NMR (75 MHz, CDCl3) δ 158.3, 
153.2, 148.1, 145.5, 145.0, 139.5, 135.8, 135.3, 132.8, 132.6, 132.4, 132.2, 131.8, 131.5, 
130.0 (2 peaks), 128.9, 128.8, 125.8, 123.3, 119.5, 101.3, 79.8, 62.4, 55.3, 52.1, 50.8, 
39.1, 27.8, 27.3, 26.3, 12.8, 12.6; 31P NMR (121 MHz, CDCl3) δ 148.7.   
N
O
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O O
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2
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(1S,2S,4S,5R)-2-((1R)-((11bS)-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-
yloxy)(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine dimer; 28h’ – 28h’. 35 % 
isolated yield. 1H NMR (300 MHz, CDCl3) δ 8.65 (1H, d, J = 4.5 Hz), 7.94-7.80 (5H, 
m), 7.56 (2H, d, J = 3.3 Hz), 7.45-7.40 (1H, m), 7.31-7.03 (8H, m), 6.02-5.98 (1H, m), 
5.60-5.48 (1H, m), 5.03 (1H, d, J = 3.6 Hz), 4.95 (1H, s), 4.41-4.30 (1H, m), 3.62 (3H, 
s), 3.34-3.29 (1H, m), 3.03-2.98 (1H, m), 2.94-2.54 (2H, m), 2.09-1.93 (1H, m), 1.76-
1.47 (1H, m), 1.51-1.27 (2H, m), 0.95-0.87 (2H, m); 13C NMR (75 MHz, CDCl3) δ 158.3, 
153.2, 148.1, 145.5, 145.0, 139.5, 135.8, 135.3, 132.8, 132.6 (3 peaks), 132.4 (2 peaks), 
132.2, 131.8 (3 peaks), 131.5, 130.0 (2 peaks), 128.9, 128.8, 125.8, 123.3, 119.5, 101.3, 
79.8, 62.4, 55.3, 52.1, 50.8, 39.1, 27.8, 27.3, 26.3, 12.5; 31P NMR (121 MHz, CDCl3) δ 
148.7.   
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C. Preparation of (E)-Methyl 4-Acetoxy-3-methylbut-2-enoate, Y.  
 
To a solution of (E)-methyl 4-hydroxy-3-methylbut-2-enoate X (1 mmol) and 
pyridine (3 mmol) in CH2Cl2 (7 mL), Ac2O (1.5 mmol) was added at room temperature 
and the mixture was stirred until completion (TLC).  After completion, the reaction 
mixture was diluted with CH2Cl2 (30 mL), washed with water (15 mL), brine and dried 
over Na2SO4.  The solvent was removed under reduced pressure and the residue was 
purified by chromatography using 30% EtOAc/hexane to yield (92 %) product Y as a 
clear oil. 1H NMR (400 MHz, CDCl3) δ 6.81 (1H, s), 4.30 (2H, s), 3.85 (3H, s), 2.08 (3H, 
s), 1.81 (3H, s); 13C NMR (100 MHz, CDCl3) δ 172.1, 170.8, 165.2, 126.9, 54.8, 23.6, 
16.8. HRMS (ESI): Exact mass calcd for C8H12O4 ie [M+H]+ 173.0814. Found 173.0881. 
 
D. General Procedure for Hydrogenation Using Metathesis Catalysts  
For monodentate ligand; 
2nd Generation Hoveyda-Grubb’s catalyst (0.3 mol %, same amount as use in 
study reaction) and 1g was dissolved in CH2Cl2 (0.5 M). The mixture was stirred for 15 
min, then alkene (0.25 mmol) was added to the mixture. The resulting mixture was 
degassed by three cycles of freeze-pump-thaw and then transferred to a Parr Bomb.  The 
bomb was pressurized to 50 bar with hydrogen and the mixture was stirred at 300 rpm 
for 16 h.  The bomb was then vented and solvent was evaporated.  The crude product 
was passed through a short silica plug using 30% EtOAc/hexanes as the eluent.  
 
 
Y
92 %
MeO
O
OH
MeO
O
OAcAc2O, pyridine
DMAP, CH2Cl2, 25 oC, 6 h
X
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For bidentate ligand;  
2nd Generation Hoveyda-Grubb’s catalyst (0.3 mol %, same amount as use in 
study reaction) and 1g was dissolved in CH2Cl2 (0.5 M) in schlenk tube under Ar 
(Balloon).  The mixture was stirred and heated to 40 oC for 12 h. Ar (balloon) was 
changed every 4 - 6 h.  Solvent and other volatile compounds were removed under 
reduced pressure. The residue was used for the next step without further purification.  
New CH2Cl2 (0.5 M) was added to the residue, then alkene (0.25 mmol) was 
added to the mixture. The resulting mixture was degassed by three cycles of freeze-
pump-thaw and then transferred to a Parr Bomb.  The bomb was pressurized to 50 bar 
with hydrogen and the mixture was stirred at 300 rpm for 16 h.  The bomb was then 
vented and solvent was evaporated.  The crude product was passed through a short silica 
plug using 30% EtOAc/hexanes as the eluent.  
 
E. General Procedure for Hydrogenation Using Ir Catalysts  
Condition A (for ester substrates);  
For monodentate ligand study;  
Ir(COD)2BARF (3 mol %) and appropriate monodentate ligand (6.6 mol %) was 
dissolved in CH2Cl2 (0.5 M).  The mixture was stirred for 15 min, then corresponding 
unsaturated ester (0.25 mmol) were added to the mixture. The resulting mixture was 
degassed by three cycles of freeze-pump-thaw and then transferred to a Parr Bomb.  The 
bomb was pressurized to 50 bar with hydrogen and the mixture was stirred at 300 rpm 
for 16 h.  The bomb was then vented and solvent was evaporated.  The crude product 
was passed through a short silica plug using 30% EtOAc/hexanes as the eluent.  The 
enantiomeric ratio was then measured through chiral GC or HPLC analysis. 
For bidentate ligand study;  
Appropriate cinchona alkaloid was added to 2nd Generation Hoveyda-Grubb’s 
catalyst (5 mol % based on cinchona alkaloid) in CH2Cl2 in schlenk tube under Ar 
(Balloon).  The mixture was stirred and heated to 40 oC for 12 h. Ar (balloon) was 
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changed every 4 - 6 h.  Solvent and other volatile compounds were removed under 
reduced pressure. The residue was used for the next step without further purification.  
Ir(COD)2BARF (3 mol %) and appropriate cinchona alkaloid ligand (from 
previous step) was dissolved in CH2Cl2 (0.5 M).  The mixture was stirred for 15 min, 
then corresponding unsaturated ester (0.25 mmol) were added to the mixture. The 
resulting mixture was degassed by three cycles of freeze-pump-thaw and then transferred 
to a Parr Bomb.  The bomb was pressurized to 50 bar with hydrogen and the mixture 
was stirred at 300 rpm for 16 h.  The bomb was then vented and solvent was evaporated.  
The crude product was passed through a short silica plug using 30% EtOAc/hexanes as 
the eluent.  The enantiomeric ratio was then measured through chiral GC or HPLC 
analysis. 
 
Condition B (for acid substrates);  
For monodentate ligand study;  
Ir(COD)2BARF or Rh(COD)2BARF (3 mol %) and appropriate monodentate 
ligand (6.6 mol %) was dissolved in MeOH (0.5 M).  The mixture was stirred for 15 
min, then corresponding unsaturated acid (0.25 mmol) and Cs2CO3 (0.13 mmol) were 
added to the mixture.  The resulting mixture was degassed by three cycles of freeze-
pump-thaw and then transferred to a Parr Bomb.  The bomb was pressurized to 50 bar 
with hydrogen and the mixture was stirred at 300 rpm for 16 h.  The bomb was then 
vented and solvent was evaporated.  The crude product was passed through a short silica 
plug using 30% EtOAc/hexanes as the eluent.  The enantiomeric ratio was then 
measured through chiral GC analysis. 
For bidentate ligand study;  
Appropriate cinchona alkaloid was added to 2nd Generation Hoveyda-Grubb’s 
catalyst (5 mol % based on cinchona alkaloid) in CH2Cl2 in schlenk tube under Ar 
(Balloon).  The mixture was stirred and heated to 40 oC for 12 h. Ar (balloon) was 
changed every 4 - 6 h.  Solvent and other volatile compounds were removed under 
reduced pressure. The residue was used for the next step without further purification.  
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Ir(COD)2BARF or Rh(COD)2BARF (3 mol %) and appropriate cinchona alkaloid 
ligand (from previous step) was dissolved in MeOH (0.5 M).  The mixture was stirred 
for 15 min, then corresponding unsaturated acid (0.25 mmol) and Cs2CO3 (0.13 mmol) 
were added to the mixture.  The resulting mixture was degassed by three cycles of 
freeze-pump-thaw and then transferred to a Parr Bomb.  The bomb was pressurized to 50 
bar with hydrogen and the mixture was stirred at 300 rpm for 16 h.  The bomb was then 
vented and solvent was evaporated.  The crude product was passed through a short silica 
plug using 30% EtOAc/hexanes as the eluent.  The enantiomeric ratio was then 
measured through chiral GC analysis. 
 
 
 
Figure E1.  Hydrogenation of the acetoxy acid Y using: a Rh catalysts from the 
monodentate ligands 27g, 27h, 28g, and 28h; and b from the same ligands after 
metathesis (as in Figure 5.9).   
 
 
 
a
AcO CO2H AcO CO2H
Y 100 %
0.03 Rh(COD)2BARF
0.066 ligands
0.5 Cs2CO3, MeOH, 50 bar H2 
25 oC, 12 h
0! 10! 20! 30! 40! 50! 60! 70! 80! 90! 100!
28h + 28h"
28g + 28g"
27h + 27h"
27g + 27g"
% ee!
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Figure E1.  continued   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b
AcO CO2H AcO CO2H
Y 100 %
0.03 Rh(COD)2BARF
0.033 ligand dimer
0.5 Cs2CO3, MeOH, 50 bar H2 
25 oC, 12 h
0! 10! 20! 30! 40! 50! 60! 70! 80! 90! 100!
28h' − 28h'"
28g' − 28g'"
27h' − 27h'"
27g' − 27g'"
% ee!
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APPENDIX F 
EXPERIMENTAL FOR CHAPTER VI 
 
A. Preparation of Compounds 30 and 32.  
 
Preparation N,N’-Di(pyren-1-yl)ethane-1,2-diimine 30.  
 
 
Glyoxal (0.15 mL, 1 mmol) was added to 1-aminopyrene (0.42 g, 2 mmol) in 10 
mL of EtOH. The mixture was added catalytic amount of formic acid (0.5 mol %).  The 
mixture was stirred rapidly at room temperature for 18 h to yield red solid.  The solid 
was filtrated and washed with cold EtOH (1 mL) and hexane (10 mL).  The product 29 
(0.40 g, 0.9 mmol, 88 %) was used with out further purification.  1H NMR (300 MHz, 
CDCl3) δ 8.97 (2H, s), 8.81 (2H, d, J = 9.3 Hz), 8.28-8.18 (8H, m), 8.12-8.11 (4H, m), 
8.08-8.02 (2H, m), 7.96 (6H, d, J = 9.0 Hz); 13C NMR (75 MHz, CDCl3) δ 204.3, 132.8, 
128.2, 128.0, 127.5, 127.2 (2 peaks), 127.0, 126.5, 126.4 (2 peaks), 126.3, 126.2, 125.3, 
125.0, 124.5, 124.3, 121.8, 119.4. MS (ESI): Exact mass calcd for C34H20N2 ie [M+H]
+ 
457.17. Found 457.17. 
H H
O
O
R-NH2
cat. HCOOH
EtOH, 25 °C 
18 h
H H
N
N
R
R
H2CO
4N HCl in dioxane
THF, 25 °C, 18 h
29
N+NR R
Cl-
30
R =
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H H
N
N
a
b
a
b
H H
N
N
a
b
b
a
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Preparation 1,3-Di(pyren-1-yl)-imidazolium Chloride 30.  
To a solution of N,N’-di(pyren-1-yl)ethane-1,2-diimine 29 (0.40 mL, 0.9 mmol) 
in THF (10 mL), formaldehyde (0.04 g, 1.3 mmol) and 4N HCl in dioxane (1.5 mL) was 
added at room temperature.  The mixture reaction was stirred rapidly for 18 h.  The 
precipitated solid was filtered and washed with cold THF (3 mL) to give pure desired 
product 30 (0.38 g, 0.7 mmol, 85 %).  1H NMR (300 MHz, DMSO-d6) δ 8.67-8.66 (1H, 
m), 8.57-8.52 (2H, m), 8.43 (1H, d, J = 6.3 Hz), 8.40-8.24 (11H, m), 8.16-8.06 (7H, m), 
8.01-7.97 (2H, m); 13C NMR (75 MHz, DMSO-d6) δ 131.6 (2 peaks), 131.1, 128.1, 
128.0 (3 peaks), 127.9 (3 peaks), 127.8, 127.7 (2 peaks), 127.2, 126.6, 126.5 (2 peaks), 
126.3, 126.2, 125.7, 125.3, 125.1, 124.3, 121.8, 119.3. MS (ESI): Exact mass calcd for 
C35H21N2Cl ie [M]
+ 469.16. Found. 469.15. 
 
 
 
b
a
N+N
Cl-
c
a
b + c
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Preparation N,N’-Di(pyren-1-yl)ethane-1,2-diamine 31.  
N,N’-Di(pyren-1-yl)ethane-1,2-diimine 29 (0.22 g, 0.5 mmol) was dissolved in 
EtOH (15 mL) and THF (10 mL), then NaBH4 (0.08 g, 2mmol) was added to the mixture.  
After stirred at room temperature for 12 h, the mixture was poured into 1N HCl.  The 
aqueous layer was basified with NaOH then extracted with CH2Cl2 (3 x 20 mL).  The 
combined organic layers were washed with water, brine and dried over Na2SO4. Solvent 
was removed under reduced pressure to yield ethylenediamine product 31 as yellow 
solid (0.16 g, 0.3 mmol, 60 %).  1H NMR (300 MHz, CDCl3) δ 8.53 (2H, d, J = 9.3 Hz), 
b
a
N+N
Cl-
c
a
b + c
H H
N
N
R
R
NaBH4
THF, EtOH
25 °C, 12 h
29
H H
NH
HN
R
R
31
N+NR R
Cl-
32
HC(OMe)3
4N HCl in dioxane
110 °C, 18 h
R =
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8.25-8.18 (8H, m), 8.12-8.10 (4H, m), 8.08-8.00 (2H, m), 7.95 (6H, d, J = 9.0 Hz), 3.56 
(4H, t, J = 6.6 Hz); 13C NMR (75 MHz, CDCl3) δ 135.2, 128.7, 128.4, 127.9, 127.3 (2 
peaks), 126.9, 126.7, 126.5 (2 peaks), 126.2, 126.1, 125.6, 125.3, 124.6, 124.3, 121.7, 
119.4, 67.3. MS (ESI): Exact mass calcd for C34H24N2 ie [M+H]
+ 461.20. Found 461.20. 
 
 
a
b
H H
NH
HN
a
b
c
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Preparation 1,3-Di(pyren-1-yl)-4,5-dihydro-imidazolium Chloride 32.  
N,N’-Di(pyren-1-yl)ethane-1,2-diamine 31 (0.16 g, 0.3 mmol) was dissolved in 
10 mL of trimethyl orthoformate.  4N HCl in dioxane (0.25 mL, 1 mmol) was added to 
solution then the mixture was refluxed using air condenser to remove methanol until 
completion (18 h).  The precipitated solid was filtered and washed with ether (3 x 10 
mL) to give dry product 32 (0.12 g, 0.23 mmol, 78%) as a yellow solid. 1H NMR (300 
MHz, CDCl3) δ 8.72-8.63 (1H, m), 8.55-8.50 (2H, m), 8.40 (1H, d, J = 6.3 Hz), 8.40-
8.19 (11H, m), 8.12-8.06 (7H, m), 4.03 (4, t, J = 3.6 Hz); 13C NMR (75 MHz, CDCl3) 
δ 131.3, 129.5, 127.2 (2 peaks), 126.6 (2 peaks), 126.5 (2 peaks), 126.4, 126.3, 126.2, 
125.7, 125.3, 125.1, 124.3, 123.1, 65.1, 64.7. MS (ESI): Exact mass calcd for 
C35H23N2Cl ie [M+]
+ 471.18 Found 471.18. 
a
b
H H
NH
HN
a
b
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b
a
N+N
Cl-
c
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b
b
a
N+N
Cl-
c
a + c
b
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Preparation N-Pyrene imidazole 51.  
 
To a solution of 1-bromopyrene (0.56 g, 1 mmol) and imidazole (0.20 g, 3 mmol) 
in DMSO (10 mL), Cu2O (0.03 g, 0.4 mmol) and KOH (0.23 g, 4 mmol) was added at 
25 °C.  The mixture was stirred for 5 h then passed through celite to remove remaining 
solid.  Solvent was removed under reduced pressure then the residue was purified by 
chromatography using 20 % EtOAc/hexane as eluent to give compound 51 (0.14 g, 0.6 
mmol, 55 %) as a yellow solid.  
 
Preparation 1,2-Di(N-pyreneimidazole)ethane 52.  
 
 
1-Pyrenyl-imidazole 51 (0.27 g, 1 mmol) and 1,2-dibromoethane (43 µL, 0.5 
mmol) were dissolved in dry MeCN under Ar.  The mixture was stirred at 70 oC for 2 
days then heated to 80 oC for another 3 days.  The mixture was allowed to ambient 
temperature then solvent was removed under reduced pressure.  The residue was washed 
with Et2O (3 x 5 mL).  The product 52 was used without further purification.  
NHN
Cu2O, KOH
DMSO, 25 oC, 5 h
Br N N
51
R N
N
51
N N
N+
N+
R
R
MeCN, 70 oC, 2 days
then 80 oC, 3 days
Br Br+
52
2Br-
R =
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Preparation 1,1'-(Pyridine-2,6-diylbis(methylene))bis(3-pyrenyl-imidazolium) 53.  
 
 
1-Pyrenyl-imidazole 51 (0.64 g, 2.4 mmol) and 2,6-bis(bromomethyl)pyridine 
(0.27 mg, 1 mmol) were dissolved in MeOH under Ar.  The mixture was stirred at 70 oC 
for 2 days then heated to 80 oC for another 3 days.  The mixture was allowed to cool to 
ambient temperature then solvent was removed under reduced pressure.  The residue was 
washed with Et2O (3 x 5 mL).  The light yellow product 53 (0.7 g, 0.9 mmol, 40 %) was 
used without further purification. 
R N
N
51
MeCN, 70 oC, 2 days
then 80 oC, 3 days
+
53
N
Br Br
N
NN
N+ N+
R R
R =
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Preparation 2-Iodo-9,9-dimethylfluorene.  
To a solution of 2-iodofluorene (0.95 g, 3.2 mmol) in 30 mL of THF, tBuOK 
(2.19 g, 19.5 mmol) was added at 0 oC. The mixture was stirred for 30 min then warmed 
to ambient temperature. Alkylhalide (3 equiv) was added to the mixture. The reaction 
was stirred for another 6 h then water (30 mL) was added. The mixture was extracted 
with Et2O (3 x 30 mL). The combined organic layers were washed with brine and dried 
over Na2SO4. Solvent was removed under reduced pressure and the residue was purified 
by chromatography using 10 % EtOAc/hexane as eluent to give product (92 %) as white 
solid. 1H NMR (300 MHz, CDCl3) δ 7.82 (1H, d, J = 1.5 Hz), 7.75-7.69 (2H, m), 7.53-
7.50 (1H, m), 7.48-7.45 (1H, m), 7.41-7.37 (2H, m), 1.52 (6H, s); 13C NMR (75 MHz, 
CDCl3) δ 155.9, 153.0, 138.9, 138.2, 136.0, 132.1, 127.9, 127.2, 122.6, 121.8, 120.2, 
92.6, 47.1, 27.0. 
HNO3, AcOH
cat. H2SO4
 0 °C then 40 °C
4 h
I I
NO2
34
NH
NO2
iPr
iPr
NHLi
iPr iPr
THF, 0 °C, 12 h
35
10 % Pd/C, 20 bar H2
EtOH, 25 °C, 12 h
NH
NH2
iPr
iPr
HC(OMe)3
p-TsOH
110 °C, 18 h
36
N
N
iPr
iPr
37
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Preparation 2-Iodo-9,9-dimethyl-3-nitrofluorene 34.  
To a solution of 2-iodo-9,9-dimethylfluorene (0.95 g, 3.2 mmol) in 20 mL of 
AcOH, conc. HNO3 was added at 0 oC followed by catalytic amount of H2SO4.  The 
mixture was stirred and heated to 40 oC for 4 h.  After allowed to cool to ambient 
temperature, the mixture was poured into saturated Na2CO3.  The aqueous layer was 
extracted with CH2Cl2.  The combined organic layers were washed with water, brine and 
dried over Na2SO4.  Solvent was evaporated and the residue was purified by 
chromatography using 30 % EtOAc/hexane as eluent to give product 34 as a white solid.  
1H NMR (300 MHz, CDCl3) δ 8.38-8.24 (1H, m), 8.18 (1H, d, J = 1.5 Hz), 7.76-7.72 
(2H, m), 7.53 (1H, d, J = 8.4 Hz), 6.80 (1H, t, J = 7.8 Hz), 1.29 (3H, s), 1.27 (3H, s); 13C 
NMR (75 MHz, CDCl3) δ 154.4, 151.4, 146.5, 138.3, 136.6, 132.5, 123.4, 122.7, 120.0, 
118.5, 118.2, 95.5, 60.4, 29.1, 22.4. MS (ESI): Exact mass calcd for C15H12INO2 ie [M]+ 
364.99. Found 364.99. 
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Preparation N-2,6-Diisopropylphenyl-9,9-dialkyl-3-nitrofluoren-2-amine 35  
To a solution of 2,6-diisopropylaniline in THF, 2.5 M n-BuLi was added at 0 oC. 
The reaction mixture was stirred for 30 min then transferred to a rapidly stirred solution 
of 2-iodo-9,9-dialkyl-3-nitrofluorene 34 in THF via cannula.  The mixture was allowed 
to warm to ambient temperature and stirred for 12 h.  Water was added dropwise to the 
mixture, then extracted with CH2Cl2.  The combined organic layers were washed with 
brine and dried over Na2SO4.  Solvent was removed under reduced pressure and residue 
was purified by chromatography using 10 % EtOAc/hexane as eluent to give product 35 
(65 %) as yellow solid.  1H NMR (300 MHz, CDCl3) δ 8.32-8.21 (2H, m), 8.15-6.82 (7H, 
m), 2.12 (2H, m), 1.27 (3H, s), 1.25 (3H, s), 1.12 (6H, d, J = 6.6 Hz), 0.98 (6H, d, J = 
6.6 Hz; 13C NMR (75 MHz, CDCl3) δ 154.5, 151.2, 150.3, 146.8, 146.5, 138.3, 136.6, 
135.4, 133.1, 132.5, 128.7, 123.4, 122.7, 121.8, 120.0, 118.5, 118.2, 95.5, 60.4, 29.1, 
25.1, 22.4, 19.3. MS (ESI): Exact mass calcd for C27H30N2O2 ie [M+H]+ 415.24. Found 
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415.24.
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Preparation of N2-(2,6-Diisopropylphenyl)-9,9-dialkyl-fluorene-2,3-diamine 36.  
10 % Pd/C (0.02 g, 0.02 mmol) was added to solution of N-2,6-
diisopropylphenyl-9,9-dialkyl-3-nitrofluoren-2-amine 35 (0.65 g, 2 mmol) in 15 mL of 
EtOH. The mixture was then placed into pressure bomb and then flushed with H2. The 
reaction was stirred under 20 bar of H2 for 12 h. The mixture was passed through celite 
and the solvent was removed under reduced pressure to yield compound 36 (0.52 g, 1.96 
mmol, 98%) as a brown solid. 1H NMR (300 MHz, CDCl3) δ 8.38-8.25 (2H, m), 8.15-
6.92 (7H, m), 2.21 (2H, m), 1.29 (3H, s), 1.24 (3H, s), 1.10 (6H, d, J = 6.6 Hz), 0.96 (6H, 
d, J = 6.6 Hz; 13C NMR (75 MHz, CDCl3) δ 154.3, 151.2, 150.4, 146.8, 146.7, 138.3, 
136.6, 135.4, 133.1, 132.5, 128.7, 123.4, 122.9, 122.8, 122.7, 121.8, 120.0, 118.5, 118.2, 
95.5, 61.4, 29.5, 25.2, 22.8, 19.4. MS (ESI): Exact mass calcd for C27H32N2 ie [M+2H]2+ 
193.14. Found 193.14. 
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Preparation of 1-(2,6-diisopropylphenyl)-9,9-dimethyl-1,9-dihydrofluoreno[2,3-
d]imidazole 37. 
N2-(2,6-Diisopropylphenyl)-9,9-dialkyl-fluorene-2,3-diamine 36 (0.60 g, 2.3 
mmol) was dissolved in 5 mL of trimethyl orthoformate.  Catalytic amount of p-
toluenesulfonic acid (0.002 g, 0.01 mmol) was added to solution then the mixture was 
refluxed using air condenser to remove methanol until completion (18 h).  Solvent was 
removed under reduce pressure and the residue was purified by chromatography using 
20 % EtOAc/hexane as eluent to give 37 (0.19 g, 0.69 mmol, 30%) as a brown solid. 1H 
NMR (300 MHz, CDCl3) δ 8.45-8.26 (2H, m), 8.18-7.05 (8H, m), 2.94-2.43 (2H, m), 
1.44 (3H, s), 1.41 (3H, s), 1.32 (6H, d, J = 6.9 Hz), 1.23 (6H, d, J = 6.9 Hz); 13C NMR 
(75 MHz, CDCl3) δ 162.0, 154.3, 151.2, 150.3, 146.8, 146.7, 138.5, 136.7, 135.4, 133.0, 
132.5, 128.6, 123.4, 122.9, 122.8, 122.7, 121.6, 120.0, 119.3, 118.5, 96.3, 61.5, 30.2, 
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25.5, 22.5, 19.8. MS (ESI): Exact mass calcd for C28H30N2 ie [M+H]+ 395.25. Found 
395.25. 
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Preparation of Adamanyl Oxazoline imidazolefluorene iodide 38.  
Adamantyl oxazoline iodide (1.80 g, 5 mmol) and 1-(2,6-diisopropylphenyl)-9,9-
dimethyl-1,9-dihydrofluoreno[2,3-d]imidazole 37 (1.39 g, 5 mmol) was dissolved in 10 
mL of DMF under Ar atmosphere.  The mixture was heated to 80 oC for 12 h.  The 
solvent was removed under reduced pressure and the residue was washed with Et2O (5 x 
5 mL) to yield compound 38 (2.39 g, 3.8 mmol, 75%) as a brown solid. 1H NMR (300 
MHz, CDCl3) δ 8.9 (1H, s), 8.42-8.25 (2H, m), 8.20-6.98 (7H, m), 4.43-4.10 (5H, m), 
3.75 (2H, m), 3.05-2.95 (1H, m), 2.92-2.70 (3H, m), 2.47 (1H, s), 1.98-1.54 (15H, m), 
1.25-1.09 (15H, m); 13C NMR (75 MHz, CDCl3) δ 185.2, 164.8, 162.8, 161.9, 161.8, 
151.2, 150.3, 147.0, 146.9, 142.7, 142.3, 141.5, 135.0, 129.6, 124.4, 123.4, 122.5, 95.1, 
73.4, 50.7, 47.2, 38.9, 38.6, 37.3, 36.4, 28.2, 28.0, 27.4, 25.1, 24.1, 23.5, 22.3 18.7. MS 
(ESI): Exact mass calcd for C43H52N3O+ ie [M+]+ 626.41. Found 626.41. 
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DMF, 80 °C, 16 h37
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Preparation of Ir Complex 39.  
 
Imidazolinium salt 38 was added to a round bottom flask along with 1.5 
equivalents lithium tert-butoxide and 0.5 equivalents of [Ir(COD)Cl]2 under Ar.  THF 
was syringed in to make the solution 0.03 M in imidazolinium salt.  The mixture was 
heated to 70 oC in an oil bath and stirred for 16 h.  After cooling to room temperature, 
the volatiles were removed under reduced pressure and 1.5 equivalents of NaBARF in 5 
mL CH2Cl2 was added.  Water (5 mL) was added and the mixture was stirred vigorously 
for 15 min. The organic layer was removed and the aqueous layer was washed with an 
additional 5 mL CH2Cl2.  The organic layers were combined, dried (Na2SO4) and the 
volatiles were removed in vacuo.  The residue was chromatographed using a short silica 
column and 10 % hexanes/CH2Cl2 as the eluent to give 39 as a solid (32 %). 1H NMR 
(300 MHz, CDCl3) δ 8.42-8.11 (2H, m), 8.20-7.90 (2H, m), 7.74 (8H, s), 7.57 (4H, 2), 
7.41-7.30 (3H, m), 7.28-6.87 (2H, m), 4.73-4.68 (1H, m), 4.35-4.25 (2H, m), 4.16-4.12 
(1H, m), 3.97-3.58 (6H, m), 3.46-3.38 (1H, m), 3.25-3.21 (1H, m), 2.95-2.89 (2H, m), 
2.68-2.59 (1H, m), 2.17-1.59 (22H, m), 1.45-1.15 (17H, m), 0.95-0.84 (2H, m); 13C 
NMR (75 MHz, CDCl3) δ 178.4, 177.5, 174.5, 163.6, 162.7, 162.0, 161.3, 160.7, 146.7, 
136.3, 134,9, 134.8, 130.0, 129.2, 129.1, 128.7 (2 peaks), 128.6, 126.4, 124.8, 122.7, 
117.5, 85.5, 62.1, 55.7, 30.2, 29.9, 29.1, 28.7, 27.4, 26.9, 25.4, 23.9, 22.9.  
3938
N
N
N
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+
i) [IrCl(COD)]2 
LiOtBu, THF 
70 °C, 16 h
ii) NaBARF 
CH2Cl2 : H2O 
(1:1)
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B. General Procedure for Heck Coupling. 
 
 
 
Pd source, base and ligand were dissolved in DMF under Ar in photoreactor.  
Acrylate and bromotoluene were added to solution then reaction mixture was stirred in 
the presence of light for 12 h.  The mixture was passed through celite and solvent was 
removed under reduced pressure.  The crude product was passed through a short silica 
plug using 30% EtOAc/hexanes as the eluent.  The enantiomeric ratio was then 
measured through chiral GC or HPLC analysis. 
 
C. Catalytic Hydrogenation Conditions 
 
The corresponding alkenes (0.25 mmol) and Ir-catalyst (1-2 mol %) were 
dissolved in CH2Cl2 (0.5 M).  The resulting mixture was degassed by three cycles of 
freeze-pump-thaw and then transferred to a Parr Bomb.  The bomb was pressurized to 50 
bar with hydrogen and the mixture was stirred at 300 rpm for 16 h.  The bomb was then 
vented and solvent was evaporated.  The crude product was passed through a short silica 
plug using 10 - 30% EtOAc/hexanes as the eluent.  The enantiomeric ratio was then 
measured through chiral GC or HPLC analysis. 
 
 
 
 
 
 
 
Br
OEt
O Pd source, ligand2.0 base
DMF, hν
OEt
O
+
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APPENDIX G 
EXPERIMENTAL FOR CHAPTER VII 
 
A. Preparation of Catalysts 40. 
 
 
Preparation of (4R,5R)-2-Chloro-1-methyl-4,5-diphenyl-4,5-dihydro-imidazole 43. 
 
 
(S,S)-N,N’-diBoc-1,2-diphenyl ethylenediamine 
To a solution of (S,S)-1,2-diphenyl ethylenediamine (658 mg, 3.1 mmol) and 
triethyl-amine (3 mL, 22 mmol) in CH2Cl2 (20 mL) was added Boc2O (1.6 mL, 7.0 
mmol) at ambient temperature under Ar and stirred for 15 h.  The resulting solution was 
diluted with CH2Cl2, poured into saturated NH4Cl (aq), and extracted with CH2Cl2.  The 
combined organic layers were dried over Na2SO4, and evaporated in vacuo.  The residue 
was purified by chromatography (CH2Cl2 to CH2Cl2/AcOEt = 10/1) to give product 
(1.228 g, 96 %) as colorless solid. mp: 208 °C. 1H NMR (400 MHz, CDCl3) δ 7.18-7.14 
(6H, m), 7.07-7.02 (4H, m), 5.58 (2H, br), 4.85 (2H, br), 1.44 (18H, s); 13C NMR (100 
MHz, CDCl3) δ 156.3, 139.2, 128.3, 127.5, 127.3, 79.7, 60.7, 28.3. HRMS (FAB): Exact 
mass calcd for C24H33N2O4 ie [M +H]+ 413.2440. Found 413.2442. 
 
(S,S)-N-methyl-1,2-diphenyl ethylenediamine 41. 
To a solution of (S,S)-N,N’-diBoc-1,2-diphenyl ethylenediamine (1.027 g, 2.49 
mmol), MeI (7.75 mL, 124 mmol), and TBAI (4.6 g, 12.5 mmol) in THF (20 mL) was 
Ph
H2N NH2
Ph
(i) Boc2O, Et3N, CH2Cl2, 25 oC, 12 h
(ii) NaH, MeI, Bu4N+I-, THF, 25 oC, 4 h
(iii) HCl, H2O, 25 oC, THF, 4 h
Ph
H2N HN
Ph
3 mmol 41, 73 %
CO(imidazole)2, Et3N
THF, 25 oC, 12 h Ph Ph
NHN
O
POCl3
110 oC, 24 h Ph Ph
NN
Cl
42, 36 % 43, 92 %
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added NaH (110 mg, 60% in oil, 2.75 mmol) at 0 °C under Ar and stirred for 13 h at 
room temperature.  The resulting solution was diluted with AcOEt, poured into saturated 
NH4Cl (aq), and washed with H2O and brine.  Organic layer was dried over Na2SO4, and 
evaporated in vacuo.  The residue was purified by SiO2 column chromatography 
(Hex/AcOEt = 5/1) to give (S,S)-N-methyl-N,N’-diBoc-1,2-diphenyl ethylenediamine 
(157 mg, 15 %) as colorless oil. 1H NMR (400 MHz, CDCl3) δ  7.31-7.12 (10H, m), 5.77 
(3H, br), 5.42 (7H, br), 2.66 (3H, s), 1.51 (9H, s), 1.41 (9H, s). HRMS (FAB): Exact 
mass calcd for C25H35N2O4 ie [M +H]+ 427.2597. Found 427.2606.  
To a solution of (S,S)-N-methyl-N,N’-diBoc-1,2-diphenyl ethylenediamine 
(151.8 mg, 0.356 mmol) in THF (5 mL) was added 2N HCl aq. (5 mL) at room 
temperature and stirred for 1 h.  The reaction mixture was added cHCl (2 mL) and stirred 
for 2 h.  The resulting solution was diluted with Et2O and extracted with 5 % H2SO4 (aq).  
Aqueous layer was basified with NaOH and extracted with CH2Cl2.  Organic layer was 
dried over Na2SO4, and evaporated in vacuo to give 41 (75.1 mg, 93%) as colorless 
amorphous. 1H NMR (400 MHz, CDCl3) δ 7.23-7.11 (10H, m), 3.98 (1H, d, J = 6.9 Hz), 
3.62 (1H, d, J = 6.9 Hz), 2.23 (3H, s); 13C NMR (100 MHz, CDCl3) δ 143.5, 140.9, 
128.0, 127.90, 127.88, 126.93, 126.90, 126.8, 71.7, 61.6, 34.6. HRMS (FAB): Exact 
mass calcd for C15H19N2 ie [M +H]+ 227.1548. Found 227.1550. 
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(4R,5R)-1-methyl-4,5-diphenylimidazolidin-2-one 42. 
To a solution of (S,S)-N-methyl-1,2-diphenyl ethylenediamine 41 in THF, Et3N 
was added.  The solution was cooled to 0 °C, then 1,1-carbonyldiimidazole was added.  
The mixture was warmed to room temperature and stirred for another 12 h.  Water was 
added and aqueous layer was extracted with EtOAc (3 x 30 mL).  The combined organic 
layers was washed with 1N HCl, saturated NaHCO3, brine and dried over Na2SO4.  
Solvent was removed under reduced pressure and residue was purified by 
chromatography (EtOAc/hexane and EtOAc/ether) to give (4R,5R)-1-methyl-4,5-
diphenylimidazolidin-2-one 42 as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.45-7.10 
(10H, m), 5.12 (1H, d, J = 6.9 Hz), 4.78 (1H, d, J = 6.9 Hz), 2.75 (3H, s); 13C NMR (100 
MHz, CDCl3) δ 162.1, 140.5, 128.4, 127.9, 127.0, 126.9, 126.8, 126.5, 65.3, 54.1, 34.7.  
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(4R,5R)-2-chloro-1-methyl-4,5-diphenyl-4,5-dihydro-imidazole 43. 
(4R,5R)-1-methyl-4,5-diphenylimidazolidin-2-one 42 was dissolved in POCl3.  
The solution was refluxed for 24 h and then cooled to ambient temperature.  The mixture 
was poured into iced-cool 1N NaOH (aq) and the aqueous layer was extracted with ether 
(3 x 20 mL).  The combined organic layers were washed with H2O, brine and dried over 
Na2SO4.  Solvent was removed under reduced pressure and the residue was purified by 
chromatography using EtOAc/hexane to give product as a white solid. 1H NMR (400 
MHz, CDCl3) δ 7.39-7.25 (10H, m), 5.27 (1H, d, J = 6.9 Hz), 4.89 (1H, d, J = 6.9 Hz), 
2.71 (3H, s); 13C NMR (100 MHz, CDCl3) δ 155.9, 140.2, 138.5, 128.6, 128.0, 127.9, 
127.5, 126.9, 126.7, 126.8, 125.9, 68.3, 63.1, 30.7. 
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General Procedure for Preparation of 2-(Dialkylphosphino)phenol 46. 
 
 
Synthesis of methoxymethyl phenyl ether 44. 
At 0 °C and with stirring, phenol (5 g, 53.1 mmol, 1 eq) was added to NaH (1.91 
g, 79.7 mmol, 1.5 eq) in dimethylformamide (26.5 mL, 2 M).  After 30 min, 
OH
MOMCl, NaH, DMF
0 oC, 15 h OMOM
(i) BuLi, TMEDA 
hexane
-78 oC, 30 min
(ii) PR2Cl 
hexane, 25 oC 
12 h44, 96 %
OMOM
PR2
HCl, MeOH, 25 oC
5 h OH
PR2
45
52 - 61 %
46
65 - 77 %
R = Ph, a; Cy, b;
       iPr, c
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chloromethyl methyl ether (6.05 mL, 79.7 mmol, 1.5 eq) was added, then the 
temperature was allowed to warm up to room temperature.  The mixture was stirred and 
the reaction was monitored by TLC (8:2 hexane/AcOEt). After 30 minutes, water (106 
mL) was added.  The product was exctracted with hexane (3 x 50 mL). The organic layer 
was dried over Na2SO4 and concentrated.  The product was purified by distillation (p = 
1.5 Torr, T = 30 – 32 °C) to give colorless oil (74 %).  1H NMR (400 MHz, CDCl3) δ 
7.38-7.31 (11H, m), 7.13 (1H, m), 6.93 (1H, m), 6.72 (1H, m); 13C NMR (100 MHz, 
CDCl3) δ 158.6, 136.9, 134.4, 134.0, 133.7, 130.4, 128.9, 128.7, 128.5, 122.2, 113.6, 
113.6, 94.3, 56.1. 
 
General Procedure for Synthesis of Methoxymethyl o-dialkylphosphinophenyl 
ether 45. 
A solution containing 1.6 M n-BuLi (10 mL, 16 mmol, 1.1 eq) and N,N,N’,N’-
tetra-methylethylenediamine (2.24 mL, 14.9 mmol, 1.03 eq) in dry hexane was added to 
an ice-cooled solution of methoxymethyl phenyl ether (2 g, 14.5 mmol, 1 eq) in dry 
hexane under Ar.  The mixture was allowed to warm up to room temperature.  The 
solution became yellow and a pale precipitate formed after 1.5 h.  The solution was 
cooled in ice and appropriate chlorodialkylphosphine (1 eq) was added slowly.  The 
resultant solution was stirred for 16 h at room temperature and the solvent was removed 
under reduced pressure.  The residue was diluted with Et2O and washed with 1 M 
aqueous Na2HPO4.  The organic layer was dried over Na2SO4 and concentrated to give a 
white solid.  The solid was dissolved in MeOH. After cooling for 30 minutes, the 
crystals were collected and recrystallized from CH2Cl2/MeOH. 
 
 
Ph2P
OMOM
45a
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Methoxymethyl o-diphenylphosphinophenyl ether 45a. 61%. 1H NMR (400 MHz, 
CDCl3) δ 7.38-7.31 (11H, m), 7.13 (1H, m), 6.93 (1H, m), 6.72 (1H, m), 5.98 (2H, s), 
3.59 (3H, s); 13C NMR (100 MHz, CDCl3) δ 158.6, 136.9, 134.4, 134.0, 133.7, 130.4, 
128.9, 128.7, 128.5, 122.2, 113.6, 113.6, 94.3, 56.1; 31P-NMR (161 MHz, CDCl3) δ        
-14.8. 
 
 
 
 
Methoxymethyl o-dicyclohexylphosphinophenyl ether 45b. 56%. 1H NMR (400 MHz, 
CDCl3) δ 7.35-7.10 (4H, m), 5.97 (2H, s), 3.41 (3H, s), 1.58-1.10 (22H, m); 13C NMR 
Cy2P
OMOM
45b
  272 
(100 MHz, CDCl3) δ 160.1, 130.1, 129.8, 129.7, 128.7, 124.1, 121.1, 110.5, 95.2, 55.5, 
34.3, 30.1, 29.0, 28.9, 26.0. 
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Methoxymethyl o-diisopropylphosphinophenyl ether 45c. 52%. 1H NMR (400 MHz, 
CDCl3) δ 7.34-7.13 (4H, m), 5.97 (2H, s), 3.41 (3H, s), 1.65 (2H, m), 0.92 (12H, d, J = 
6.6 Hz); 13C NMR (100 MHz, CDCl3) δ 159.9, 129.8, 128.8, 124.3, 121.0, 111.0, 94.3, 
55.8, 29.8, 18.5, 18.4. 
 
 
iPr2P
OMOM
45c
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General Procedure for Synthesis of o-dialkylphosphinophenol 46. 
A solution of 4N HCl in diethyl ether was added to 5 mL of dry methanol.  
Methoxy-methyl o-dialkylphosphinophenyl ether (1 g, 3.1 mmol, 1 eq) was added at 
room temperature and under argon.  The resulting solution was stirred for 1 h then the 
solvent was removed under reduced pressure giving a yellow oil.  The residue was 
dissolved in dry MeOH (3 mL), then water was added until the cloud point was reached.  
The solution was stirred under argon while cooling, and the resulting white solid was 
filtered.  
 
 
o-Diphenylphosphinophenol 46a. 77%. 1H NMR (400 MHz, CDCl3) δ 7.43-7.26 (11H, 
m), 7.05-6.86 (3H, m), 6.42 (1H, br); 13C NMR (100 MHz, CDCl3) δ 159.9, 134.5, 134.4, 
133.7, 133.6, 130.1, 128.8 (2 peaks), 128.7 (2 peaks), 121.6, 115.8; 31P NMR (121 MHz, 
CDCl3) δ -26.6. 
 
Ph2P
OH
46a
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o-Dicyclohexylphosphinophenol 46b. 65%. 1H NMR (400 MHz, CDCl3) δ 7.35-7.10 
(4H, m), 6.42 (1H, br), 1.55-1.40 (22H, m); 13C NMR (100 MHz, CDCl3) δ 159.7, 130.2, 
129.1, 125.8, 120.9, 115.3, 34.5, 34.3, 30.4, 28.9, 26.1. 
 
Cy2P
OH
46b
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o-Diisopropylphosphinophenol 46c. 75%. 1H NMR (400 MHz, CDCl3) δ 7.21-6.95 
(4H, m), 6.42 (1H, br), 1.60 (2H, m), 0.93 (12H, d, J = 6.6 Hz); 13C NMR (100 MHz, 
CDCl3) δ 159.3, 130.2, 129.2, 125.7, 120.9, 115.3, 29.9, 18.8. 
 
iPr2P
OH
46c
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  278 
General Procedure for Preparation of (4R,5R)-2-(2-(Dialkylphosphino)phenoxy)-1-
methyl-4,5-diphenyl-4,5-dihydro-imidazole 47. 
 
 
NaH was added to a stirred solution of o-dialkylphosphinophenol (1 mmol, 1 eq) 
in DMF 10 mL at 0 °C.  The solution was allowed to warmed to room temperature and 
stirred for 2 h, then solution of (4R,5R)-2-chloro-1-methyl-4,5-diphenyl-4,5-dihydro-
imidazole (1 eq) in DMF was added.  The mixture was heated to 80 °C and stirred for 12 
h.  The reaction mixture was cooled to room temperature, poured into ice-cold water, 
and extracted with ethyl acetate (2 × 50 mL).  The combined organic extracts were dried 
over Na2SO4.  Solvent was removed under reduced pressure to provide the crude 
material as a yellow solid.  Recrystallization from ethyl acetate/hexane afforded the 
desired product as a white solid. 
 
 
(4R,5R)-2-(2-(Diphenylphosphino)phenoxy)-1-methyl-4,5-diphenyl-4,5-dihydro-
imidazole 47a. 78%. 1H NMR (400 MHz, CDCl3) δ 7.44-7.11 (17H, m), 7.02-6.83 (7H, 
m), 5.73 (1H, d, J = 6.9 Hz), 5.25 (1H, d, J = 6.9 Hz), 3.21 (3H, s); 13C NMR (100 MHz, 
CDCl3) δ 160.4, 157.8, 138.2, 137.2, 134.5, 133.7, 133.6, 128.7, 128.6, 128.4, 128.0, 
127.0, 125.9, 121.3, 115.8, 67.9, 65.8, 30.1. 
NaH, DMF
 
80 oC, 12 hR2P
OH
Ph Ph
NN
Cl
Ph Ph
NN
O
R2P
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+
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O
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(4R,5R)-2-(2-(Dicyclohexylphosphino)phenoxy)-1-methyl-4,5-diphenyl-4,5-dihydro-
imidazole 47b. 59%. 1H NMR (400 MHz, CDCl3) δ 7.45-7.02 (14H, m), 5.65 (1H, d, J = 
6.6 Hz), 5.28 (1H, d, J = 6.6 Hz), 3.05 (3H, s), 1.63-1.40 (22H, m); 13C NMR (100 MHz, 
CDCl3) δ 158.7, 157.6, 130.1, 129.2, 128.6, 128.5, 127.3, 127.0, 125.9, 125.6, 120.8, 
115.3, 67.5, 61.3, 34.3, 34.1, 30.3, 29.1, 28.9, 26.0. 
 
 
 
Ph Ph
NN
O
Cy2P
47b
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(4R,5R)-2-(2-(Diisopropylphosphino)phenoxy)-1-methyl-4,5-diphenyl-4,5-dihydro-
imidazole 47c. 63%. 1H NMR (400 MHz, CDCl3) δ 7.31-6.95 (14H, m), 5.33 (1H, d, J = 
6.3 Hz), 5.12 (1H, d, J = 6.3 Hz), 3.44 (3H, s), 1.59 (2H, m), 0.95 (12H, d, J = 6.6 Hz); 
13C NMR (100 MHz, CDCl3) δ 158.7, 157.8, 140.3, 138.3, 130.1, 129.0, 128.6 (2 peaks), 
128.4, 127.9, 127.7, 125.8, 120.1, 64.6, 61.6, 32.2, 29.9, 18.5. 
 
 
 
Ph Ph
NN
O
iPr2P
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General Procedure for Preparation of Iridium Catalyst 40. 
 
(4R,5R)-2-(2-(Dialkylphosphino)phenoxy)-1-methyl-4,5-diphenyl-4,5-dihydro-
imidazole 47 was added to a round bottom flask along with 0.5 equivalents of 
[Ir(COD)Cl]2 under Ar.  THF was syringed in to make the solution 0.03 M in 
imidazolium salt.  The mixture was heated to 70 oC in an oil bath and stirred for 16 h.  
After cooling to room temperature, the volatiles were removed under reduced pressure 
and 1.5 equivalents of NaBARF in 5 mL CH2Cl2 was added.  Water (5 mL) was added 
and the mixture was stirred vigorously for 15 min.  The organic layer was removed and 
the aqueous layer was washed with an additional 5 mL CH2Cl2.  The organic layers were 
combined, dried (Na2SO4) and the volatiles were removed in vacuo.  The residue was 
chromatographed using a short silica column and 10 % hexanes/CH2Cl2 as the eluent. 
 
 
(η4-1,5-Cyclooctadiene)[(4R,5R)-2-(2-(Diphenylphosphino)phenoxy)-1-methyl-4,5-
diphenyl-4,5-dihydro-imidazole]iridium(I) Tetrakis(3,5-bis(trifluoromethyl)-
phenyl)borate 40a. (32 %). 1H NMR (400 MHz, CDCl3) δ 7.75 (8H, s), 7.56 (4H, s), 
7.41-7.12 (16H, m), 7.05-6.85 (8H, m), 5.73 (1H, d, J = 6.0 Hz), 5.13 (1H, d, J = 6.0 Hz), 
4.74-4.60 (2H, m), 4.16-4.12 (2H, m), 3.97-3.58 (8H, m), 2.98 (3H, s); 13C NMR (100 
(i) [Ir(COD)Cl]2, THF
70 oC, 16 h
(ii) NaBARF, CH2Cl2, H2O
25 oC, 3 h
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MHz, CDCl3) δ 160.2, 158.8, 138.0, 137.5, 136.3, 134,9, 134.8, 134.5, 133.7, 133.6 (2 
peaks), 128.7 (2 peaks), 128.6, 128.4 (2 peaks), 128.0, 127.0, 124.8, 122.7, 125.9, 121.3, 
115.8, 85.5, 67.5, 66.3, 30.4.  
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 (η4-1,5-Cyclooctadiene)[(4R,5R)-2-(2-(Dicyclohexylphosphino)phenoxy)-1-methyl-
4,5-diphenyl-4,5-dihydro-imidazole]iridium(I) Tetrakis(3,5-bis(trifluoromethyl)-
phenyl)borate 40b. (27 %).  1H NMR (400 MHz, CDCl3) δ 7.75 (8H, s), 7.57 (4H, s), 
7.44-7.05 (14H, m), 5.84 (1H, d, J = 6.0 Hz), 5.25 (1H, d, J = 6.0 Hz), 4.70-4.63 (2H, m), 
4.41-4.29 (2H, m), 4.01-3.59 (8H, m), 2.95 (3H, s), 1.75-1.33 (22H, m); 13C NMR (100 
MHz, CDCl3) δ 158.9, 157.8, 146.7, 136.3, 134,9, 130.5, 129.5, 129.2, 129.1, 128.7 (2 
peaks), 128.6, 128.5, 127.3, 127.0, 120.8, 115.5, 67.6, 61.0, 39.3, 34.3, 34.1, 30.3, 29.1, 
28.6, 26.2. 
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(η4-1,5-Cyclooctadiene)[(4R,5R)-2-(2-(Diisopropylphosphino)phenoxy)-1-methyl-
4,5-diphenyl-4,5-dihydro-imidazole]iridium(I) Tetrakis(3,5-bis(trifluoromethyl)-
phenyl)borate 40c. (45 %).  1H NMR (400 MHz, CDCl3) δ 7.74 (8H, s), 7.57 (4H, s), 
7.44-7.05 (14H, m), 5.56 (1H, d, J = 6.0 Hz), 5.11 (1H, d, J = 6.0 Hz), 4.66-4.56 (2H, m), 
4.41-4.32 (2H, m), 3.88-3.56 (6H, m), 1.65 (2H, m), 0.92 (12H, d, J = 6.6 Hz); 13C NMR 
(100 MHz, CDCl3) δ 158.5, 146.7, 140.3, 138.3, 136.3, 134,9, 130.0, 129.0, 128.6, 128.7, 
128.4, 127.9, 127.7, 125.8, 120.1, 64.6, 62.1, 61.6, 31.5, 28.8, 23.9, 22.9, 18.3.  
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B. Catalytic Hydrogenation Conditions 
The corresponding alkenes (0.1 mmol) and 40 (1 mol %) were dissolved in 
CH2Cl2 (0.5 M).  The resulting mixture was degassed by three cycles of freeze-pump-
thaw and then transferred to a Parr Bomb.  The bomb was pressurized to 50 bar with 
hydrogen and the mixture was stirred at 300 rpm for 16 h.  The bomb was then vented 
and solvent was evaporated.  The crude product was passed through a short silica plug 
using 30% EtOAc/hexanes as the eluent.  The enantiomeric ratio was then measured 
through chiral GC or HPLC analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
